Bibliography - Mental Health Research Institute

BIBLIOGRAPHY
Colin L. Masters, MD
June, 2012
1968
68.01 Masters CL. The effects of arousal and attention on responses evoked from the human
auditory pathway [dissertation]. Thesis for the Degree of Bachelor of Medical Science,
Department of Physiology, University of Western Australia, 1967.
1969
69.01 Masters CL. Quarantine at Albany 1829-1909: An account of the background and events
leading up to the establishment of a Quarantine Station at Albany, its subsequent use
and decline [dissertation]. Department of Medicine, University of Western Australia,
1969.
69.02 Masters CL, Bignold LP, Morgan EH. Plasma protein metabolism and transfer to the
fetus during pregnancy in the rat. Am J Physiol 1969; 216: 876-883.
1970
70.01 Masters CL, Kakulas BA, Gajdusek DC, Gibbs CJ Jr. The significance of the recent
experimental observations on slow virus infections to neuropathology. In: Proceedings
of the Sixth International Congress of Neuropathology: August 31-September 4, 1970; Paris.
Masson et Cie, Paris; 1970: 943-951.
1975
75.01 Masters CL, Kakulas BA, Alpers MP, Gajdusek DC, Gibbs CJ Jr. Preclinical lesions and
their progression in the experimental spongiform encephalopathies (kuru and
Creutzfeldt-Jakob disease) in primates. In: Proceedings of the Seventh International
Congress of Neuropathology: August-September, 1974; Budapest. Edited by St. Tariska Y,
Gosztonyi G. Excerpta Medica, Amsterdam. International Congress Series 1975; No.
362: 23-26.
75.02 Masters CL, Alpers MP, Kakulas BA. Virus induced hydrocephalus: pathogenesis of
the delayed form of hydrocephalus following oro-nasal inoculation with reovirus type
1. In: Proceedings of the Seventh International Congress of Neuropathology: August-
September, 1974; Budapest. Edited by St. Tariska Y, Gosztonyi G. Excerpta Medica,
Amsterdam. International Congress Series 1975; No. 362: 669-671.
1976
76.01 Masters CL, Kakulas BA, Alpers MP, Gajdusek DC, Gibbs CJ Jr. Preclinical lesions and
their progression in the experimental spongiform encephalopathies (kuru and
Creutzfeldt-Jakob disease) in primates. J Neuropathol Exp Neurol 1976; 35: 593-605.
76.02 Masters CL, Alpers MP, Gajdusek DC, Gibbs CJ Jr, Kakulas BA. Experimental kuru in
the gibbon and sooty mangabey and Creutzfeldt-Jakob disease in the pigtailed
macaque: with a summary of the host range of the subacute spongiform virus
encephalopathies. J Med Primatol 1976; 5: 205-209.
1

June, 2012
76.03 Masters CL, Cala LA, Hughes TD. Posterior fossa, aqueduct and fourth ventricle of the
living mouse studied by positive contrast and plain radiography. Neuroradiology
1976; 11: 93-97.
1977
77.01 Masters C, Alpers M, Kakulas B. Pathogenesis of reovirus Type 1 hydrocephalus in
mice: significance of aqueductal changes. Arch Neurol 1977; 34: 18-28.
77.02 Hockey A, Masters CL. Menkes’ kinky (steely) hair disease. Australas J Dermatol 1977;
18: 77-80.
77.03 Masters CL. The pathogenesis of hydrocephalus [dissertation]. Thesis for the Degree of
Doctor of Medicine, University of Western Australia, 1977.
77.04 Masters CL, Dawkins RL, Zilko PJ, Simpson JA, Leedman RJ, Lindstrom J.
Penicillamine-associated myasthenia gravis, antiacetylcholine receptor and
antistriational antibodies. Am J Med 1977; 63: 689-694.
77.05 Masters C. The pathogenesis of human post-infective hydrocephalus: the significance
of aqueductal changes. In: Proceedings of the Sheffield Meeting of the Society for Research
into Hydrocephalus and Spina Bifida: 1977; Sheffield. Edited by Brocklehurst G. Z Kinder
Grenzgebiete 1977; 22: 395-412.
1978
78.01 Cala LA, Mastaglia FL, Masters CL. Evolution of post-infective and post-haemorrhagic
hydrocephalus determined by computerised tomography. In: The Diagnostic Limitations
of Computerised Axial Tomography. Edited by Bories J. Berlin: Springer Verlag; 1978: 110-
114.
78.02 Masters CL. Pathogenesis of the Arnold-Chiari malformation: the significance of
hydrocephalus and aqueduct stenosis. J Neuropathol Exp Neurol 1978; 37: 56-74.
78.03 Masters CL and Richardson EP Jr. Subacute spongiform encephalopathy (Creutzfeldt-
Jakob disease): the nature and progression of spongiform change. Brain 1978; 101: 333-
344.
78.04 Gibbs CJ Jr, Gajdusek DC, Masters CL. Considerations of transmissible subacute and
chronic infections, with a summary of the clinical, pathological and virological
characteristics of kuru, Creutzfeldt-Jakob disease and scrapie. In: Senile Dementia: A
Biomedical Approach (Conference Proceedings): March, 1978; St. Louis. Edited by Nandy K.
Elsevier/North Holland Biomedical Press; New York, 1978: 115-130.
1979
79.01 Masters CL, Harris JO, Gajdusek DC, Gibbs CJ Jr, Bernoulli C, Asher DM. Creutzfeldt-
Jakob disease: patterns of worldwide occurrence and the significance of familial and
sporadic clustering. Ann Neurol 1979; 5: 177-188.
2

June, 2012
79.02 Gibbs CJ, Masters CL, Gajdusek DC. Bibliography of Creutzfeldt-Jakob Disease. NIH
Publication No. 79-1952. Bethesda: Public Health Service, National Institute of Health;
US Department of Health, Education and Welfare. 1979: 169pp.
79.03 Masters CL, Harris JO, Gajdusek DC, Gibbs CJ Jr, Bernoulli C, Asher DM. Creutzfeldt-
Jakob disease: patterns of worldwide occurrence. In: Slow Transmissible Diseases of the
Nervous System, Volume 1: Clinical, Epidemiological, Genetic and Pathological Aspects of the
Spongiform Encephalopathies. Edited by Prusiner SB, Hadlow WJ. New York: Academic
Press; 1979: 113-142.
79.04 Masters CL, Gajdusek DC, Gibbs CJ Jr, Bernoulli C, Asher DM. Familial Creutzfeldt-
Jakob disease and other familial dementias: an inquiry into possible modes of
transmission of virus-induced familial diseases. In: Slow Transmissible Diseases of the
Nervous System, Volume 1: Clinical, Epidemiological, Genetic and Pathological Aspects of the
Spongiform Encephalopathies. Edited by Prusiner SB, Hadlow WJ. New York: Academic
Press; 1979: 143-194.
79.05 Bernoulli CC, Masters CL, Gajdusek DC, Gibbs C Jr, Harris JO. Early clinical features of
Creutzfeldt-Jakob disease (subacute spongiform encephalopathy). In: Slow Transmissible
Diseases of the Nervous System, Volume 1: Clinical, Epidemiological, Genetic and Pathological
Aspects of the Spongiform Encephalopathies. Edited by Prusiner SB, Hadlow WJ. New
York: Academic Press; 1979: 229-251.
1980
80.01 Galvez S, Masters CL, Gajdusek DC. Descriptive epidemiology of Creutzfeldt-Jakob
disease in Chile. Arch Neurol 1980; 37: 11-14.
80.02 Baringer JR, Gajdusek DC, Gibbs CJ Jr, Masters CL, Stern EW, Terry RD. Transmissible
dementias: current problems in tissue handling. Neurology 1980; 30: 302-303.
80.03 Masters CL, Gajdusek DC, Gibbs CJ Jr. The spongiform encepalopathies: the natural
history of Creutzfeldt-Jakob disease and its relationship to kuru and scrapie. In: Search
for the Cause of Multiple Sclerosis and Other Chronic Diseases of the Central Nervous System -
The First International Symposi[um] of Hertie Foundation: September, 1979; Frankfurt.
Edited by Boese A. Verlag Chemie; Weinheim, 1980: 295-313.
80.04 Galvez S, Gajdusek DC, Masters CL. Transmission experimental de la enfermedad de
Creutzfeldt-Jakob al cobayo. Rev Med Chil 1980; 108: 299-303.
80.05 Goudsmit J, Morrow CH, Asher DM, Yanigahara RT, Masters CL, Gibbs CJ Jr,
Gajdusek DC. Evidence for and against the transmissibility of Alzheimer disease.
Neurology 1980; 30: 945-950.
80.06 Gibbs CJ Jr, Amyx HL, Bacote A, Masters CL, Gajdusek DC. Oral transmission of kuru,
Creutzfeldt-Jakob disease and scrapie to nonhuman primates. J Infect Dis 1980; 142:
205-208. [See also 04.24]
3

June, 2012
1981
81.01 Masters CL, Gajdusek DC, Gibbs CJ Jr. Problems of case ascertainment and diagnosis in
the epidemiology of dementia occurring in geographic isolates and worldwide. In: The
Epidemiology of Dementia. Edited by Mortimer JA, Schuman LM. London: Oxford
University Press; 1981: 155-170.
81.02 Schoene WC, Masters CL, Gibbs CJ Jr, Gajdusek DC, Tyler HR, Moore FD, Dammin GJ.
Transmissible spongiform encephalopathy (Creutzfeldt-Jakob disease): atypical clinical
and pathological findings. Arch Neurol 1981; 38: 473-477.
81.03 Masters CL, Gajdusek DC, Gibbs CJ Jr. The familial occurrence of Creutzfeldt-Jakob
disease and Alzheimer’s disease. Brain 1981; 104: 535-558.
81.04 Masters CL, Gajdusek DC, Gibbs CJ, Jr. Creutzfeldt-Jakob disease virus isolations from
the Gerstmann-Sträussler syndrome: with an analysis of the various forms of amyloid
plaque deposition in the virus-induced spongiform encephalopathies. Brain 1981; 104:
559-588.
81.05 Franko MC, Masters CL, Gibbs CJ Jr, Gajdusek DC. Monoclonal antibodies to central
nervous system antigens. J Neuroimmunol 1981; 1: 391-411.
81.06 Tan NT, Kakulas BA, Masters CL, Chen K-M, Gibbs CJ Jr, Gajdusek DC.
Neuropathology of the cortical lesions of the Parkinsonian-dementia (PD) complex of
Guam. Clin Exp Neurol 1981; 17: 227-234.
81.07 Landis DMD, Williams RS, Masters CL. Golgi and electronmicroscopic studies of
spongiform encephalopathy. Neurology 1981; 31: 538-549.
81.08 Monreal J, Collins GH, Masters CL, Fisher CM, Kim RC, Gibbs CJ Jr, Gajdusek DC.
Creutzfeldt-Jakob disease in an adolescent. J Neurol Sci 1981; 52: 341-350.
1982
82.01 Masters CL, Gajdusek DC. The spectrum of Creutzfeldt-Jakob disease and the virusinduced
subacute spongiform encephalopathies. In: Recent Advances in Neuropathology,
Volume 2. Edited by Smith WT, Cavanagh JB. Edinburgh: Churchill Livingstone; 1982:
139-163.
82.02 Nyberg P, Almay BGL, Carlsson A, Masters C, Winblad B. Brain monoamine
abnormalities in the two types of Creutzfeldt-Jakob disease. Acta Neurol Scand 1982;
66: 16-24.
82.03 Lagenaur C, Masters C, Schachner M. Changes in expression of glial antigens M1 and
C1 after cerebellar injury. J Neurosci 1982; 2: 470-476.
82.04 Moreau-Dubois M-C, Brown P, Rohwer RG, Masters CL, Franko M, Gajdusek DC.
Experimental scrapie in golden Syrian hamsters: temporal comparison of in vitro cellfusing
activity with brain infectivity and histopathological changes. Infect Immun
1982; 37: 195-199.
4

June, 2012
82.05 Masters CL. Is scrapie a zoonotic disease? In: Proceedings of an International Seminar on
Viral Diseases in South-East Asia and the Western Pacific: February, 1982; Canberra. Edited
by Mackenzie JS. Academic Press; Sydney, 1982: 670-671.
1983
83.01 Asher DM, Masters CL, Gajdusek DC, Gibbs CJ Jr. Familial spongiform
encephalopathies. In: Research Publications of the Association for Research in Nervous and
Mental Diseases, Volume 60: Genetics of Neurological and Psychiatric Disorders. Edited by
Kety SS, Rowland LP, Sidman RL, Matthysse SW. New York: Raven Press; 1983: 273-
291.
83.02 Merz PA, Wisniewski HM, Somerville RA, Bobin SA, Masters CL, Iqbal K.
Ultrastructural morphology of amyloid fibrils from neuritic and amyloid plaques. Acta
Neuropathol 1983; 60: 113-124.
83.03 Salazar AM, Masters CL, Gajdusek DC, Gibbs CJ Jr. Syndromes of amyotrophic lateral
sclerosis and dementia: relation to transmissible Creutzfeldt-Jakob disease. Ann
Neurol 1983; 14: 17-26.
83.04 Scrimgeour EM, Masters CL, Alpers MP, Kaven J, Gajdusek DC. A clinico-pathological
study of a case of kuru. J Neurol Sci 1983; 59: 265-275.
83.05 Schachner M, Sommer I, Lagenaur C, Masters C. Glial antigens C1 and M1 in normal
and abnormal development and after injury. In: Nervous System Regeneration, Volume 19:
Birth Defects: Original Article Series. Edited by Haber B, Perez-Polo JR, Hashim GA,
Stella AMG. New York: Alan R Liss; 1983: 315-325
83.06 Masters CL. CJD surveillance - Western Australia. Commun Dis Intell 1983; 83/25: 2-4.
1984
84.01 Masters CL, Rohwer RG, Franko MC, Brown P, Gajdusek DC. The sequential
development of spongiform change and gliosis of scrapie in the golden Syrian hamster.
J Neuropathol Exp Neurol 1984; 43: 242-252.
84.02 Masters CL. Virus-induced subacute spongiform encephalopathies (kuru and
Creutzfeldt-Jakob disease). In: Textbook of Clinical Virology. Edited by Belshe RB.
Littleton, Massachusetts: PSG Publishing Company Inc; 1984: 997-1010.
84.03 Masters CL. Etiology and pathogenesis of Alzheimer’s disease. Pathology 1984; 16: 233-
234.
84.04 Tan N, Kakulas BA, Masters CL, Gajdusek DC, Garruto RM, Chen KM, Gibbs CJ Jr.
Observations on the clinical presentations and the neuropathological findings of ALS in
Australia and Guam. In: Amyotrophic Lateral Sclerosis in Asia and Oceanea. Proceedings of
the Sixth Asian and Oceanean Congress of Neurology Amyotrophic Lateral Sclerosis Workshop:
November, 1983; Taipei. Edited by Chen KM, Yase Y. Shyan-Fu Chou, National Taiwan
University, 1984: 31-40.
5

June, 2012
1985
85.01 Masters CL, McDonald BL, Lagenauer C, Schachner M,Franko MC. Loop arrays in
mouse brain demonstrated with antisera to cytokeratins and monoclonal antibodies to
several classes of intermediate filaments: strain differences and developmental
expression. Brain Res 1985; 334: 267-279.
85.02 Masters CL, Jacobsen P, Kakulas BA. Decontamination of fixed cerebral tissues by
autoclaving in Creutzfeldt-Jakob disease without loss of microscopic visual quality. J
Neuropathol Exp Neurol1985; 44: 304-306.
85.03 Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K.
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl
Acad Sci USA 1985; 82: 4245-4249.
85.04 Martins RN, Stokes GB, Masters CL. Regulation of the 1 multiple molecular forms of
rat liver glucose 6-phosphate dehydrogenase by insulin and dietary restriction.
Biochem Biophys Res Commun 1985; 127: 136-142.
85.05 Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K. Neuronal
origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the
same protein as the amyloid of plaque cores and blood vessels. EMBO J 1985; 4: 2757-
2763.
1986
86.01 Harper CG, Day TJ, Masters CL. Rapidly progressive dementia with ataxia. Med J Aust
1986; 144: 24-28.
86.02 Martins RN, Stokes GB, Masters CL. Regulation of liver and brain hexose
monophosphate dehydrogenases by insulin and dietary intake in the female rat. Mol
Cell Biochem 1986; 70: 169-175.
86.03 Martins RN, Harper CG, Stokes GB, Masters CL. Increased cerebral glucose-6phosphate
dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J
Neurochem 1986; 46: 1042-1045.
86.04 Beyreuther K, Multhaup G, Simms G, Pottgeisser J, Schroder W, Martins R Masters CL.
Neurofibrillary tangles of Alzheimer's disease and 'aged' Down’s syndrome contain the
same protein as the amyloid of plaque cores and blood vessels. In: Discussions in
Neurosciences, Volume 3: Molecular Mechanisms of Pathogenesis of Central Nervous System
Disorders. Edited by Bignami A, Bolis L, Gajdusek DC. Geneva: Fondation pour l'Etude
du Systeme Nerveux; 1986: 68-79,143-157.
86.05 Masters C, Beyreuther K. The structure of amyloid filaments in Alzheimer's disease
and the unconventional virus infections of the nervous system. Psychol Med 1986; 16:
735-737.
6

June, 2012
86.06 Tan N, Kakulas BA, Masters CL, Gajdusek DC, Garruto RM, Chen KM, Gibbs CJ Jr.
Observations on the clinical presentations and the neuropathological findings of
amyotrophic lateral sclerosis in Australia and Guam. Ann Acad Med Singap 1986; 15:
62-66.
86.07 Masters CL, Jacobsen PF, Kakulas BA. Decontamination of formaldehyde fixed tissues
of Creutzfeldt-Jakob disease [Reply to Taylor DM]. J Neuropathol Exp Neurol 1986; 45:
760-761.
86.08 Masters CL, Beyreuther K. Amyloidogenic proteins in human central nervous system
diseases. In: Amyloidosis. Edited by Marrink J, van Rijswijk MH. Dordrecht: Martinus
Nijhoff; 1986: 149-157.
86.09 Masters CL. Amyloid proteins in Alzheimer's disease. Neurobiol Aging 1986; 7: 441-
443.
86.10 Masters CL. Disordered innervation of cerebral vasculature as a cause of Alzheimer's
disease plaques and tangles. Neurobiol Aging 1986; 7: 516.
1987
87.01 DropuliC B, Masters CL. Culture of mouse brain capillary endothelial cell lines that
express factor VIII, γ-glutamyl transpeptidase, and form junctional complexes in vitro.
In Vitro Cell Dev Biol1987; 23: 775-781.
87.02 Masters CL. Epidemiology of Creutzfeldt-Jakob disease: studies on the natural
mechanisms of transmission. In: Prions: Novel Infectious Pathogens Causing Scrapie and
Creutzfeldt-lakob Disease. Edited by Prusiner SB, McKinley MP. New York: Academic
Press; 1987: 511-522.
87.03 Masters CL, Beyreuther K. Neuronal origin of cerebral amyloidogenic proteins: their
role in Alzheimer's disease and unconventional virus diseases of the nervous system.
In: Ciba Foundation Symposium, Number 126: Selective Neuronal Death. Edited by Bock G,
OIConnor M. Chichester: Wiley; 1987: 49-64.
87.04 Guiroy DC, Miyazaki M, Multhaup G, Fischer P, Garruto RM, Beyreuther K, Masters
CL, Simms G, Gibbs CJ Jr, Gajdusek DC. Amyloid of neurofibrillary tangles of
Guamanian parkinsonism-dementia and Alzheimer disease share identical amino acid
sequence. Proc Natl Acad Sci USA 1987; 84: 2073-2077.
87.05 Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grzeschik K-H,
Multhaup G, Beyreuther K, Miiller-Hill B. The precursor of Alzheimer's disease
amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733-736.
87.06 Van Broeckhoven C, Genthe AM, Vandenberghe A, Horsthemke B, Backhovens H,
Raeymaekers P, Van Hul W, Wehnert A, Gheuens J, Cras P, Bruyland M, Martin JJ,
Salbaum M, Multhaup G, Masters CL, Beyreuther K, Gurling HMD, Mullan MJ,
Holland A, Barton A, Irving N, Williamson R, Richards SJ, Hardy JA. Failure of familial
Alzheimer's disease to segregate with the A4-amyloid gene in several European
families. Nature 1987; 329: 153-155.
7

June, 2012
87.07 Zabel BU, Salbaum JM, Multhaup G, Masters CL, Bohl J, Beyreuther K. Sublocalization
of the gene for the precursor of Alzheimer's disease amyloid A4 protein on
chromosome 21. In: Human Gene Mapping 9, Ninth International Workshop on Human
Gene Mapping: September, 1987; Paris. Cytogenet Cell Genet 1987; 46: 725-726.
1988
88.01 Masters CL, Beyreuther K. The blood-brain barrier in Alzheimer's disease and normal
aging. Neurobiol Aging 1988; 9: 43-44.
88.02 Masters CL, Beyreuther K. Neuropathology of unconventional virus infections:
molecular pathology of spongiform change and amyloid plaque deposition. In: Ciba
Foundation Symposium, Number 135: Novel Infectious Agents and the Central Nervous
System. Edited by Bock G, March J. Chichester: John Wiley & Sons Ltd; 1988: 24-36.
88.03 Masters CL, Beyreuther K. Amyloidogenic A4 protein subunit: clues to the
pathogenesis of the neurofibrillary tangle, Alzheimer plaque, and congophilic
angiopathy. In: Aging and the Brain, Volume 32. Edited by Terry RD. New York: Raven
Press; 1988: 183-204.
88.04 Zimmerman K, Herget T, Salbaum JM, Schubert W, Hilbich C, Cramer M, Masters CL,
Multhaup G, Kang J, Lemaire H-G, Beyreuther K, Starzinski-Powitz A. Localization of
the putative precursor of Alzheimer’s disease-specific amyloid at nuclear envelopes of
adult human muscle. EMBO J 1988; 7: 367-372.
88.05 Papadimitriou JM, Hockey A, Tan N, Masters CL. Rett syndrome: abnormal
membrane-bound lamellated inclusions in neurons and oligodendroglia. Am J Med
Genet 1988; 29: 365-368.
88.06 Dyrks T, Weidemann A, Multhaup G, Salbaum JM, Lemaire H-G, Kang J, Müller-Hill
B, Masters CL, Beyreuther K. Identification, transmembrane orientation and biogenesis
of the amyloid A4 precursor of Alzheimer's disease. EMBO J 1988; 7: 949-957.
88.07 Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, Beyreuther K,
Masters CL. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease:
prevalence in aged brains determined by immunocytochemistry compared with
conventional neuropathlogic techniques. Neurology 1988; 38: 1688-1693.
88.08 Beyreuther K, Beer J, Hilbich C, Dyrks T, Fischer P, Weidemann A, Mönning U,
Multhaup G, Cramer M, Salbaum JM, Wehr S, Martins R, Simms G, Rumble B, Fuller S,
Hutchinson L, Masters CL. Molecular pathology of amyloid deposition in Alzheimer's
disease. In: Etiology of Dementia of Alzheimer's Type. Dahlem Konferenzen. Edited by
Henderson AS, Henderson JH. Chichester: John Wiley & Sons Ltd; 1988: 125-134.
88.09 Masters CL, Martins R, Simms G, Rumble B, Fuller S, Hutchinson L, Beer J, Hilbich C,
Dyrks T, Fischer P, Weidemann A, Mönning U, Multhaup G, Cramer M, Salbaum JM,
Wehr S, Beyreuther K. The molecular basis of cerebral amyloidosis in Alzheimer's
disease and the unconventional virus diseases. In: Research and Perspectives in
Alzheimer's Disease: Immunology and Alzheimer's Disease. Edited by Pouplard-Barthelaix
A, Emile J, Christen Y. Berlin: Fondation Ipsen, Springer Verlag; 1988: 88-95.
8

June, 2012
88.10 Beyreuther K, Salbaum JM, Dyrks T, Genthe A, Weidemann A, Hilbich C, Multhaup G,
Horsthemke B, Zabel P, Masters CL. Genetics, expression and localization of the
amyloid precursor of Alzheimer's disease. In: Research and Perspectives in Alzheimer's
Disease: Immunology and Alzheimer's Disease. Edited by Pouplard-Barthelaix A, Emile J,
Christen Y. Berlin: Fondation Ipsen, Springer Verlag; 1988: 96-97.
88.11 Masters CL, Martins R, Simms G, Rumble B, Fuller S Beer J, Hilbich C, Dyrks T, Fischer
P, Weidemann A, Mönning U, Multhaup G, Salbaum JM, Beyreuther K. Cerebral
amyloidosis in Alzheimer's disease and the unconventional virus diseases. In:
Discussions in Neuroscience, Volume 5: Molecular Genetic Mechanisms in Neurological
Disorders. Edited by Brown P, Bolis CL, Gajdusek DC. Paris: Fondation pour l'Etude du
Système Nerveux. 1988; 5: 51-57,145-162.
88.12 Beyreuther K, Weidemann A, Salbaum JM, Dyrks T, Multhaup G, Fischer GP, Hilbich
C, König G, Beer J, Bunke D, Mönning U, Simms G, Martins R, Rumble B, Masters CL.
Alzheimer's disease A4 protein and the PAD gene product. In: The Molecular Biology of
Alzheimer's Disease: Current Communications in Molecular Biology. Edited by Finch CE,
Davies P. New York: Cold Spring Harbor Press; 1988: 71-79.
88.13 Masters CL, Multhaup G, Salbaum JM, Weidemann A, Dyrks T, Hilbich C, Martins R,
Simms G, Rumble B, Beyreuther K. Alzheimer's disease and the precursor of the A4
amyloid protein. In: The Molecular Biology of Alzheimer's Disease: Current Communications
in Molecular Biology. Edited by Finch CE, Davies P. New York: Cold Spring Harbor
Press; 1988: 129-136.
88.14 Salbaum JM, Weidemann A, Lemaire H-G, Masters CL, Beyreuther K. The promoter of
Alzheimer's disease amyloid A4 precursor gene. EMBO J 1988; 7: 2807-2813.
1989
89.01 Weidemann A, König G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K.
Identification, biogenesis, and localization of precursors of Alzheimer's disease A4
amyloid protein. Cell 1989; 57: 115-126.
89.02 Rozemuller JM, Eikelenboom P, Stam FC, Beyreuther K, Masters CL. A4 protein in
Alzheimer’s disease: primary and secondary cellular events in extracellular amyloid
deposition. J Neuropathol Exp Neurol 1989; 48: 674-691.
89.03 Nochlin D, Sumi SM, Bird TD, Snow AD, Leventhal CM, Beyreuther K, Masters CL.
Familial dementia with PrP-positive amyloid plaques: a variant of Gerstmann-
Sträussler syndrome. Neurology 1989; 39: 910-918.
89.04 Ghetti B, Tagliavini F, Masters CL, Beyreuther K, Giaccone G, Verga L, Farlow MR,
Conneally PM, Dlouhy SR, Azzarelli B, Bugiani O. Gerstmann-Sträussler-Scheinker
disease: II. Neurofibrillary tangles and plaques with PrP-amyloid coexist in an affected
family. Neurology 1989; 39: 1453-1461.
9

June, 2012
89.05 Mastaglia FL, Masters CL, Beyreuther K, Kakulas BA. Deposition of Alzheimer's
disease amyloid (A4) protein in the cerebral cortex in Parkinson's disease. In:
Alzheimer's Disease and Related Disorders: Progress in Clinical and Biological Research.
Edited by Iqbal K, Wisniewski HM, Winblad B. New York: Alan R Liss Inc; 1989: 475-
484.
89.06 Dyrks T, König G, Hilbich C, Masters CL, Beyreuther K. Molecular pathology of the
amyloid A4 precursor of Alzheimer's disease. In: Alzheimer's Disease and Related
Disorders: Progress in Clinical and Biological Research. Edited by Iqbal K, Wisniewski HM,
Winblad B. New York: Alan R Liss Inc; 1989: 877-891.
89.07 Salbaum JM, Weidemann A, Masters CL, Beyreuther K. The promoter of Alzheimer's
disease amyloid A4 precursor gene. In: Alzheimer's Disease and Related Disorders:
Progress in Clinical and Biological Research. Edited by Iqbal K, Wisniewski HM, Winblad
B. New York: Alan R Liss Inc; 1989: 277-283.
89.08 Konig G, Beyreuther K, Masters CL, Schmitt HP, Salbaum JM. PreA4 mRNA
distribution in brain areas. In: Alzheimer's Disease and Related Disorders: Progress in
Clinical and Biological Research. Edited by Iqbal K, Wisniewski HM, Winblad B. New
York: Alan R Liss Inc; 1989: 1027-1036.
89.09 Masters CL, Beyreuther K. The molecular pathology of the amyloid A4 precursor
(PreA4) and its gene (PAD) in Alzheimer's disease. In: Proceedings of the Australian
Rotary Health Research Fund 3rd International Conference on Alzheimer's Disease: October,
1988; Canberra. Allanby Press, Melbourne. Aust J Aging 1989; 105-110.
89.10 Hyman BT, Van Hoesen GW, Beyreuther K, Masters CL. A4 amyloid protein
immunoreactivity is present in Alzheimer's disease neurofibrillary tangles. Neurosci
Lett 1989; 101: 352-355.
89.11 Masters CL, Beyreuther K. The pathology of the amyloid A4 precursor of Alzheimer's
disease. Ann Med 1989; 21: 89-90.
89.12 Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, Hockey A,
Montgomery P, Beyreuther K, Masters CL. Amyloid A4 protein and its precursor in
Down's syndrome and Alzheimer's disease. N Engl J Med 1989; 320: 1446-1452.
89.13 Masters CL, Martins R, Simms G, Rumble B, Fuller S, Beer J, Hilbich C, Dyrks T, Fischer
P, Weidemann A, Mönning U, Multhaup G, Cramer M, Salbaum JM, Wehr S,
Beyreuther K. The molecular basis of amyloid protein deposition in Alzheimer's
disease and the unconventional virus diseases. In: Familial Alzheimer's Disease: Molecular
Genetics and Clinical Perspectives. Edited by Miner GD, Richter RW, Blass JP, Valentine
JL, Winters-Miner LA. New York: Marcel Dekker; 1989: 173-182.
89.14 Mann DMA, Brown A, Prinja D, Davies CA, Landon M, Masters CL, Beyreuther K. An
analysis of the morphology of senile plaques in Down's syndrome patients of different
ages using immunocytochemical and lectin histochemical techniques. Neuropathol
Appl Neurobiol 1989; 15: 317-329.
10

June, 2012
89.15 Masters CL. Creutzfeldt-Jakob disease: its origins. (Appendix 1: Bibliography of Alfons
Jakob. Appendix 2: Creutzfeldt-Jakob disease: synonyms, equivalents and variations
thereof). Alzheimer Dis Assoc Disord 1989; 3: 46-51.
89.16 Salbaum JM, Masters C, Beyreuther K. The amyloid gene of Alzheimer's disease and
neuronal dysfunction. In: Biological Markers of Alzheimer's Disease: Research and
Perspectives in Alzheimer's Disease. Edited by Boller F, Katzman R, Rascol A, Signoret J-
L, Christen Y. Berlin: Fondation Ipsen, Springer-Verlag; 1989: 118-122.
89.17 Masters CL, Beyreuther K. Amyloid A4 protein and its precursor in Down's syndrome
and Alzheimer's disease. N Engl J Med 1989; 321: 1197.
89.18 Masters CL. Alzheimer's link still unproven [Reply to Ashton JF, Laura RS].
Aluminium and health: the risks of dietary aluminium. Search (Syd) 1989; 20: 182.
89.19 Guo Y-P, Masters CL, Feng Y-K, Huang H-F, Gao S-F, Zhang X-G, Han Z-Y, Zhao M-L,
Zhang S, Wang G-X. [Virus-induced subacute spongiform encephalopathy
(Creutzfeldt-Jakob disease): A report of 10 cases with clinico-pathological study].
Zhonghua Shen Jing Jing Shen Ke Za Zhi 1989; 22: 289-293.
89.20 Beyreuther K, Multhaup G, Salbaum JM, Weidemann A, Dyrks T, Hilbich C, Fischer P,
Bunke D, König G, Mönning U, Beer J, Schubert W, Masters CL. The role of the
amyloid (PAD/APP) gene in Alzheimer's disease: molecular pathology and therapeutic
implications. In: Pharmacological Interventions on Central Cholinergic Mechanisms in Senile
Dementia (Alzheimer's Disease). Edited by Kewitz H, Thomsen T, Bickel U. Munchen: W.
Zuckschwerdt Verlag GmbH; 1989: 65-72.
1990
90.01 Beyreuther K, Dyrks T, Multhaup G, Salbaum JM, Schubert W, Weidemann A, Masters
CL. Molecular genetics of dementia of Alzheimer’s type: towards an early warning and
treatment for individuals at risk. In: Biological Markers in Dementia of Alzheimer Type.
Proceedings of the Stiftelsen Gamla Tjänarinnor Symposium on Aging and Aging Disorders
No. 1. Edited by Fowler CJ, Carlson LA, Gottfries C-G, Winblad B. Smith-Gordon,
London; 1990: 49-60.
90.02 Masters CL, Beyreuther K. Amyloid deposition in Alzheimer’s disease: the molecular
pathology of precursor-product interactions. In: Molecular Biology and Genetics of
Alzheimer’s Disease. Proceedings of the International Symposium on Dementia: November
11-14, 1989; Niigata, Japan. Edited by Miyatake T, Selkoe DJ, Ihara Y. Excerpta Medica,
Amsterdam. International Congress Series 1990; No. 884: 123-135.
90.03 Masters CL, Beyreuther K. Amyloid βA4 protein deposition in Alzheimer’s disease and
Down’s syndrome. In: Molecular Mechanisms of Aging. Edited by Beyreuther K, Schettler
G. Berlin: Springer; 1990: 185-194.
90.04 Masters CL, Beyreuther K. Protein abnormalities in neurofibrillary tangles: their
relation to the extracellular amyloid deposits of the A4 protein in Alzheimer’s disease.
In: Alzheimer’s Disease: Advances in Basic Research and Therapies. Proceedings of the Fifth
Meeting of the International Study Group on the Pharmacology of Memory Disorders
11

June, 2012
Associated with Aging: January, 1989; Zurich. Edited by Wurtman RJ, Corkin S,
Growden JH, Ritter-Walker E. Center for Brain Sciences and Metabolism Charitable
Trust, Cambridge (MA, USA); 1990: 235-267. Also in: Alzheimer’s Disease. Edited by
Wurtman RJ, Corkin S, Groudin JH, Ritter-Walker E. New York: Raven Press. Adv
Neurol 1990; 51: 151-161.
90.05 Masters CL, Beyreuther K. The molecular pathology of the amyloid A4 precursor
(PreA4) and its gene (PAD) in Alzheimer’s disease. In: Brain Aging: Molecular Biology,
the Aging Process and Neurodegenerative Disease. Proceedings of the 5th Annual International
Symposium on Neuronal Control of Bodily Function – Basic and Clinical Aspects. November
8-11, 1988; Indianapolis. Edited by Hendrie HC, Mendelsohn LG, Readhead C. Hogrefe
and Huber, Toronto; 1990: 81-98.
90.06 Beyreuther K, Masters CL. Nomenclature of amyloid A4 proteins and their precursors
in Alzheimer’s disease and Down’s syndrome. Neurobiol Aging 1990; 11: 66-68.
90.07 Dropulić B, Masters CL. Entry of neurotropic arboviruses into the central nervous
system. An in vitro study using mouse brain endothelium. J Infect Dis 1990; 161: 685-
691.
90.08 Irving WL, Crimmins DS, Masters CL, Cunningham AL. Creutzfeldt-Jakob disease and
slow infections: a review. Aust N Z J Med 1990; 20: 283-290.
90.09 Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P,
Masters CL, Price DL. Precursor of amyloid protein in Alzheimer disease undergoes
fast anterograde axonal transport. Proc Natl Acad Sci USA 1990; 87: 1561-1565.
90.10 Richards S-J, Waters JJ, Rogers DC, Martel FL, Sparkman DR, White CL, Beyreuther K,
Masters CL, Dunnett SB. Hippocampal grafts derived from embryonic trisomy 16 mice
exhibit amyloid (A4) and neurofibrillary pathology. Prog Brain Res 1990; 82: 215-223.
90.11 Walker LC, Masters C, Beyreuther K, Price DL. Amyloid in the brains of aged squirrel
monkeys. Acta Neuropathol 1990; 80: 381-387.
90.12 Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, Currie J, Ames D,
Weidemann A, Fischer P, Multhaup G, Beyreuther K, Masters C. The amyloid
precursor protein of Alzheimer’s disease is released by human platelets. J Biol Chem
1990; 265: 15977-15983.
90.13 Salbaum JM, König G, Beer J, Multhaup G, Masters CL, Beyreuther K. Regulation of the
amyloid gene of Alzheimer’s disease. In: Molecular Mechanisms of Aging. Edited by
Beyreuther K, Schettler G. Berlin: Springer; 1990: 89-96.
90.14 Catteruccia N, Willingale-Theune J, Bunke D, Prior R, Masters CL, Crisanti A,
Beyreuther K. Ultrastructural localization of the putative precursors of A4 amyloid
protein associated with Alzheimer’s disease. Am J Pathol 1990; 137: 19-26.
12

June, 2012
90.15 Delaère P, Duyckaerts C, Masters C, Beyreuther K, Piette F, Hauw J-J. Large amounts of
neocortical βA4 deposits without neuritic plaques nor tangles in a psychometrically
assessed, non-demented person. Neurosci Lett 1990; 116: 87-93.
90.16 König G, Masters CL, Beyreuther K. Retinoic acid induced differentiated
neuroblastoma cells show increased expression of the βA4 amyloid gene of Alzheimer’s
disease and an altered splicing pattern. FEBS Lett 1990; 269: 305-310.
90.17 Weidemann A, König G, Fischer P, Bunke D, Salbaum JM, Beer J, Mönning U, Schubert
W, Masters CL, Beyreuther K. Biosynthesis, localization and processing of precursors
of amyloid A4 protein in Alzheimer’s disease. In: Taniguchi Symposia on Brain Sciences,
No. 13: Aging of the Brain: Cellular and Molecular Aspects of Brain Aging and Alzheimer’s
Disease. Edited by Nagatsu T, Hayaishi O. Tokyo: Japan Scientific Societies Press; 1990;
279-287.
90.18 Cork LC, Masters CL, Beyreuther K, Price DL. Development of senile plaques:
Relationships of neuronal abnormalities and amyloid deposits. Am J Pathol 1990; 137:
1383-1392.
90.19 Sorimachi K, Craik DJ, Lloyd EJ, Beyreuther K, Masters CL. Identification of a β-turn in
the tertiary structure of a peptide fragment of the Alzheimer amyloid protein. Biochem
Int 1990; 22: 447-454.
90.20 Masters CL. Immunoreactive epidermal growth factor receptors in neuritic plaques
from patients with Alzheimer’s disease. Transmission: Biol Psychiat Clin Pract 1990;
2: 11, 18.
90.21 Mönning U, König G, Prior R, Mechler H, Schreiter-Gasser U, Masters CL, Beyreuther
K. Synthesis and secretion of Alzheimer amyloid βA4 precursor protein by stimulated
human peripheral blood leucocytes. FEBS Lett 1990; 277: 261-266.
90.22 Masters CL, Beyreuther K. Amyloid deposition in Alzheimer’s disease: the molecular
pathology of precursor-product interactions. Chiron 1990; 2: 15-17.
90.23 Masters CL, Beyreuther K. Alzheimer’s disease: the role of βA4 amyloid precursor
protein. Curr Opin Neurol Neurosurg 1990; 3: 963-965.
1991
91.01 Bunke D, Mönning U, Kypta RM, Courtneidge SA, Masters CL, Beyreuther KT.
Tyrosine phosphorylation of the cytoplasmic domain of Alzheimer protein precursors.
In: Alzheimer’s Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies. Proceedings
of Second International Conference on Alzheimer’s Disease and Related Disorders: July 15-20,
1990; Toronto. Edited by Iqbal K, McLachlan DRC, Winblad B, Wisniewski HM. John
Wiley and Sons Ltd, Chichester; 1991: 229-235.
91.02 Dyrks T, Mack E, Masters CL, Beyreuther K. Membrane insertion prevents aggregation
of precursor fragments containing the β/A4 sequence of Alzheimer’s disease. In:
Alzheimer’s Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies. Proceedings of
Second International Conference on Alzheimer’s Disease and Related Disorders: July 15-20,
13

June, 2012
1990; Toronto. Edited by Iqbal K, McLachlan DRC, Winblad B, Wisniewski HM. John
Wiley and Sons Ltd, Chichester; 1991: 281-287.
91.03 Beer J, Salbaum JM, Schlichtmann E, Hoppe P, Earley S, Carlson GA, Masters CL,
Beyreuther K. Transgenic mice and Alzheimer’s disease. In: Alzheimer’s Disease: Basic
Mechanisms, Diagnosis and Therapeutic Strategies. Proceedings of Second International
Conference on Alzheimer’s Disease and Related Disorders: July 15-20, 1990; Toronto. Edited
by Iqbal K, McLachlan DRC, Winblad B, Wisniewski HM. John Wiley and Sons Ltd,
Chichester; 1991: 473-478.
91.04 Richards S-J, Waters JJ, Wischik C, Sparkman DR, White CL III, Beyreuther K, Masters
C, Abraham CR, Dunnett SB. A new model for studying the neuropathology of
Alzheimer’s disease derived from transplantation of trisomy 16 CNS tissues. In:
Alzheimer’s Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies. Proceedings of
Second International Conference on Alzheimer’s Disease and Related Disorders: July 15-20,
1990; Toronto. Edited by Iqbal K, McLachlan DRC, Winblad B, Wisniewski HM. John
Wiley and Sons Ltd, Chichester; 1991: 487-497.
91.05 Prior R, Mönning U, Weidemann A, Fischer P, Blennow K, Wallin A, Gottfries CG,
Masters CL, Beyruther K. ELISA quantitation of the amyloid A4 precursor protein in
cerebrospinal fluid. In: Alzheimer’s Disease: Basic Mechanisms, Diagnosis and Therapeutic
Strategies. Proceedings of Second International Conference on Alzheimer’s Disease and Related
Disorders: July 15-20, 1990; Toronto. Edited by Iqbal K, McLachlan DRC, Winblad B,
Wisniewski HM. John Wiley and Sons Ltd, Chichester; 1991: 533-540.
91.06 Bush AI, Beyreuther K, Masters CL. Circulating forms of amyloid precursor protein of
Alzheimer’s disease. In: Alzheimer’s Disease: Basic Mechanisms, Diagnosis and Therapeutic
Strategies. Proceedings of Second International Conference on Alzheimer’s Disease and Related
Disorders: July 15-20, 1990; Toronto. Edited by Iqbal K, McLachlan DRC, Winblad B,
Wisniewski HM. John Wiley and Sons Ltd, Chichester; 1991: 547-555.
91.07 Mönning U, Schreiter-Gasser U, Hilbich C, Bunke D, Prior R, Masters CL, Beyreuther
K. Alzheimer amyloid β/A4 protein-reactive antibodies in human sera and CSF. In:
Alzheimer’s Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies. Proceedings of
Second International Conference on Alzheimer’s Disease and Related Disorders: July 15-20,
1990; Toronto. Edited by Iqbal K, McLachlan DRC, Winblad B, Wisniewski HM. John
Wiley and Sons Ltd, Chichester; 1991: 557-563.
91.08 Masters CL, Beyreuther K. The role of amyloid formation in Alzheimer’s disease. In:
Proceedings of the XIth International Congress of Neuropathology: September 2-8, 1990;
Kyoto. Japanese Society of Neuropathology, Kyoto; Neuropathology 1991; Suppl 4:
128-135.
91.09 Masters CL, Beyreuther K. Molecular pathology of the amyloid βA4 precursor protein.
In: Proceedings of Medical Bioscience Symposium on the Biological Aspects of Alzheimer’s
Disease: September 14, 1990; Kumamoto. Kumamoto University Medical School,
Kumamoto. Kumamoto Med J 1991; 42 (Suppl):S4-S5.
14

June, 2012
91.10 Beyreuther K, Masters CL. Mechanisms and implications of amyloid depositions in
Alzheimer’s disease. In: Proceedings of Medical Bioscience Symposium on the Biological
Aspects of Alzheimer’s Disease: September 14, 1990; Kumamoto. Kumamoto University
Medical School, Kumamoto. Kumamoto Med J 1991; 42 (Suppl): S6-S8.
91.11 Prior R, Mönning U, Schreiter-Gasser U, Weidemann A, Blennow K, Gottfries CG,
Masters CL, Beyreuther K. Quantitative changes in the amyloid βA4 precursor protein
in Alzheimer cerebrospinal fluid. Neurosci Lett 1991; 124: 69-73.
91.12 Richards S-J, Waters JJ, Beyreuther K, Masters CL, Wischik CM, Sparkman DR, White
CL, Abraham CR, Dunnett SB. Transplants of mouse trisomy 16 hippocampus provide
a model of Alzheimer’s disease neuropathology. EMBO J 1991; 10: 297-303.
91.13 Masters CL. Virus-induced subacute spongiform encephalopathies (Kuru and
Creutzfeldt-Jakob disease). In: Textbook of Human Virology, Second edition. Edited by
Belshe RB. St. Louis: Mosby Year Book; 1991; 1001-1011.
91.14 Martin JJ, Gheuens J, Bruyland M, Cras P, Vandenberghe A, Masters CL, Beyreuther K,
Dom R, Ceuterick C, Lübke U, Van Heuverswijn H, De Winter G, Van Broeckhoven C.
Early-onset Alzheimer’s disease in 2 large Belgian families. Neurology 1991; 41: 62-68.
91.15 Le Coz P, Mikol J, Ferrand J, Woimant F, Masters C, Beyreuther K, Haguenau M,
Cophignon J, Pepin B. Granulomatous angiitis and cerebral amyloid angiopathy
presenting as a mass lesion. Neuropathol Appl Neurobiol 1991; 17: 149-155.
91.16 Martin LJ, Sisodia SS, Koo EH, Cork LC, Dellovade TL, Weidemann A, Beyreuther K,
Masters C, Price DL. Amyloid precursor protein in aged nonhuman primates. Proc
Natl Acad Sci USA 1991; 88: 1461-1465.
91.17 Masters CL, Beyreuther K. Molecular pathology of amyloid βA4 protein deposition in
Alzheimer’s disease and Down’s syndrome. In: Modern Trends in Neurology. Edited by
Chopra JS, Jagannathan K, Sawhney IMS. New Delhi: B.I. Churchill Livingstone; 1991;
183-191.
91.18 Masters CL, Beyreuther K. Amyloid: Cause or effect in Alzheimer’s disease? In:
Neurodegenerative Disorders: Mechanisms and Prospects for Therapy. Report of the Dahlem
Workshop on New Biological Approaches to Neurological Disorders: Pathogenesis and
Treatment, August 5-10, 1991; Berlin. Edited by Price DL, Thoenen H, Aguayo AJ. John
Wiley & Sons, Berlin; 1991: 75-86.
91.19 Harding AE, Anderton BH, Beyreuther K, Dyrks T, Goedert M, Goldgaber DY, Masters
CL, Prusiner SB, Schubert W, Tanzi RE, Unterbeck AJ. Group Report: Molecular genetic
mechanisms of neurological diseases. In: Neurodegenerative Disorders: Mechanisms and
Prospects for Therapy. Report of the Dahlem Workshop on New Biological Approaches to
Neurological Disorders: Pathogenesis and Treatment, August 5-10, 1991; Berlin. Edited by
Price DL, Thoenen H, Aguayo AJ. John Wiley & Sons, Berlin; 1991: 251-258.
15

91.20 Prior R, Masters CL, Beyreuther K. Molekulare Pathogenese der Alzheimerschen
Krankeit. CLB Chem Labor Biotech 1991; 42: 483-486.
June, 2012
91.21 König G, Salbaum JM, Wiestler O, Lang W, Schmitt HP, Masters CL, Beyreuther K.
Alternative splicing of the βA4 amyloid gene of Alzheimer’s disease in cortex of control
and Alzheimer’s disease patients. Mol Brain Res 1991; 9: 259-262.
91.22 Matkovic Z, Davis S, Gonzales M, Kalnins R, Masters CL. Surgical risk of hemorrhage
in cerebral amyloid angiopathy. Stroke 1991; 22: 456-461.
91.23 Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Aggregation and
secondary structure of synthetic amyloid βA4 peptides of Alzheimer’s disease. J Mol
Biol 1991; 218: 149-163.
91.24 Small DH, Moir RD, Fuller SJ, Michaelson S, Bush AI, Li Q-X, Milward E, Hilbich C,
Weidemann A, Beyreuther K, Masters CL. A protease activity associated with
acetylcholinesterase releases the membrane-bound form of the amyloid protein
precursor of Alzheimer’s disease. Biochemistry 1991; 30: 10795-10799.
91.25 Schubert W, Prior R, Weidemann A, Dircksen H, Multhaup G, Masters CL, Beyreuther
K. Localization of Alzheimer βA4 amyloid precursor protein at central and peripheral
synaptic sites. Brain Res 1991; 563: 184-194.
91.26 Masters CL. The medical background to Alzheimer’s disease. In: When I Grow Too Old
to Dream - Coping with Alzheimer’s Disease. Edited by Naughtin G, Laidler T. Melbourne:
Collins Dove; 1991: 9-14.
91.27 Beyreuther K, Bush AI, Dyrks T, Hilbich C, König G, Mönning U, Multhaup G, Prior R,
Rumble B, Schubert W, Small DH, Weidemann A, Masters CL. Mechanisms of amyloid
deposition in Alzheimer’s disease. In: Aging and Alzheimer’s Disease: Sensory Systems,
Neuronal Growth and Neuronal Metabolism. Proceedings of the Sixth Meeting of the
International Study Group on the Pharmacology of Memory Disorders Associated with Aging:
February, 1991; Zurich. Edited by Growdon JH, Corkin S, Ritter-Walker E, Wurtmann
RJ. Ann N Y Acad Sci 1991; 640: 129-139.
91.28 Rumble BA, Beyreuther K, Masters CL. The molecular pathology of Alzheimer’s
disease. Today’s Life Sci 1991; 4: 24-31.
91.29 Gajdusek DC, Beyreuther K, Brown P, Cork LC, Cunningham DD, Frangione B, Gibbs
CJ, Goldfarb LG, Goldgaber D, Hsiao KK, Koo EH, Martin LJ, Masters CL, Odenwald
WF, Price DD, Prusiner SB, Ruddle FH, Safar J, Scangos G, Schmechel DE, Shashikant
CS, Schlichta PJ, Sisodia SS, Trapp BD, Unterbeck A, Van Nostrand WE, Violette SM,
Walker LC, Wirak D. Regulation and genetic control of brain amyloid. Brain Res Rev
1991; 16: 83-114. [See also: Beyreuther K, Masters CL. Amyloid genes and neuronal
dysfunction. Brain Res Rev 1991; 16: 86-88]
91.30 Mackenzie IRA, McKelvie PA, Beyreuther K, Masters CL. βA4 amyloid protein
deposition in the cerebellum in Alzheimer’s disease and Down’s syndrome. Dementia
1991; 2: 237-242.
16

June, 2012
91.31 Godec MS, Asher DM, Masters CL, Kozachuk WE, Freidland RP, Gibbs CJ Jr, Gajdusek
DC, Rapoport SI, Schapiro MB. Evidence against the transmissibility of Alzheimer’s
disease. Neurology 1991; 41: 1320.
91.32 Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Human and rodent
sequence analogs of Alzheimer’s amyloid βA4 share similar properties and can be
solubilized in buffers of pH 7.4. Eur J Biochem 1991; 201: 61-69.
91.33 Bauer J, König G, Strauss S, Jonas U, Ganter U, Weidemann A, Mönning U, Masters CL,
Volk B, Berger M, Beyreuther K. In-vitro matured human macrophages express
Alzheimer’s βA4-amyloid precursor protein indicating synthesis in microglial cells.
FEBS Lett 1991; 282: 335-340.
91.34 Masters CL, Beyreuther K. Alzheimer’s disease: molecular basis of structural lesions.
Brain Pathol 1991; 1:226-227.
91.35 Beyreuther K, Masters CL. Amyloid precursor protein (APP) and βA4 amyloid in the
etiology of Alzheimer’s disease: precursor-product relationships in the derangement of
neuronal function. Brain Pathol 1991; 1: 241-251.
91.36 Beyreuther K, Multhaup G, Masters CL. Demenz vom Alzheimer-Typ. Biochemische
Aspekte. Akademie für Pharmazeutische Fortbildung der Landesapothekerkammer,
Giessen. Deutsche Apotheker Zeitung 1991; 131: 1414-1422.
91.37 Bush AI, Beyreuther K, Masters CL. Studies of circulating forms of amyloid precursor
protein of Alzheimer’s disease. In: Proceedings of the Scientific Meeting accompanying the
57th Beattie Smith Lecture: The University, Psychiatry and the Care of the Mentally Ill.
Department of Psychiatry, The University Of Melbourne: March 26, 1991; Melbourne.
Edited by Burrows GD. The University of Melbourne, Melbourne 1991: 14-23.
91.38 Masters CL, Beyreuther K. The pathology of amyloid deposition: cause or effect in
Alzheimer’s disease? In: Frontiers of Alzheimer Research. Proceedings of the 5th
International Symposium of the Psychiatric Research Institute of Tokyo (PRIT): September
10-12, 1990; Tokyo. Edited by Ishii T, Allsop D, Selkoe DJ. Excerpta Medica,
Amsterdam; 1991: 75-85.
91.39 Masters CL. Spongiform encephalopathies: structural lesions. Neuroscience Facts 1991;
2(No. 19): 4.
91.40 Beyreuther K, Masters CL. Molekularbiologie und Genetik der Alzheimer Krankheit.
In: Materie und Prozesse: Vom Elementaren zum Komplexen. Verhandlungen der Gesellschaft
Deutscher Naturforscher und Ärzte: September 22-25, 1990; Berlin. Edited by Gerok W,
Martienssen W, Roesky HW, Scriba PC, Trautner TA, Krauch H, Gibian H, Truscheit E.
Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart; 1991: 225-250.
91.41 Beyreuther K, Masters CL. Alzheimersche Krankheit - Den Ursachen auf der Spur.
Geriatrie Praxis 1991; 3: 44-50.
17

June, 2012
91.42 Beyreuther K, Masters CL. Alzheimersche Krankheit - Sind Ansätze für die kausale
Therapie möglich? Geriatrie Praxis 1991; 3: 61-64.
91.43 Martins RN, Robinson PJ, Chleboun JO, Beyreuther K, Masters CL. The molecular
pathology of amyloid deposition in Alzheimer’s disease. Mol Neurobiol 1991; 5: 389-
398.
1992
92.01 Dyrks T, Dyrks E, Hartmann T, Masters C, Beyreuther K. Amyloidogenicity of βA4 and
βA4 -bearing amyloid protein precursor fragments by metal catalysed oxidation. J Biol
Chem 1992; 267: 18210-18217.
92.02 Bush AI, Whyte S, Thomas LD, Williamson TG, Van Tiggelen CJ, Currie J, Small DH,
Moir RD, Li Q-X, Rumble B, Mönning U, Beyreuther K, Masters CL. An abnormality of
plasma amyloid protein precursor in Alzheimer’s disease. Ann Neurol 1992; 32: 57-65.
92.03 Beyreuther K, Multhaup G, Prior R, Masters CL. Neurobiologie der Alzheimerschen
Krankheit. In: Psychische Krankheiten und Hirnfunktion im Alter. Edited by Häfner H,
Hennerici M. Stuttgart: Gustav Fischer; 1992: 61-78.
92.04 Prior R, Mönning U, Masters CL, Beyreuther K. Unravelling the molecular defect in
Alzheimer’s disease. In: Biology of Aging. Edited by Zwilling R, Balduini C. Berlin:
Springer; 1992: 72-81.
92.05 König G, Masters CL, Beyreuther K. Expression of Alzheimer’s amyloid gene in
development, aging and Alzheimer’s disease. In: Biology of Aging. Edited by Zwilling R,
Balduini C. Berlin: Springer; 1992: 82-99.
92.06 Beyreuther K, Hilbich C, König G, Multhaup G, Masters CL. Molecular pathology and
aetiology of Alzheimer’s disease. In: Genetic Research in Psychiatry. Second Collegium
Internationale NeuroPsychopharmacologicum, C.I.N.P. President’s Workshop: September 12-
15, 1991; Munich. Edited by Mendlewicz J, Hippius H. Springer, Berlin; 1992: 88-105.
92.07 Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, Masters CL.
The amyloid protein precursor of Alzheimer’s disease is a mediator of the effects of
nerve growth factor on neurite outgrowth. Neuron 1992; 9: 129-137.
92.08 Small DH, Nurcombe V, Moir R, Michaelson S, Monard D, Beyreuther K, Masters CL.
Association and release of the amyloid protein precursor of Alzheimer’s disease from
chick brain extracellular matrix. J Neurosci 1992; 12: 4143-4150.
92.09 Moir RD, Martins RN, Bush AI, Small DH, Milward EA, Rumble BA, Multhaup G,
Beyreuther K, Masters CL. Human brain βA4 amyloid protein precursor of Alzheimer’s
disease: purification and partial characterization. J Neurochem 1992; 59: 1490-1498.
92.10 Pollwein P, Masters CL, Beyreuther K. The expression of the amyloid precursor protein
(APP) is regulated by two GC-elements in the promoter. Nucleic Acids Res 1992; 20:
63-68.
18

June, 2012
92.11 König G, Mönning U, Czech C, Prior R, Banati R, Schreiter-Gasser U, Bauer J, Masters
CL, Beyreuther K. Identification and differential expression of a novel alternative splice
isoform of the βA4 amyloid precursor protein (APP) mRNA in leukocytes and brain
microglial cells. J Biol Chem 1992; 267: 10804-10809.
92.12 Mönning U, König G, Banati RB, Mechler H, Czech C, Gehrmann J, Schreiter-Gasser U,
Masters CL, Beyreuther K. Alzheimer βA4-amyloid protein precursor in
immunocompetent cells. J Biol Chem 1992; 267: 23950-23956.
92.13 Beyreuther K, Dyrks T, Hilbich C, Mönning U, König G, Multhaup G, Pollwein P,
Masters CL. Amyloid precursor protein (APP) and βA4 amyloid in Alzheimer’s disease
and Down syndrome. In: Down Syndrome and Alzheimer Disease. Proceedings of the
National Down Syndrome Society Conference on Down Syndrome and Alzheimer Disease:
January 16-17, 1992; New York. Edited by Nadel L, Epstein CJ. Wiley-Liss, New York;
1992: 159-182.
92.14 Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Substitutions of
hydrophobic amino acids reduce the amyloidogenicity of Alzheimer’s disease βA4
peptides. J Mol Biol 1992; 228: 460-473.
92.15 Beyreuther K, Multhaup G, Masters CL. Molecular biology of Alzheimer’s disease. In:
Biomarkers of Aging: Expression and Regulation (Proceedings). Edited by Licastro F,
Caldarera CM. Editrice CLUEB, Bologna; 1992: 103-118.
92.16 Dyrks T, Dyrks E, Masters C, Beyreuther K. Membrane inserted APP fragments
containing the βA4 sequence of Alzheimer’s disease do not aggregate. FEBS Lett 1992;
309: 20-24.
92.17 Multhaup G, Bush AI, Pollwein P, Masters CL, Beyreuther K. Specific binding of the
Alzheimer βA4 amyloid precursor to collagen, laminin and heparin. J Protein Chem
1992; 11: 398-399.
92.18 Bush AI, Beyreuther K, Masters CL. βA4 amyloid protein and its precursor in
Alzheimer’s disease. Pharmacol Ther 1992; 56:9 7-117.
1993
93.01 Beyreuther K, Pollwein P, Multhaup, G, Mönning U, König G, Dyrks T, Schubert W,
Masters CL. Regulation and expression of the Alzheimer’s β/A4 amyloid protein
precursor in health, disease and Down’s syndrome. In: Alzheimer’s Disease: Amyloid
Precursor Proteins, Signal Transduction, and Neuronal Transplantation. Proceedings of the
Seventh Meeting of the International Study Group of the Pharmacology of Memory Disorders
Associated with Aging: February 12-14, 1993: Zurich. Edited by Nitsch RM, Growdon JH,
Corkin S, Wurtman RJ. Center for Brain Sciences and Metabolism Charitable Trust,
Cambridge (USA); 1993: 103-115. Ann NY Acad Sci 1993; 695: 91-102.
19

June, 2012
93.02 Small DH, Nurcombe V, Clarris H, Beyreuther K, Masters CL. The role of extracellular
matrix in the processing of the amyloid protein precursor of Alzheimer’s disease In:
Alzheimer’s Disease: Amyloid Precursor Proteins, Signal Transduction, and Neuronal
Transplantation. Proceedings of the Seventh Meeting of the International Study Group of the
Pharmacology of Memory Disorders Associated with Aging: February 12-14, 1993: Zurich.
Edited by Nitsch RM, Growdon JH, Corkin S, Wurtman RJ. Center for Brain Sciences
and Metabolism Charitable Trust, Cambridge (USA); 1993: 187-192. Ann NY Acad Sci
1993; 695: 169-174.
93.03 Bush AI, Beyreuther K, Masters CL. The βA4 amyloid protein precursor in human
circulation. In: Alzheimer’s Disease: Amyloid Precursor Proteins, Signal Transduction, and
Neuronal Transplantation. Proceedings of the Seventh Meeting of the International Study
Group of the Pharmacology of Memory Disorders Associated with Aging: February 12-14,
1993: Zurich. Edited by Nitsch RM, Growdon JH, Corkin S, Wurtman RJ. Center for
Brain Sciences and Metabolism Charitable Trust, Cambridge (USA); 1993: 143-150. Ann
NY Acad Sci 1993; 695: 175-182.
93.04 Sandbrink R, Banati R, Masters CL, Beyreuther K, König G. Expression of L-APP
mRNA in brain cells. In: Alzheimer’s Disease: Amyloid Precursor Proteins, Signal
Transduction, and Neuronal Transplantation. Proceedings of the Seventh Meeting of the
International Study Group of the Pharmacology of Memory Disorders Associated with Aging:
February 12-14, 1993: Zurich. Edited by Nitsch RM, Growdon JH, Corkin S, Wurtman
RJ. Center for Brain Sciences and Metabolism Charitable Trust, Cambridge (USA); 1993:
151-157. Ann NY Acad Sci 1993; 695: 183-189.
93.05 Gearing M, Wilson RW, Unger ER, Shelton ER, Chan HW, Masters CL, Beyreuther K,
Mirra SS. Amyloid precursor protein (APP) in the striatum in Alzheimer’s disease: An
immunohistochemical study. J Neuropathol Exp Neurol 1993; 52: 22-30.
93.06 Masters CL, Beyreuther K. Molecular studies on the cognitive disorders of aging: the
role of βA4 amyloid protein precursor in Alzheimer’s disease. In: The 1992 Sandoz
Lectures in Gerontology: Prospects in Aging. Edited by Dall JLC, Ermini M, Herrling PL,
Lehr U, Meier-Rouge W, Stähelin HB. London: Academic Press; 1993: 109-125.
93.07 Beyreuther K, Multhaup G, Masters CL. Molecular biology and pathology of
Alzheimer’s disease. In: Cellular Metabolism of the Arterial Wall and Central Nervous
System - Selected Aspects. Edited by Schettler G, Greten H, Habenicht AJR. Berlin:
Springer-Verlag; 1993: 35-54.
93.08 Masters CL, Beyreuther K. Beta-A4 amyloid protein precursor in Alzheimer’s disease.
Medicographia 1993; 15: 48-53.
93.09 Whyte S, Bush AI, Beyreuther K, Masters CL. An abnormality of plasma βA4 amyloid
protein precursor in Alzheimer’s disease. In: Alzheimer’s Disease: Advances in Clinical and
Basic Research. Edited by Corain B, Iqbal K, Nicolini M, Winblad B, Wisniewski H, Zatta
P. Chichester: Wiley; 1993: 89-95.
20

June, 2012
93.10 König G, Mönning U, Jones LL, Banati R, Masters CL, Beyreuther K. Novel splice
isoforms of Alzheimer’s βA4-amyloid protein precursor gene with altered structure
proximal to the βA4 region. In: Alzheimer’s Disease: Advances in Clinical and Basic
Research. Edited by Corain B, Iqbal K, Nicolini M, Winblad B, Wisniewski H, Zatta P.
Chichester: Wiley; 1993: 243-254.
93.11 Li Q-X, Bush AI, Beyreuther K, Masters CL. The human platelet as a model to study the
function of the βA4 amyloid protein precursor of Alzheimer’s disease. In: Alzheimer’s
Disease: Advances in Clinical and Basic Research. Edited by Corain B, Iqbal K, Nicolini M,
Winblad B, Wisniewski H, Zatta P. Chichester: Wiley; 1993: 397-403.
93.12 Dyrks T, Dyrks E, Hartmann T, Masters CL, Beyreuther K. Radicals as mediators for
the amyloidogenic transformation of βA4-bearing APP fragments. In: Alzheimer’s
Disease: Advances in Clinical and Basic Research. Edited by Corain B, Iqbal K, Nicolini M,
Winblad B, Wisniewski H, Zatta P. Chichester: Wiley; 1993: 497-506.
93.13 Weidemann A, Prior R, Masters CL, Beyreuther K. Cytoplasmic isoforms of the
amyloid precursor protein result from alternative initiation of translation. In:
Alzheimer’s Disease: Advances in Clinical and Basic Research. Edited by Corain B, Iqbal K,
Nicolini M, Winblad B, Wisniewski H, Zatta P. Chichester: Wiley; 1993: 405-410.
93.14 Bush AI, Multhaup G, Moir RD, Williamson TG, Small DH, Rumble B, Pollwein P,
Beyreuther K, Masters CL. A novel zinc(II) binding site modulates the function of the
βA4 amyloid protein precursor of Alzheimer’s disease. J Biol Chem 1993; 268: 16109-
16112.
93.15 Beyreuther K, Multhaup G, Masters CL. Disentanglement from Alzheimer’s Disease.
In: Dementias: Neurochemistry, Neuropathology, Neuroimaging, Neuropsychology, Genetics.
Proceedings of the International Symposium during the 2 nd Congress of the Paneuropean
Society of Neurology: December 8-12; Vienna. Edited by Maurer K. Vieweg,
Braumschweig; 1993: 103-118.
93.16 Beyreuther K, Multhaup G, Masters CL. Molecular biology and pathology of
Alzheimer’s disease. In: Restorative Neurology, Volume 6: Neuronal Cell Death and Repair.
Edited by Cuello AC. Amsterdam: Elsevier; 1993; 61-73.
93.17 Multhaup G, Masters CL, Beyreuther K. A molecular approach to Alzheimer’s disease.
Biol Chem Hoppe Seyler 1993; 374: 1-8.
93.18 Cacabelos R, Hofman A, Mullan M, Ferris SH, Portera A, Frey H, Swaab DF, de Leon
M, Terry R, Masters CL, Iqbal K, Wisniewski HM, Takeda M, Giacobini E, Nordberg A,
Winblad B. Alzheimer’s disease: Scientific progress for future trends. Drug News &
Perspectives 1993; 6: 242-243.
93.19 Dyrks T, Dyrks E, Masters CL, Beyreuther K. Amyloidogenicity of rodent and human
βA4 sequences. FEBS Lett 1993; 324: 231-236.
21

June, 2012
93.20 Evin G, Portbury S, Moir R, Beyreuther K, Masters CL. Design of synthetic peptide
models to study the proteases involved in the formation of Alzheimer’s disease βA4
amyloid. In: Peptides. Proceedings of the 22 nd European Peptide Symposium. Edited by
Schneider CH, Eberle AN. ESCOM Science Publishers, Leiden; 1993: 157-158.
93.21 Bailey KA, Bray J, Beyreuther K, Masters CL. Effects of aging on the levels of brainderived
neurotrophic factor and TRK B mRNA in the mouse brain. In: Advances in the
Biosciences, Volume 87. Alzheimer’s Disease and Related Disorders. Edited by Nicolini M,
Zatta PF, Corain B. Oxford: Pergamon Press; 1993: 301-302.
93.22 Milward EA, Dottori M, Papadopoulos R, Moir RD, Fuller SJ, Beyreuther K, Masters
CL. Neurotrophic and ci[y]totoxic ac[a]tions of amyloid protein precursor of
Alzheimer’s disease. In: Advances in the Biosciences, Volume 87. Alzheimer’s Disease and
Related Disorders. Edited by Nicolini M, Zatta PF, Corain B. Oxford: Pergamon Press;
1993: 349-350.
93.23 Dichgans M, Mönning U, König G, Sandbrink R, Masters CL, Beyreuther K. APP
expression in primary neuronal cell cultures from P6 mice during in vitro
differentiation. Dementia 1993; 4: 301-307.
93.24 Czech C, Mönning U, Tienari PJ, Hartmann T, Masters C, Beyreuther K, Förstl H.
Apolipoprotein E-ε4 allele and Alzheimer’s disease. Lancet 1993; 342: 1309-1310.
93.25 Hilbich C, Mönning U, Grund C, Masters CL, Beyreuther K. Amyloid-like properties of
peptides flanking the epitope of amyloid precursor protein-specific monoclonal
antibody 22C11. J Biol Chem 1993; 268: 26571-26577.
93.26 Schubert W, Masters CL, Beyreuther K. APP+ T lymphocytes selectively sorted to
endomysial tubes in polmyositis displace NCAM-expressing muscle fibers. Eur J Cell
Biol 1993; 62: 333-342.
1994
94.01 Sandbrink R, Masters CL, Beyreuther K. βA4-amyloid protein precursor mRNA
isoforms without exon 15 are ubiquitously expressed in rat tissues including brain, but
not in neurons. J Biol Chem 1994; 269: 1510-1517.
94.02 Thomas LD, Gonzales MF, Chamberlain A, Beyreuther K, Masters CL, Flicker L.
Comparison of clinical state, retrospective informant interview and the
neuropathologic diagnosis of Alzheimer’s disease. Int J Geriat Psych 1994; 9: 233-236.
94.03 Czech C, Masters C, Beyreuther K. Alzheimer’s disease and transgenic mice. J Neural
Transm 1994; 44: 219-230.
94.04 Multhaup G, Bush AI, Pollwein P, Masters CL. Interaction between the zinc(II) and the
heparin binding site of the Alzheimer’s disease βA4 amyloid precursor protein (APP).
FEBS Lett 1994; 355: 151-154.
22

June, 2012
94.05 Whyte S, Beyreuther K, Masters CL. Rational therapeutic strategies for Alzheimer’s
disease. In: Neurodegenerative Diseases. Edited by Calne DB. Philadelphia: Saunders;
1994: 647-664.
94.06 Li Q-X, Berndt MC, Bush AI, Rumble B, Mackenzie I, Friedhuber A, Beyreuther K,
Masters CL. Membrane-associated forms of the βA4 amyloid protein precursor of
Alzheimer’s disease in human platelet and brain: surface expression on the activated
human platelet. Blood 1994; 84: 133-142.
94.07 Small DH, Nurcombe V, Reed G, Clarris H, Moir R, Beyreuther K, Masters CL. A
heparin-binding domain in the amyloid protein precursor of Alzheimer’s disease is
involved in the regulation of neurite outgrowth. J Neurosci 1994; 14: 2117-2127.
94.08 Godec MS, Asher DM, Kozachuk WE, Masters CL, Rubi JU, Payne JA, Rubi-Villa DJ,
Wagner EE, Rapoport SI, Schapiro MB. Blood buffy coat from Alzheimer’s disease
patients and their relatives does not transmit spongiform encephalopathy to hamsters.
Neurology 1994; 44: 1111-1115.
94.09 Clarris HJ, Nurcombe V, Small DH, Beyreuther K, Masters CL. Secretion of nerve
growth factor from septum stimulates neurite outgrowth and release of the amyloid
protein precursor of Alzheimer’s disease from hippocampal explants. J Neurosci Res
1994; 38: 248-258.
94.10 Sandbrink R, Masters CL, Beyreuther K. Similar alternative splicing of a nonhomologous
domain in βA4-amyloid protein precursor-like proteins. J Biol Chem 1994;
269: 14227-14234.
94.11 Masters CL, Beyreuther K, Trillet M, Christen Y (Eds.). Research and Perspectives in
Alzheimer’s Disease. Amyloid Protein Precursor in Development, Aging and Alzheimer’s
Disease. Heidelberg: Springer-Verlag; 1994: 257pp.
94.12 Masters CL, Beyreuther K. Strategic thoughts on the Alzheimer’s disease amyloid
protein precursor : The way forward. In: Research and Perspectives in Alzheimer’s Disease.
Amyloid Protein Precursor in Development, Aging and Alzheimer’s Disease. Edited by
Masters CL, Beyreuther K, Trillet M, Christen Y. Heidelberg: Springer-Verlag; 1994; 1-8.
94.13 Hilbich C, Kisters-Woike B, Masters CL, Beyreuther K. Amyloid βA4 of Alzheimer’s
disease: Structural requirements for folding and aggregation. In: Research and
Perspectives in Alzheimer’s Disease. Amyloid Protein Precursor in Development, Aging and
Alzheimer’s Disease. Edited by Masters CL, Beyreuther K, Trillet M, Christen Y.
Heidelberg: Springer-Verlag; 1994; 21-35.
94.14 Small DH, Nurcombe V, Reed G, Clarris H, Beyreuther K and Masters CL. The role of
the extracellular matrix in regulating the function of the amyloid protein precursor of
Alzheimer’s disease. In: Research and Perspectives in Alzheimer’s Disease. Amyloid Protein
Precursor in Development, Aging and Alzheimer’s Disease. Edited by Masters CL,
Beyreuther K, Trillet M, Christen Y. Heidelberg: Springer-Verlag; 1994; 65-75.
23

94.15 Osuntokun BO, Ogunniyi A, Akang EEU, Aghadiuno PU, Ilori A, Bamgboye EA,
Beyreuther K, Masters C. βA4-amyloid in the brains of non-demented Nigerian
Africans. Lancet 1994; 343: 56.
June, 2012
94.16 Masters CL, Beyreuther K. Alzheimer’s disease: A clearer definition of the genetic
components. Med J Aust 1994; 160: 243-244.
94.17 Masters Colin L, Beyreuther K. Molecular pathology of β/A4-amyloid protein
precursor in Alzheimer’s disease. In: Annals of Psychiatry: Basic and Clinical
Neurosciences, Volume 4. Alzheimer’s Disease. Edited by Cacabelos R, Winblad B.
Barcelona: Prous Science; 1994; 4: 137-145. [see also Drugs Today (Barc) 1994; 30: 257-
263.]
94.18 Bush AI, Pettingell WH, Multhaup G, d. Paradis M, Vonsattel J-P, Gusella JF,
Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer Aβ amyloid
formation by zinc. Science 1994; 265: 1464-1467.
94.19 Sandbrink R, Masters CL, Beyreuther K. Complete nucleotide and deduced amino acid
sequence of rat amyloid protein precursor-like protein 2 (APLP2/APPH): two amino
acids length difference to human and murine homologues. Biochim Biophys Acta
1994; 1219:167-170.
94.20 Mönning U, Sandbrink R, Banati RB, Masters CL, Beyreuther K. Transforming growth
factor β mediates increase of mature transmembrane amyloid precursor protein in
microglial cells. FEBS Lett 1994; 342: 267-272.
94.21 Sandbrink R, Masters CL, Beyreuther K. APP gene family: unique age-associated
changes in splicing of Alzheimer’s βA4-amyloid protein precursor. Neurobiol Dis
1994; 1: 13-24.
94.22 Hesse L, Beher D, Masters CL, Multhaup G. The βA4 amyloid precursor protein
binding to copper. FEBS Lett 1994; 349: 109-116.
94.23 Beyreuther K, Masters CL. Catching the culprit prion. Nature 1994; 370: 419-420.
94.24 Evin G, Beyreuther K, Masters CL. Alzheimer’s disease amyloid precursor protein
(AβPP): proteolytic processing, secretases and βA4 amyloid production. Amyloid 1994;
1: 263-280.
94.25 Czech C, Förstl H, Hentschel F, Mönning U, Besthorn C, Geiger-Kabisch C, Sattel H,
Masters C, Beyreuther K. Apolipoprotein E-4 gene dose in clinically diagnosed
Alzheimer’s disease: prevalence, plasma cholesterol levels and cerebrovascular change.
Eur Arch Psychiatry Clin Neurosci 1994; 243: 291-292.
94.26 Förstl H, Czech C, Sattel H, Geiger-Kabisch C, Besthorn C, Kreger S, Mönning U,
Hartmann T, Masters C, Beyreuther K. Apolipoprotein E und Alzheimer-Demenz.
Eigene Ergebnisse und kurze Literaturübersicht. Nervenarzt 1994; 65: 780-786.
24

June, 2012
1995
95.01 Williamson TG, Nurcombe V, Beyreuther K, Masters CL, Small DH. Affinity
purification of proteoglycans that bind to the amyloid protein precursor of Alzheimer’s
disease. J Neurochem 1995; 65: 2201-2208.
95.02 Richardson EP Jr, Masters CL. The nosology of Creutzfeldt-Jakob disease and
conditions related to the accumulation of PrP CJD in the nervous system. Brain Pathol
1995; 5: 33-41.
95.03 Fuller SJ, Storey E, Li Q-X, Smith AI, Beyreuther K, Masters CL. Intracellular
production of βA4 amyloid of Alzheimer’s disease: modulation by phosphoramidon
and lack of coupling to the secretion of the amyloid precursor protein. Biochemistry
1995; 34: 8091-8098.
95.04 Li Q-X, Evin G, Small DH, Multhaup G, Beyreuther K, Masters CL. Proteolytic
processing of Alzheimer’s disease βA4 amyloid precursor protein in human platelets. J
Biol Chem 1995; 270: 14140-14147.
95.05 Li Q-X, Beyreut[h]er K, Masters CL. Amyloid protein precursor of Alzheimer disease in
human platelets, plasma and CSF. In: Aging of Brain and Alzheimer Disease, Volume 1.
Alzheimer Disease and System Engineering. Edited by Zheng G-C. Shanghai: Shanghai
Scientific and Technological Literature Publishing House; 1995; 157-166.
95.06 Evin G, Beyreuther K, Masters CL. A synthetic substrate assay for the gamma-secretase
of the β-A4 amyloid of Alzheimer’s disease. J Pept Sci 1995; 1: 132-139.
95.07 Beyreuther K, Masters CL. Neurodegeneration and dementia. Alzheimer’s disease as a
model. Arzneimittelforschung 1995; 45: 347-350.
95.08 Masters CL, Beyreuther K. Molecular neuropathology of Alzheimer’s disease.
Arzneimittelforschung 1995; 45: 410-412.
95.09 Beer J, Masters CL, Beyreuther K. Cells from peripheral tissues that exhibit high APP
expression are characterized by their high membrane fusion activity.
Neurodegeneration 1995; 4: 51-59.
95.10 Mönning U, Sandbrink R, Weidemann A, Banati RB, Masters CL, Beyreuther K.
Extracellular matrix influences the biogenesis of amyloid precursor protein in
microglial cells. J Biol Chem 1995; 270: 7104-7110.
95.11 Small DH, Reed G, Fuller SJ, Weidemann A, Beyreuther K Masters CL. Proteolytic
processing of amyloid protein precursor of Alzheimer’s disease. In: Methods in
Neurosciences, Volume 23. Peptidases and Neuropeptide Processing. Edited by Smith AI. San
Diego: Academic Press; 1995; 317-327.
95.12 Clarris HJ, Key B, Beyreuther K, Masters CL, Small DH. Expression of the amyloid
protein precursor of Alzheimer’s disease in the developing rat olfactory system. Dev
Brain Res 1995; 88: 87-95.
25

June, 2012
95.13 Culvenor JG, Friedhuber A, Fuller SJ, Beyreuther K and Masters CL. Expression of the
amyloid precursor protein of Alzheimer’s disease on the surface of transfected HeLa
cells. Exp Cell Res 1995; 220: 474-481.
95.14 Multhaup G, Mechler H, Masters CL. Characterization of the high affinity heparin
binding site of the Alzheimer’s disease βA4 amyloid precursor protein (APP) and its
enhancement by zinc(II). J Mol Recognit 1995; 8: 247-257.
95.15 Evin G, Cappai R, Li Q-X, Culvenor JG, Small DH, Beyreuther K, Masters CL.
Candidate γ-secretases in the generation of the carboxyl terminus of the Alzheimer’s
disease βA4 amyloid: Possible involvement of cathepsin D. Biochemistry 1995; 34:
14185-14192.
95.16 Collins S, Masters CL. Transmissibility of Creutzfeldt-Jakob disease and related
disorders. Sci Prog 1995; 78: 217-227.
95.17 Masters CL. Neurodegenerative diseases of the elderly. J Clin Neurosci 1995; 2: 283-
284.
95.18 Storey E, Masters CL. Amyloid, aluminium and the aetiology of Alzheimer’s disease.
Med J Aust 1995; 163: 256-259. [See also: Amyloid, aluminium and the aetiology of
Alzheimer’s disease. Med J Aust 1996; 164: 253 [Reply to letter from Exley C] and
Amyloid, aluminium and the aetiology of Alzheimer’s disease. Med J Aust 1996; 164:
383 [Reply to letter from Walton JR].]
95.19 Beyreuther K, Multhaup G, Masters CL. Alzheimer Krankheit - Molekulare
Pathogenese und deren Implikationen für die Therapieforschung. In: Mitteilungsblatt
der Konferenz der deutschen Akademien der Wissenschaften e. V. Verlag Philipp von Zabern,
Mainz. Akademie-Journal 1995; 2: 28-39.
95.20 Li Q-X, Whyte S, Birchall I, Beyreut[h]er K, Masters CL. The amyloid protein precursor
of Alzheimer’s disease in human platelets and kidney. In: Non-Neuronal Cells in
Alzheimer’s Disease. Edited by Zatta P, Nicolini M. Singapore: World Scientific; 1995; 62-
70.
95.21 LePage RN, Fosang AJ, Fuller SJ, Murphy G, Evin G, Beyreuther K, Masters CL, Small
DH. Gelatinase A possesses a β-secretase-like activity in cleaving the amyloid protein
precursor of Alzheimer’s disease. FEBS Lett 1995; 377: 267-270.
1996
96.01 Beyreuther K, Multhaup G, Mönning U, Sandbrink R, Beher D, Hesse L, Small DH,
Masters CL. Regulation of APP expression, biogenesis and metatoblism by extracellular
matrix and cytokines. In: The Neurobiology of Alzheimer’s Disease. Proceedings of the Eighth
Meeting of the International Study Group on the Pharmacology of Memory Disorders
Associated with Aging: February 17-19, 1995: Zurich. Edited by Nitsch RM, Growdon JH,
Corkin S, Wurtman RJ. Center for Brain Sciences and Metabolism Charitable Trust,
Cambridge (USA); 1996: 83-85. [See also Ann NY Acad Sci 1996; 777: 74-76.]
26

June, 2012
96.02 Sandbrink R, Masters CL, Beyreuther K. APP gene family: alternative splicing
generates functionally related isoforms. In: The Neurobiology of Alzheimer’s Disease.
Proceedings of the Eighth Meeting of the International Study Group on the Pharmacology of
Memory Disorders Associated with Aging: February 17-19, 1995: Zurich. Edited by Nitsch
RM, Growdon JH, Corkin S, Wurtman RJ. Center for Brain Sciences and Metabolism
Charitable Trust, Cambridge (USA); 1996: 331-338. [See also Ann NY Acad Sci 1996;
777: 281-287.]
96.03 Small DH, Williamson T, Reed G, Clarris H, Beyreuther K, Masters CL, Nurcombe V.
The role of heparan sulfate proteoglycans in the pathogenesis of Alzheimer’s disease.
In: The Neurobiology of Alzheimer’s Disease. Proceedings of the Eighth Meeting of the
International Study Group on the Pharmacology of Memory Disorders Associated with Aging:
February 17-19, 1995: Zurich. Edited by Nitsch RM, Growdon JH, Corkin S, Wurtman J.
Center for Brain Sciences and Metabolism Charitable Trust, Cambridge (USA); 1996:
369-374. [See also Ann NY Acad Sci 1996; 777: 316-321.]
96.04 Storey E, Spurck T, Pickett-Heaps J, Beyreuther K, Masters CL. The amyloid precursor
protein of Alzheimer’s disease is found on the surface of static but not actively motile
portions of neurites. Brain Res 1996; 735: 59-66.
96.05 Storey E, Beyreuther K, Masters CL. Alzheimer’s disease amyloid precursor protein on
the surface of cortical neurons in primary culture co-localizes with adhesion patch
components. Brain Res 1996; 735: 217-231.
96.06 Multhaup G, Schlicksupp A, Hesse L, Beher D, Ruppert T, Masters CL, Beyreuther K.
The amyloid precursor protein of Alzheimer’s disease in the reduction of copper(II) to
copper(I). Science 1996; 271: 1406-1409.
96.07 Beyreuther K, Multhaup G, Förstl H, Masters CL. Die Rolle des Amyloid bei der
Alzheimer Krankheit. In: Demenz - Die Herausforderung. Dokumentation der 2.
Jahresversammlung der Deutschen Gesellschaft für Gerontopsychiatrie und –psychotherapie:
February 2-4, 1995: Hamburg. Edited by Wächtler C, Hirsch RD, Kortus R, Stoppe G.
Verlag Egbert Ramin, Singen; 1996; 25-36.
96.08 Sandbrink R, Zhang D, Schaeffer S, Masters CL, Bauer J, Förstl H, Beyreuther K.
Missense mutations of the PS-1/S182 gene in German early-onset Alzheimer’s disease
patients. Ann Neurol 1996; 40: 265-266.
96.09 Hartmann T, Bergsdorf C, Sandbrink R, Tienari PJ, Multhaup G, Ida N, Bieger S, Dyrks
T, Weidemann A, Masters CL, Beyreuther K. Alzheimer’s disease βA4 protein release
and amyloid precursor protein sorting are regulated by alternative splicing. J Biol
Chem 1996; 271: 13208-13214.
96.10 Beyreuther K, Tienari PJ, Ikonenen E, Multhaup G, Hartmann T, Simons M, Dotti CG,
Masters CL. [Abstract] The amyloid hypothesis in Alzheimer’s disease and its
implication for therapy: A review of evidence. In: Proceedings of the ECNP Regional
Meeting: May 8-11, 1996: Istanbul. Edited by Ayhan IH, Palaoglu O, Gogus A, Akarsu
ES, Ulusahin A. Eur Neuropsychopharmacol 1996; 6: (Supp4) 24-25.
27

June, 2012
96.11 Simpson DA, Masters CL, Ohlrich G, Purdie G, Stuart G, Tannenberg AEG. Iatrogenic
Creutzfeldt-Jakob disease and its neurosurgical implications. J Clin Neurosci 1996; 3:
118-123.
96.12 Beher D, Hesse L, Masters CL, Multhaup G. Regulation of amyloid protein precursor
(APP) binding to collagen and mapping of the binding sites on APP and collagen type
I. J Biol Chem 1996; 271: 1613-1620.
96.13 Collins SJ, Cappai R, Masters CL. Recent developments in the transmissible spongiform
encephalopathies: implications for clinical practice. J Clin Neurosci 1996; 3: 97-101.
96.14 Masters CL, Collins SJ. Prion disease. In: McGraw-Hill Yearbook of Science and Technology,
1997. New York: McGraw-Hill; 1996: 380-383.
96.15 Masters CL. [Book Review] Neurobiology of Alzheimer’s Disease. Edited by Dawbarn D,
Allen SJ. Trends Neurosci 1996; 19: 157-158.
96.16 Beyreuther K, Multhaup G, Masters CL. Alzheimer’s disease: genesis of amyloid. In:
Ciba Foundation Symposium, Number 199: The Nature and Origin of Amyloid Fibrils. Edited
by Bock GR, Goode JA. Chichester: Wiley; 1996: 119-131.
96.17 Sandbrink R, Hartmann T, Masters CL, Beyreuther K. Genes contributing to
Alzheimer’s disease. Mol Psychiatry 1996; 1: 27-40.
96.18 Beyreuther K, Multhaup G, Masters CL. Molecular neuropathology in the causation of
Alzheimer’s disease. In: Psychiatry in Progress Series, Volume 3. Neuropsychiatry in Old
Age: An Update. Edited by Stefanis C, Hippius H, Müller-Spahn F. Seattle: Hogrefe and
Huber; 1996: 43-54.
96.19 Collins S, Masters, CL. Iatrogenic and zoonotic Creutzfeldt-Jakob disease: the
Australian perspective. Med J Aust 1996; 164: 598-602.
96.20 Small DH, Clarris HL, Williamson TG, Reed G, Key B, Mok SS, Beyreuther K, Masters
CL, Nurcombe V. Neurite-outgrowth regulating functions of the amyloid protein
precursor of Alzheimer’s disease. Alzheimers Dis Rev 1996; 1: 21-29.
96.21 Collins S, Fletcher A, De Luise T, Boyd A, Masters CL. Creutzfeldt-Jakob disease in
Australia. In: Transmissible Subacute Spongiform Encephalopathies: Prion Diseases. Edited
by Court L, Dodet B. Paris: Elsevier; 1996: 405-415.
96.22 Kapsa RMI, Jean-Francois MJB, Lertrit P, Weng S, Siregar N, Ojaimi J, Donnan G,
Masters CL, Byrne E. Mitochondrial DNA polymorphism in substantia nigra.
J Neurol Sci 1996; 144: 204-211.
96.23 Masters CL. Emergence of a new variant of Creutzfeldt-Jakob disease in Europe? J Clin
Neurosci 1996; 3: 203-204.
28

June, 2012
96.24 Williamson TG, Mok SS, Henry A, Cappai R, Lander AD, Nurcombe V, Beyreuther K,
Masters CL, Small DH. Secreted glypican binds to the amyloid precursor protein of
Alzheimer’s disease (APP) and inhibits APP-induced neurite outgrowth. J Biol Chem
1996; 271: 31215-31221.
96.25 Tienari PJ, De Strooper B, Ikonen E, Simons M, Weidemann A, Czech C, Hartmann T,
Ida N, Multhaup G, Masters CL, Van Leuven F, Beyreuther K, Dotti CG. The β-amyloid
domain is essential for axonal sorting of amyloid precursor protein. EMBO J 1996; 15:
5218-5229.
96.26 Ida N, Hartmann T, Pantel J, Schröder J, Zerfass R, Förstl H, Sandbrink R, Masters CL,
Beyreuther K. Analysis of heterogeneous βA4 peptides in human cerebrospinal fluid
and blood by a newly developed sensitive Western blot assay. J Biol Chem 1996; 271:
22908-22914.
96.27 Ida N, Masters CL, Beyreuther K. Rapid cellular uptake of Alzheimer amyloid βA4
peptide by cultured human neuroblastoma cells. FEBS Lett 1996; 394: 174-178.
96.28 Beyreuther K, Multhaup G, Förstl H, Masters CL. Alzheimer’s disease - an update. In:
New Research in Psychiatry. Edited by Häfner H, Wolpert EM. Göttingen: Hogrefe and
Huber; 1996: 167-174.
96.29 Beyreuther K, Masters CL. Tangle disentanglement. Nature 1996; 383: 476-477.
[See also Correction. Nature 1996; 383: 764.]
96.30 Tienari PJ, De Strooper B, Ikonen E, Ida N, Simons M, Masters CL, Dotti CG,
Beyreuther K. Neuronal sorting and processing of amyloid precursor protein:
implications for Alzheimer’s disease. In: Cold Spring Harbor Symposia on Quantitative
Biology, Volume LXI. New York: Cold Spring Harbor Press; 1996: 575-585.
1997
97.01 Henry A, Masters CL, Beyreuther K, Cappai R. Expression of human amyloid
precursor protein ectodomains in Pichia pastoris: analysis of culture conditions,
purification, and characterization. Protein Expr Purif 1997; 10: 283-291.
97.02 McLean CA, Masters CL, Vladimirtsev VA, Prokhorova IA, Goldfarb LG, Asher DM,
Vladimirtsev AI, Alekseev VP, Gajdusek DC. Viliuisk encephalomyelitis - review of the
spectrum of pathological changes. Neuropathol Appl Neurobiol 1997; 23: 212-217.
97.03 Coulson EJ, Barrett GL, Storey E, Bartlett PF, Beyreuther K, Masters CL. Downregulation
of the amyloid protein precursor of Alzheimer’s disease by antisense
oligonucleotides reduces neuronal adhesion to specific substrata. Brain Res 1997; 770:
72-80.
97.04 Sandbrink R, Mönning U, Masters CL, Beyreuther K. Expression of the APP gene
family in brain cells, brain development and aging. Gerontology 1997; 43: 119-131.
29

June, 2012
97.05 Clarris HJ, Cappai R, Heffernan D, Beyreuther K, Masters CL, Small DH. Identification
of heparin-binding domains in the amyloid precursor protein of Alzheimer’s disease by
deletion mutagenesis and peptide mapping. J Neurochem 1997; 68: 1164-1172.
97.06 Esiri MM, Hyman BT, Beyreuther K, Masters CL. Ageing and Dementia. In: Greenfield’s
Neuropathology, Sixth Edition, Volume 2. Edited by Graham DI, Lantos PL. London:
Arnold; 1997: 153-233.
97.07 Mok SS, Evin G, Li Q-X, Smith AI, Beyreuther K, Masters CL, Small DH. A novel
metalloprotease in rat brain cleaves the amyloid precursor protein of Alzheimer’s
disease generating amyloidogenic fragments. Biochemistry 1997; 36: 156-163.
97.08 Tienari PJ, Ida N, Ikonen E, Simons M, Weidemann A, Multhaup G, Masters CL, Dotti
CG, Beyreuther K. Intracellular and secreted Alzheimer β-amyloid species are
generated by distinct mechanisms in cultured hippocampal neurons. Proc Natl Acad
Sci USA 1997; 94: 4125-4130.
97.09 Weidemann A, Paliga K, Dürrwang U, Czech C, Evin G, Masters CL, Beyreuther K.
Formation of stable complexes between two Alzheimer’s disease gene products:
Presenilin-2 and β-amyloid precursor protein. Nat Med 1997; 3: 328-332.
97.10 Paliga K, Weidemann A, Peraus G, Kreger S, Dürrwang U, Masters CL, Beyreuther K.
Molecular cloning and characterization of the human amyloid precursor-like protein 1
(hAPLP1). In: Alzheimer’s Disease: Biology, Diagnosis and Therapeutics. Edited by Iqbal K,
Winblad B, Nishimura T, Takeda M, Wisniewski HM. Chichester: John Wiley & Sons
Ltd; 1997: 117-124.
97.11 Whyte S, Jones L, Coulson EJ, Moir RD, Bush AI, Beyreuther K, Masters CL. The
metabolism of the amyloid precursor protein of Alzheimer’s disease and dietary zinc.
In: Alzheimer’s Disease: Biology, Diagnosis and Therapeutics. Edited by Iqbal K, Winblad B,
Nishimura T, Takeda M, Wisniewski HM. Chichester: John Wiley & Sons Ltd; 1997:
417-422.
97.12 Williamson TG, Clarris HJ, Mok SS, Henry A, Cappai R, Nurcombe V, Beyreuther K,
Masters CL, Small DH. Secreted glypican binds to the amyloid protein precursor (APP)
of Alzheimer’s disease and inhibits APP-induced neurite outgrowth. In: Alzheimer’s
Disease: Biology, Diagnosis and Therapeutics. Edited by Iqbal K, Winblad B, Nishimura T,
Takeda M, Wisniewski HM. Chichester: John Wiley & Sons Ltd; 1997: 423-427.
97.13 Multhaup G, Schlicksupp A, Hesse L, Beher D, Ruppert T, Masters CL, Beyreuther K.
The amyloid precursor protein of Alzheimer’s disease binds copper(II) and participates
in a copper(II)-induced redox reaction. In: Alzheimer’s Disease: Biology, Diagnosis and
Therapeutics. Edited by Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM.
Chichester: John Wiley & Sons Ltd; 1997: 529-535.
30

June, 2012
97.14 Allsop D, Christie G, Gray C, Holmes S, Markwell R, Owen D, Smith L, Wadsworth H,
Ward RV, Hartmann T, Lichtenthaler SF, Evin G, Fuller S, Tanner J, Masters CL,
Beyreuther K, Roberts GW. Studies on inhibition of β-Amyloid formation in APP751transfected
IMR-32 cells, and SPA4CT-transfected SHSY5Y cells. In: Alzheimer’s Disease:
Biology, Diagnosis and Therapeutics. Edited by Iqbal K, Winblad B, Nishimura T, Takeda
M, Wisniewski HM. Chichester: John Wiley & Sons Ltd; 1997: 717-727.
97.15 Paliga K, Peraus G, Kreger S, Dürrwang U, Hesse L, Multhaup G, Masters CL,
Beyreuther K, Weidemann A. Human amyloid precursor-like protein 1. cDNA cloning,
ectopic expression in COS-7 cells and identification of soluble forms in the
cerebrospinal fluid. Eur J Biochem 1997; 250: 354-363.
97.16 Lichten[t]haler SF, Ida N, Multhaup G, Masters CL, Beyreuther K. Mutations in the
transmembrane domain of APP altering γ-secretase specificity. Biochemistry 1997; 36:
15396-15403.
97.17 Peraus GC, Masters CL, Beyreuther K. Late compartments of amyloid precursor
protein transport in SY5Y cells are involved in β-amyloid secretion. J Neurosci 1997; 17:
7714-7724.
97.18 McLean CA, Beyreuther K, Masters CL. Commentary on the consensus
recommendations for the post mortem diagnosis of Alzheimer’s disease. Neurobiol
Aging 1997; 18: S89-S90.
97.19 Sberna G, Sáez-Valero J, Beyreuther K, Masters CL, Small DH. The amyloid β-protein
of Alzheimer’s disease increases acetylcholinesterase expression by increasing
intracellular calcium in embryonal carcinoma P19 cells. J Neurochem 1997; 69: 1177-
1184.
97.20 Culvenor JG, Maher F, Evin G, Malchiodi-Albedi F, Cappai R, Underwood JR, Davis JB,
Karran EH, Roberts GW, Beyreuther K, Masters CL. Alzheimer’s disease-associated
presenilin 1 in neuronal cells: Evidence for localization to the endoplasmic reticulum-
Golgi intermediate compartment. J Neurosci Res 1997; 49: 719-731.
97.21 Whyte S, Wilson N, Currie J, Maruff P, Malone V, Shafiq-Antonacci R, Tyler P, Derry
KL, Underwood J, Li Q-X, Beyreuther K, Masters CL. Collection and normal levels of
the amyloid precursor protein in plasma. Ann Neurol 1997; 41: 121-124.
97.22 Hartmann T, Bieger SC, Brühl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL,
Dotti CG, Unsicker K, Beyreuther K. Distinct sites of intracellular production for
Alzheimer’s disease Aβ40/42 amyloid peptides. Nat Med 1997; 3: 1016-1020.
97.23 Beyreuther K, Masters CL. Serpents on the road to dementia and death. Nat Med 1997;
3: 723-725.
97.24 Mok SS, Sberna G, Heffernan D, Cappai R, Galatis D, Clarris HJ, Sawyer WH,
Beyreuther K, Masters CL, Small DH. Expression and analysis of heparin-binding
regions of the amyloid precursor protein of Alzheimer’s disease. FEBS Lett 1997; 415:
303-307.
31

June, 2012
97.25 Masters CL, Beuyreuther K. Spongiform encephalopathies: Tracking turncoat prion
proteins. Nature 1997; 388: 228-229.
97.26 Tienari P, Masters CL, Beyreuther K. Métabolisme de l’APP dans les neurones. In: De la
Neurophysiologie à la Maladie d’Alzheimer. Symposium en Hommage à Yvon Lamour. Edited
by Besson J-M, Bassant M-H, Calvino B, Epelbaum J, Forette F, Lamour M, Pierrot-
Deseilligny C, Christen Y. Solal éditeurs, Marseille; 1997: 121-140.
97.27 Beyreuther K, Masters CL. Alzheimer’s disease: does intracellular transport hold the
key? In: The News. Dementia, Issue 3. Hoechst Marion Roussel; 1997: 2-4.
97.28 Collins S, Masters CL. Iatrogenic and zoonotic Creutzfeldt-Jakob disease: the
Australian perspective. In: International Diseases Emergencies Report. Proceedings of the
Workshop on the Implications of International Disease Emergencies. BSE A case study:
October 30-31, 1996: Sydney. Edited by Davis IGR. Department of Primary Industries
and Energy (Office of the Australian Chief Veterinary Officer), Canberra; 1997: 2-14.
97.29 Sáez-Valero J, Sberna G, McLean CA, Masters CL, Small DH. Glycosylation of
acetylcholinesterase as diagnostic marker for Alzheimer’s disease. Lancet 1997; 350:
929.
97.30 Masters CL, Beyreuther K. Alzheimer’s disease: Unravelling the genetic and
environmental pathways towards pathogenesis. Aust J Ageing 1997; 16: 116-119.
97.31 Schröder J, Pantel J, Ida N, Essig M, Hartmann T, Knopp MV, Schad LR, Sandbrink R,
Sauer H, Masters CL, Beyreuther K. Cerebral changes and cerebrospinal fluid βamyloid
in Alzheimer’s disease: a study with quantitative magnetic resonance imaging.
Mol Psychiatry 1997; 2: 505-507.
97.32 Bayer TA, Weggen S, Hesse L, Cappai R, Masters CL, Beyreuther K, Multhaup G.
Distribution of amyloid precursor-like protein 2 in normal and Alzhemier’s disease
hippocampal formation. Alzheimers Res 1997; 3: 199-203.
97.33 Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Beher D, Masters CL, Beyreuther K.
Reactive oxygen species and Alzheimer’s disease. Biochem Pharmacol 1997; 54: 533-
539.
97.34 Beyreuther K, Masters CL. Alzheimer’s disease: The ins and outs of amyloid-β. Nature
1997; 389: 677-678.
97.35 Aguzzi A, Barbara J, Brown P, Budka H, Diringer H, Dormont D, Flanagan P, Heeschen
W, Hope J, Hörnlimann B, Kenney K, Masters C, et al. Medicinal and other products
and human and animal transmissible spongiform encephalopathies: Memorandum
from a WHO meeting. Bull World Health Organ 1997; 75: 505-513.
32

June, 2012
1998
98.01 Li Q-X, Whyte S, Tanner JE, Evin G, Beyreuther K, Masters CL. Secretion of
Alzheimer’s disease Aβ amyloid peptide by activated human platelets. Lab Invest
1998; 78: 461-469.
98.02 Moir RD, Lynch T, Bush AI, Whyte S, Henry A, Portbury S, Multhaup G, Small DH,
Tanzi RE, Beyreuther K, Masters CL. Relative increase in Alzheimer’s disease of soluble
forms of cerebral Aβ amyloid protein presursor containing the Kunitz protease
inhibitory domain. J Biol Chem 1998; 273: 5013-5019.
98.03 Taddei K, Yang D, Fisher C, Clarnette R, Hallmayer J, Barnetson R, Maller R, Brooks
WS, Whyte S, Nicholson GA, Masters CL, Broe GA, Gandy SE, Martins RN. No
association of presenilin-1 intronic polymorphism and Alzheimer’s disease in
Australia. Neurosci Lett 1998; 246: 178-180.
98.04 Culvenor JG, Henry A, Hartmann T, Evin G, Galatis D, Friedhuber A, Jayasena ULHR,
Underwood JR, Beyreuther K, Masters CL, Cappai R. Subcellular localization of the
Alzheimer’s disease amyloid precursor protein and derived polypeptides expressed in
a recombinant yeast system. Amyloid 1998; 5: 79-89.
98.05 Henry A, Li Q-X, Galatis D, Hesse L, Multhaup G, Beyreuther K, Masters CL, Cappai R.
Inhibition of platelet activation by the Alzheimer’s disease amyloid precursor protein.
Brit J Haematol 1998; 103: 402-415.
98.06 Postuma RB, Martins RN, Cappai R, Beyreuther K, Masters CL, Strickland DK, Mok SS,
Small DH. Effects of the amyloid protein precursor of Alzheimer’s disease and other
ligands of the LDL receptor-related protein on neurite outgrowth from sympathetic
neurons in culture. FEBS Lett 1998; 428: 13-16.
98.07 Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Bill E, Pipkorn R, Masters CL,
Beyreuther K. Copper-binding amyloid precursor protein undergoes a site-specific
fragmentation in the reduction of hydrogen peroxide. Biochemistry 1998; 37: 7224-
7230.
98.08 McLean CA, Ironside JW, Alpers MP, Brown PW, Cervenakova L, Anderson RMcD,
Masters CL. Comparative neuropathology of kuru with the new variant of Creutzfeldt-
Jakob disease: evidence for strain of agent predominating over genotype of host. Brain
Pathol 1998; 8: 429-437.
98.09 Le Brocque D, Henry A, Cappai R, Li Q-X, Tanner JE, Galatis D, Gray C, Holmes S,
Underwood JR, Beyreuther K, Masters CL, Evin G. Processing of the Alzheimer’s
disease amyloid precursor protein in Pichia pastoris: Immunodetection of α-, β- and γsecretase
products. Biochemistry 1998; 37: 14958-14965.
98.10 Li Q-X, Cappai R, Evin G, Tanner JE, Gray CW, Beyreuther K, Masters CL. Products of
the Alzheimer’s disease amyloid precursor protein generated by β-secretase are present
in human platelets, and secreted upon degranulation. Am J Alzheimers Dis 1998; 13:
236-244.
33

June, 2012
98.11 Sberna G, Sáez-Valero J, Li Q-X, Czech C, Beyreuther K, Masters CL, McLean CA,
Small DH. Acetylcholinesterase is increased in the brains of transgenic mice expressing
the C-terminal fragment (CT100) of the β-amyloid protein precursor of Alzheimer’s
disease. J Neurochem 1998; 71: 723-731.
98.12 Masters CL. Creutzfeldt-Jakob disease: rare transmissible spongiform encephalopathy
with an important message. In: Humanities Research Centre Monograph Series No 13: Mad
Cows and Modernity: Cross-disciplinary Reflections on the Crisis of Creutzfeldt-Jakob Disease.
Edited by McCalman I, Penny B, Cook M. Canberra: The Australian National
University; 1998: 71-81.
98.13 Multhaup G, Masters CL, Beyreuther K, Cappai R. The biological activities and
function of the amyloid precursor protein of Alzheimer’s disease. In: The Molecular
Biology of Alzheimer’s Disease: Genes and Mechanisms Involved in Amyloid Generation.
Edited by Haass, C. Amsterdam: Harwood Academic Publishers; 1998: 75-94.
98.14 Masters C. [Book Review] Prion Diseases. Edited by Collinge J and Palmer MS. Amyloid
1998; 5: 148-149.
98.15 Masters CL, Beyreuther K. Science, medicine, and the future: Alzheimer’s disease. Br
Med J 1998; 316: 446-448.
98.16 White AR, Zheng H, Galatis D, Maher F, Hesse L, Multhaup G, Beyreuther K, Masters
CL, Cappai R. Survival of cultured neurons from amyloid precursor protein knock-out
mice against Alzheimer’s amyloid-β toxicity and oxidative stress. J Neurosci 1998; 18:
6207-6217.
98.17 Fossgreen A, Brückner B, Czech C, Masters CL, Beyreuther K, Paro R. Transgenic
Drosophila expressing human amyloid precursor protein show γ-secretase activity and
a blistered-wing phenotype. Proc Natl Acad Sci USA 1998; 95: 13703-13708.
98.18 Multhaup G, Masters CL, Beyreuther K. Oxidative stress in Alzheimer’s disease.
Alzheimers Rep 1998; 1: 147-154.
98.19 Masters CL. [Book Review] No laughing matter. The Trembling Mountain: A Personal
Account of Kuru, Cannibals and Mad Cow Disease. Klitzman R. Nature 1998; 394: 239-240.
98.20 Taddei K, Kwok JBJ, Kril JJ, Halliday GM, Creasey H, Hallupp M, Fisher C, Brooks WS,
Chung C, Andrews C, Masters CL, Schofield PR, Martins RN. Two novel presenilin-1
mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer’s
disease. Neuroreport 1998; 9: 3335-3339.
98.21 Masters CL. Interazioni fra presenilina e APP. In: La Malattia di Alzheimer dalla
Epidemiologia Genetica alla Genetica Molecolare: May 10-11, 1997: Catanzaro. Editrice
Pisani, Roma. Riv Neurobiol 1998; 32: 236-239.
34

June, 2012
98.22 Masters CL, Beyreuther K. Alzheimer’s disease: Unravelling the genetic and
environmental pathways towards pathogenesis. In: Programme of the 19 th Awards
Ceremony of King Faisal International Prize. The 1997 King Faisal International Prize: March
27, 1997: Riyadh. King Faisal Foundation, Riyadh; 1998; 48-58.
1999
99.01 Storey E, Katz M, Brickman Y, Beyreuther K, Masters CL. Amyloid precursor protein of
Alzheimer’s disease: Evidence for a stable, full-length, trans-membrane pool in primary
neuronal cultures. Eur J Neurosci 1999; 11: 1779-1788.
99.02 Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JDA, Hanson GR,
Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J,
Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AI. Cu(II)
potentiation of Alzheimer Aβ neurotoxicity. Correlation with cell-free hydrogen
peroxide production and metal reduction. J Biol Chem 1999; 274: 37111-37116.
99.03 Borchardt T, Camakaris J, Cappai R, Masters CL, Beyreuther K, Multhaup G. Copper
inhibits β-amyloid production and stimulates the non-amyloidogenic pathway of
amyloid-precursor-protein secretion. Biochem J 1999; 344: 461-467.
99.04 Beher D, Elle C, Underwood J, Davis JB, Ward R, Karran E, Masters CL, Beyreuther K,
Multhaup G. Proteolytic fragments of Alzheimer’s disease-associated presenilin 1 are
present in synaptic organelles and growth cone membranes of rat brain. J Neurochem
1999; 72: 1564-1573.
99.05 Multhaup G, Hesse L, Borchardt T, Ruppert T, Cappai R, Masters CL, Beyreuther K.
Autoxidation of amyloid precursor protein and formation of reactive oxygen species.
In: Proceedings of a Satellite Meeting of the European Human Genetic Society on Copper
Transport and its Disorders: Molecular and Cellular Aspects: May 21-25, 1997: Sestri
Levante. Edited by Leone A, Mercer JFB. Kluwer Academic/Plenum Publishers, New
York. Adv Exp Med Biol 1999; 448: 183-192.
99.06 Ojaimi J, Masters CL, Opeskin K, McKelvie P, Byrne E. Mitochondrial respiratory chain
activity in the human brain as a function of age. Mech Ageing Dev 1999; 111: 39-47.
99.07 Cherny RA, Masters CL, Beyreuther K, Bush AI. Isolating components of human brain:
The purification of Aβ and the Alzheimer’s amyloid precursor protein. In: Using CNS
Tissue in Psychiatric Research: A Practical Guide. Edited by Dean B, Kleinman JE, Hyde
TM. Singapore: Harwood Academic Publishers; 1999; 141-158.
99.08 Weidemann A, Paliga K, Dürrwang U, Reinhard FBM, Schuckert O, Evin G, Masters
CL. Proteolytic processing of the Alzheimer’s disease amyloid precursor protein within
its cytoplasmic domain by caspase-like proteases. J Biol Chem 1999; 274: 5823-5829.
99.09 Jobling MF, Barrow CJ, White AR, Masters CL, Collins SJ, Cappai R. The synthesis and
spectroscopic analysis of the neurotoxic prion peptide 106-126: Comparative use of
manual Boc and Fmoc chemistry. Lett Pept Sci 1999; 6: 129-134.
35

June, 2012
99.10 White AR, Collins SJ, Maher F, Jobling MF, Stewart LR, Thyer JM, Beyreuther K,
Masters CL, Cappai R. Prion protein-deficient neurons reveal lower glutathione
reductase activity and increased susceptibility to hydrogen peroxide toxicity. Am J
Pathol 1999; 155: 1723-1730.
99.11 Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, Beyreuther K,
Tanzi RE, Masters CL, Bush AI. Aqueous dissolution of Alzheimer’s disease Aβ
amyloid deposits by biometal depletion. J Biol Chem 1999; 274: 23223-23228.
99.12 Smith MJ, Gardner RJM, Knight MA, Forrest SM, Beyreuther K, Storey E, McLean CA,
Cotton RGH, Cappai R, Masters CL. Early-onset Alzheimer’s disease caused by a novel
mutation at codon 219 of the presenilin-1 gene. Neuroreport 1999; 10: 503-507.
99.13 Rossjohn J, Cappai R, Feil SC, Henry A, McKinstry WJ, Galatis D, Hesse L, Multhaup
G, Beyreuther K, Masters CL, Parker MW. Crystal structure of the N-terminal, growth
factor-like domain of Alzheimer amyloid precursor protein. Nat Struct Biol 1999; 6:
327-331.
99.14 Lichtenthaler SF, Wang R, Grimm H, Uljon SN, Masters CL, Beyreuther K. Mechanism
of the cleavage specificity of Alzheimer’s disease γ-secretase identified by
phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid
precursor protein. Proc Natl Acad Sci USA 1999; 96: 3053-3058. [See also: Kosik KS.
Commentary - A notable cleavage: winding up with β-amyloid. Proc Natl Acad Sci
USA 1999; 96: 2574-2576]
99.15 Evin G, Reed G, Tanner JE, Li Q-X, Culvenor JG, Fuller SJ, Wadsworth H, Allsop D,
Ward RV, Karran EH, Gray CW, Hartmann T, Lichtenthaler SF, Weidemann A,
Beyreuther K, Masters CL. Characterization of γ-secretase candidates from human
brain using a novel western blot assay. In: Alzheimer’s Disease and Related Disorders:
Etiology, Pathogenesis and Therapeutics. Edited by Iqbal K, Swaab DF, Winblad B,
Wisniewski HM. Chichester: John Wiley and Sons Ltd; 1999: 411-417.
99.16 Cappai R, Stewart L, Jobling MF, Thyer JM, White AR, Beyreuther K, Collins SJ,
Masters CL, Barrow CJ. Familial prion disease mutation alters the secondary structure
of recombinant mouse prion protein: Implications for the mechanism of prion
formation. Biochemistry 1999; 38: 3280-3284.
99.17 Collins S, Law MG, Fletcher A, Boyd A, Kaldor J, Masters CL. Surgical treatment and
risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet 1999; 353: 693-
697.
99.18 Cappai R, Mok SS, Galatis D, Tucker DF, Henry A, Beyreuther K, Small DH, Masters
CL. Recombinant human amyloid precursor-like protein 2 (APLP2) expressed in the
yeast Pichia pastoris can stimulate neurite outgrowth. FEBS Lett 1999; 442: 95-98.
99.19 White AR, Multhaup G, Maher F, Bellingham S, Camakaris J, Zheng H, Bush AI,
Beyreuther K, Masters CL, Cappai R. The Alzheimer’s disease amyloid precursor
protein modulates copper-induced toxicity and oxidative stress in primary neuronal
cultures. J Neurosci 1999; 19: 9170-9179.
36

June, 2012
99.20 White AR, Bush AI, Beyreuther K, Masters CL, Cappai R. Exacerbation of copper
toxicity in primary neuronal cultures depleted of cellular glutathione. J Neurochem
1999; 72: 2092-2098.
99.21 Christie G, Markwell RE, Gray CW, Smith L, Godfrey F, Mansfield F, Wadsworth H,
King R, McLaughlin M, Cooper DG, Ward RV, Howlett DR, Hartmann T, Lichtenthaler
SF, Beyreuther K, Underwood J, Gribble SK, Cappai R, Masters CL, Tamaoka A,
Gardner RL, Rivett AJ, Karran EH, Allsop D. Alzheimer’s disease: correlation of the
suppression of β-amyloid peptide secretion from cultured cells with inhibition of the
chymotrypsin-like activity of the proteasome. J Neurochem 1999; 73: 195-204.
99.22 Ojaimi J, Masters CL, McLean C, Opeskin K, McKelvie P, Byrne E. Irregular
distribution of cytochrome c oxidase protein subunits in aging and Alzheimer’s
disease. Ann Neurol 1999; 46: 656-660.
99.23 McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI,
Masters CL. Soluble pool of Aβ amyloid as a determinant of severity of
neurodegeration in Alzheimer’s disease. Ann Neurol 1999; 46: 860-866.
99.24 Jobling MF, Stewart LR, White AR, McLean C, Friedhuber A, Maher F, Beyreuther K,
Masters CL, Barrow CJ, Collins SJ, Cappai R. The hydrophobic core sequence
modulates the neurotoxic and secondary structure properties of the prion peptide 106-
126. J Neurochem 1999; 73: 1557-1565.
99.25 Li Q-X, Maynard C, Cappai R, McLean CA, Cherny RA, Lynch T, Culvenor JG,
Trevaskis J, Tanner JE, Bailey KA, Czech C, Bush AI, Beyreuther K, Masters CL.
Intracellular accumulation of detergent-soluble amyloidogenic Aβ fragment of
Alzheimer’s disease precursor protein in the hippocampus of aged transgenic mice. J
Neurochem 1999; 72: 2479-2487.
99.26 Bayer TA, Cappai R, Masters CL, Beyreuther K, Multhaup G. It all sticks together – the
APP-related family of proteins and Alzheimer’s disease. Mol Psychiatry 1999; 4: 524-
528.
99.27 Bayer TA, Jäkälä P, Hartmann T, Havas L, McLean C, Culvenor JG, Li Q-X, Masters CL,
Falkai P, Beyreuther K. α-Synuclein accumulates in Lewy bodies in Parkinson’s disease
and dementia with Lewy bodies but not in Alzheimer’s disease β-amyloid plaque
cores. Neurosci Lett 1999; 266: 213-216.
99.28 Westermark P, Araki S, Benson MD, Cohen AS, Frangione B, Masters CL, Saraiva MJ,
Sipe JD, Husby G, Kyle RA, Selkoe D. Editorial, Part 1: Nomenclature of amyloid fibril
proteins. Report from the meeting of the International Nomenclature Committee on
Amyloidosis: August 8-9, 1998: Rochester, Minnesota. Amyloid 1999; 6: 63-66.
99.29 Masters CL, Beyreuther K. [Letter to editor] Amyloid Nomenclature Committee.
Amyloid 1999; 6: 151.
37

June, 2012
99.30 Diehlmann A, Ida N, Weggen S, Grünberg J, Haass C, Masters CL, Bayer TA,
Beyreuther K. Analysis of presenilin 1 and presenilin 2 expression and processing by
newly developed monoclonal antibodies. J Neurosci Res 1999; 56: 405-419.
99.31 Li Q-X, Fuller SJ, Beyreuther K, Masters CL. The amyloid precursor protein of
Alzheimer disease in human brain and blood. J Leukoc Biol 1999; 66: 567-574.
99.32 Masters CL. [Book Review] Neurobiology of Primary Dementia. Edited by Folstein MF.
Aust N Z J Psych 1999; 33: 297-298.
99.33 Culvenor JG, McLean CA, Cutt S, Campbell BCV, Maher F, Jäkälä P, Hartmann T,
Beyreuther K, Masters CL, Li Q-X. Non-Aβ component of Alzheimer’s disease amyloid
(NAC) revisited: NAC and α-synuclein are not associated with Aβ amyloid. Am J Pathol
1999; 155: 1173-1181. [see also Correspondence: Hashimoto M et al. The role of NAC in
amyloidogenesis in Alzheimer’s disease. Am J Pathol 2000; 156: 734-735, and Reply
from authors: Am J Pathol 2000; 156: 735-736]
99.34 White AR, Reyes R, Mercer JFB, Camakaris J, Zheng H, Bush AI, Multhaup G,
Beyreuther K, Masters CL, Cappai R. Copper levels are increased in the cerebral cortex
and liver of APP and APLP2 knockout mice. Brain Res 1999; 842: 439-444.
99.35 Lichtenthaler SF, Multhaup G, Masters CL, Beyreuther K. A novel substrate for
analyzing Alzheimer’s disease γ-secretase. FEBS Lett 1999; 453: 288-292.
99.36 Multhaup G, Masters CL. Metal binding and radical generation of proteins in human
neurological disease and aging. In: Metal Ions in Biological Systems, Volume 36.
Interrelations Between Free Radicals and Metal Ions in Life Processes. Edited by Sigl A, Sigl
H. New York: Marcel Dekker; 1999: 365-387.
99.37 Weidemann A, Paliga K, Dürrwang U, Reinhard FBM, Evin G, Masters CL, Beyreuther
K. Cleavage of the Alzheimer’s disease amyloid precursor protein during apoptosis by
activated caspases. In: Alzheimer’s Disease and Related Disorders: Etiology, Pathogenesis and
Therapeutics. Edited by Iqbal K, Swaab DF, Winblad B, Wisniewski HM. Chichester:
John Wiley and Sons; 1999: 391-396.
99.38 Caswell MD, Mok SS, Henry A, Cappai R, Klug G, Beyreuther K, Masters CL, Small
DH. The amyloid β-protein precursor of Alzheimer’s disease is degraded
extracellularly by a Kunitz protease inhibitor domain-sensitive trypsin-like serine
protease in cultures of chick sympathetic neurons. Eur J Biochem 1999; 266: 509-516.
99.39 Masters CL. [Book Review] Story of an obsession. Prion Biology and Diseases. Edited by
Prusiner SB. Nature 1999; 402: 581-582.
99.40 Small DH, Clarris HL, Williamson TG, Reed G, Key B, Mok SS, Beyreuther K, Masters
CL, Nurcombe V. Neurite-outgrowth regulating functions of the amyloid protein
precursor of Alzheimer’s disease. J Alzheimers Dis 1999; 1: 275-285.
2000
38

June, 2012
00.01 Mok SS, Clippingdale AB, Beyreuther K, Masters CL, Barrow CJ, Small DH. Aβ
peptides and calcium influence secretion of the amyloid protein precursor from chick
sympathetic neurons in culture. J Neurosci Res 2000; 61: 449-457.
00.02 Smith MJ, Humphrey KE, Cappai R, Beyreuther K, Masters CL, Cotton RGH. Correct
heteroduplex formation for mutation detection analysis. Mol Diagn 2000; 5: 67-73.
00.03 Lichtenthaler SF, Masters CL, Beyreuther K. Proteolytic processing of the amyloid
precursor protein of Alzheimer’s disease. In: Handbook of Experimental Pharmacology,
Volume 140: Retinoids; Proteases as Targets for Therapy. Edited by von der Helm K, Korant
BD, Cheronis JC. Berlin: Springer-Verlag; 2000: 359-374.
00.04 Emilien G, Maloteaux J-M, Beyreuther K, Masters CL. Alzheimer disease: mouse
models pave the way for therapeutic opportunities. Arch Neurol 2000; 57: 176-181.
00.05 Masters CL, Beyreuther K. Genetic basis of resistance to Alzheimer’s disease and
related neurodegenerative diseases. In: Genes and Resistance to Disease. Edited by
Boulyjenkov V, Berg K, Christen Y. Berlin: Springer; 2000: 121-131.
00.06 Masters CL, Beyreuther K. Genomic Neurology. Arch Neurol 2000; 57: 53.
00.07 Bergsdorf C, Paliga K, Kreger S, Masters CL, Beyreuther K. Identification of ciselements
regulating exon 15 splicing of the amyloid precursor protein pre-mRNA.
J Biol Chem 2000; 275: 2046-2056.
00.08 Ritchie C, McLean C, Beyreuther K, Masters C. The role of Aβ amyloid in the
pathogenesis of Alzheimer’s disease. In: Dementia, Second Edition. Edited by O’Brien J,
Ames D, Burns A. London: Arnold; 2000: 493-504.
00.09 Collins S, Boyd A, Fletcher A, Byron K, Harper C, McLean CA, Masters CL. Novel
prion protein gene mutation in an octogenarian with Creutzfeldt-Jakob disease. Arch
Neurol 2000; 57: 1058-1063.
00.10 Kwok JBJ, Li Q-X, Hallupp M, Whyte S, Ames D, Beyreuther K, Masters CL, Schofield
PR. Novel Leu723Pro amyloid precursor protein mutation increases amyloid β42(43)
peptide levels and induces apoptosis. Ann Neurol 2000; 47: 249-253.
00.11 Postuma RB, He W, Nunan J, Beyreuther K, Masters CL, Barrow CJ, Small DH.
Substrate-bound β-amyloid peptides inhibit cell adhesion and neurite outgrowth in
primary neuronal cultures. J Neurochem 2000; 74: 1122-1130.
00.12 Culvenor JG, Evin G, Cooney MA, Wardan H, Sharples RA, Maher F, Reed G,
Diehlmann A, Weidemann A, Beyreuther K, Masters CL. Presenilin 2 expression in
neuronal cells: induction during differentiation of embryonic carcinoma cells. Exp Cell
Res 2000; 255: 192-206.
00.13 Thompson A, White AR, McLean C, Masters CL, Cappai R, Barrow CJ.
Amyloidogenicity and neurotoxicity of peptides corresponding to the helical regions of
PrP c . J Neurosci Res 2000; 62: 293-301.
39

June, 2012
00.14 Evin G, Le Brocque D, Culvenor JG, Galatis D, Weidemann A, Beyreuther K, Masters
CL, Cappai R. Presenilin 1 expression in yeast lowers secretion of the amyloid
precursor protein. Neuroreport, 2000; 11: 405-408.
00.15 Emilien G, Beyreuther K, Masters CL, Maloteaux J-M. Prospects for pharmacological
intervention in Alzheimer disease. Arch Neurol 2000; 57: 454-459.
00.16 Coulson EJ, Paliga K, Beyreuther K, Masters CL. What the evolution of the amyloid
protein precursor supergene family tells us about its function. Neurochem Int 2000; 36:
175-184.
00.17 Collins S, Boyd A, Fletcher A, Gonzales M, McLean CA, Byron K, Masters CL.
Creutzfeldt-Jakob disease: diagnostic utility of 14-3-3 protein immunodetection in
cerebrospinal fluid. J Clin Neurosci 2000; 7: 203-208.
00.18 Collins S, Boyd A, Fletcher A, Gonzales MF, McLean CA, Masters CL. Recent advances
in the pre-mortem diagnosis of Creutzfeldt-Jakob disease. J Clin Neurosci 2000; 7: 195-
202.
00.19 Campbell BCV, Li Q-X, Culvenor JG, Jäkälä P, Cappai R, Beyreuther K, Masters CL,
McLean CA. Accumulation of insoluble α-synuclein in dementia with Lewy bodies.
Neurobiol Dis 2000; 7: 192-200.
00.20 Cherny RA, Barnham KJ, Lynch T, Volitakis I, Li Q-X, McLean CA, Multhaup G,
Beyreuther K, Tanzi RE, Masters CL, Bush AI. Chelation and intercalation:
complementary properties in a compound for the tretment of Alzheimer’s disease. J
Struct Biol 2000; 130: 209-216.
00.21 Weidemann A, Paliga K, Dürrwang U, Reinhard F, Zhang D, Sandbrink R, Evin G,
Masters CL, Beyreuther K. Interaction of the presenilins with the amyloid precursor
protein (APP). In: Methods in Molecular Medicine, Volume 32: Alzheimer’s Disease: Methods
and Protocols. Edited by Hooper NM. Totowa, NJ: Humana Press; 2000: 333-344.
00.22 Fassbender K, Masters C, Beyreuther K. Alzheimer’s disease: An inflammatory
disease? Neurobiol Aging 2000; 21: 433-436.
00.23 Borchardt T, Schmidt C, Camakaris J, Cappai R, Masters CL, Beyreuther K, Multhaup
G. Differential effects of zinc on amyloid precursor protein (APP) processing in copperresistant
variants of cultured Chinese hamster ovary cells. Cell Mol Biol 2000; 46: 785-
795.
00.24 Masters CL. [Book Review] Neurodegenerative Dementias: Clinical Features and
Pathological Mechanisms. Edited by Clark CM, Trojanowski JQ. J Alzheimers Dis 2000;
2: 303-304.
40

June, 2012
2001
01.01 Masters CL, Beyreuther K. The Worster-Drought syndrome and other syndromes of
dementia with spastic paraparesis: the paradox of molecular pathology. J Neuropathol
Exp Neurol 2001; 60: 317-319.
01.02 Yakubovskaya MG, Neschastnova AA, Humphrey KE, Babon JJ, Popenko VI, Smith
MJ, Lambrinakos A, Lipatova ZV, Dobrovolskaia MA, Cappai R, Masters CL, Belitsky
GA, Cotton RG. Interaction of linear homologous DNA duplexes via Holliday junction
formation. Eur J Biochem 2001; 268: 7-14.
01.03 Jayasena ULHR, Gribble SK, McKenzie A, Beyreuther K, Masters CL, Underwood JR.
Identification of structural variations in the carboxyl terminus of Alzheimer’s diseaseassociated
βA4[1-42] amyloid using a monoclonal antibody. Clin Exp Immunol 2001;
124: 297-305.
01.04 Smith MJ, Kwok JBJ, McLean CA, Kril JJ, Broe GA, Nicholson GA, Cappai R, Hallupp
M, Cotton RGH, Masters CL, Schofield PR, Brooks WS. Variable phenotype of
Alzheimer’s disease with spastic paraparesis. Ann Neurol 2001; 49: 125-129.
01.05 McLean CA, Beyreuther K, Masters CL. Molecular pathology of early onset dementia.
In: Early-Onset Dementia: A Multidisciplinary Approach. Edited by Hodges JR. Oxford:
Oxford University Press; 2001: 165-189.
01.06 Beher D, Wrigley JDJ, Nadin A, Evin G, Masters CL, Harrison T, Castro JL, Shearman
MS. Pharmacological knockdown of the presenilin 1 heterodimer by a novel γ-secretase
inhibitor – implications for presenilin biology. J Biol Chem 2001; 276: 45394-45402.
01.07 Campbell BCV, McLean CA, Culvenor JG, Gai WP, Blumbergs PC, Jäkälä P, Beyreuther
K, Masters CL, Li Q-X. The solubility of α-synuclein in multiple system atrophy differs
from that of dementia with Lewy bodies and Parkinson’s disease. J Neurochem 2001;
76: 87-96.
01.08 Evin G, Sharples RA, Weidemann A, Reinhard FBM, Carbone V, Culvenor JG,
Holsinger RMD, Sernee MF, Beyreuther K, Masters CL. Aspartyl protease inhibitor
pepstatin binds to the presenilins of Alzheimer’s disease. Biochemistry 2001; 40: 8359-
8368.
01.09 White AR, Guirguis R, Brazier MW, Jobling MF, Hill AF, Beyreuther K, Barrow CJ,
Masters CL, Collins SJ, Cappai R. Sublethal concentrations of prion peptide PrP106-126
or the amyloid beta peptide of Alzheimer's disease activates expression of proapoptotic
markers in primary cortical neurons. Neurobiol Dis 2001; 8: 299-316.
01.10 White AR, Huang X, Jobling MF, Barrow CJ, Beyreuther K, Masters CL, Bush AI,
Cappai R. Homocysteine potentiates copper- and amyloid beta peptide-mediated
toxicity in primary neuronal cultures: possible risk factors in the Alzheimer’s-type
neurodegnerative pathways. J Neurochem 2001; 76: 1509-1520.
41

June, 2012
01.11 Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ,
Volitakis I, Fraser FW, Kim Y-S, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther
K, Zheng H, Tanzi RE, Masters CL, Bush AI. Treatment with a copper-zinc chelator
markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease
transgenic mice. Neuron 2001; 30: 665-676. [see also Previews: Gouras GK, Beal MF.
Metal chelator decreases Alzheimer β-amyloid plaques. Neuron 2001; 30: 641-642.]
01.12 Collie A, Maruff P, Shafiq-Antonacci R, Smith M, Hallup M, Schofield PR, Masters CL,
Currie J. Memory decline in healthy older people: Implications for identifying mild
cognitive impairment. Neurology 2001; 56: 1533-1538.
01.13 Masters CL, Beyreuther K. Henryk M. Wisniewski and the amyloid theory of
Alzheimer's disease. J Alzheimers Dis 2001; 3: 83-86.
01.14 Stewart LR, White AR, Jobling MF, Needham BE, Maher F, Thyer J, Beyreuther K,
Masters CL, Collins SJ, Cappai R. Involvement of the 5-lipoxygenase pathway in the
neurotoxicity of the prion peptide PrP106-126. J Neurosci Res 2001; 65: 565-572.
01.15 Jobling MF, Huang X, Stewart LR, Barnham KJ, Curtain C, Volitakis I, Perugini M,
White AR, Cherny RA, Masters CL, Barrow CJ, Collins SJ, Bush AI, Cappai R. Copper
and zinc binding modulates the aggregation and neurotoxic properties of the prion
peptide PrP106-126. Biochemistry 2001; 40: 8073-8084.
01.16 Collins S, McLean CA, Masters CL. Gerstmann-Sträussler-Scheinker syndrome, fatal
familial insomnia, and kuru: a review of these less common human transmissible
spongiform encephalopathies. J Clin Neurosci 2001; 8: 387-397.
01.17 Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ,
Masters CL, Bush AI, Barnham KJ. Alzheimer's disease amyloid-β binds copper and
zinc to generate an allosterically ordered membrane-penetrating structure containing
superoxide dismutase-like subunits. J Biol Chem 2001; 276: 20466-20473.
01.18 McLean CA, Beyreuther K, Masters CL. Amyloid Aβ levels in Alzheimer's disease – A
diagnostic tool and the key to understanding the natural history of Aβ? J Alzheimer
Dis 2001; 3: 305-312.
01.19 Beyreuther K, Christen Y, Masters CL (Eds.). Research and Perspectives in Alzheimer’s
Disease. Neurodegenerative Disorders: Loss of Function Through Gain of Function. Berlin:
Springer-Verlag; 2001: pp189.
01.20 Masters CL, Beyreuther K. The natural history of Alzheimer's disease: Minding the
gaps in understanding the mechanisms of neurodegeneration. In: Research and
Perspectives in Alzheimer’s Disease. Neurodegenerative Disorders: Loss of Function Through
Gain of Function. Edited by Beyreuther K, Christen Y, Masters CL. Berlin: Springer-
Verlag; 2001: 1-21.
42

June, 2012
01.21 Beyreuther K, Masters CL. Alzheimer's disease: Physiological and pathogenetic role of
the amyloid precursor protein (APP), its Aβ-amyloid domain and free Aβ-amyloid
peptide. In: Research and Perspectives in Alzheimer’s Disease. Neurodegenerative Disorders:
Loss of Function Through Gain of Function. Edited by Beyreuther K, Christen Y, Masters
CL. Berlin: Springer-Verlag; 2001: 97-117.
01.22 Masters CL. The emerging European epidemic of variant Creutzfeldt-Jakob disease and
bovine spongiform encephalopathy: Lessons for Australia. Med J Aust 2001; 174: 160-
161.
01.23 Nunan J, Shearman MS, Checler F, Cappai R, Evin G, Beyreuther K, Masters CL, Small
DH. The C-terminal fragment of the Alzheimer’s disease amyloid protein precursor is
degraded by a proteasome-dependent mechanism distinct from γ-secretase. Eur J
Biochem 2001; 268: 5329-5336.
01.24 Chan SWY, Collins S, Masters CL, Walker DM. Classical and variant Creutzfeldt-Jakob
diseases and their potential impact on the practice of clinical dentistry in Australia.
Aust Dent J 2001; 46: 251-257.
01.25 Bush AI, Masters CL. Clioquinol’s return: cautions from Japan. Science 2001; 292: 2251-
2252 [Response to letter from Tabira T].
01.26 Boyd A, Fletcher A, Lee JS, Lewis V, Masters CL, Collins SJ. Transmissible spongiform
encephalopathies in Australia. Commun Dis Intell 2001; 25: 248-252.
01.27 Fassbender K, Masters C, Beyreuther K. Alzheimer’s disease: Molecular concepts and
therapeutic targets. Naturwissenschaften 2001; 88: 261-267.
2002
02.01 Fuller SJ, Storey E, Li Q-X, Beyreuther K, Masters CL. Alzheimer’s disease Aβ peptides
are secreted by fresh and transformed human lymphocytes. Alzheimers Rep 2002; 5:
29-40.
02.02 Hamilton JA, Whitty G, White AR, Jobling MF, Thompson A, Barrow CJ, Cappai R,
Beyreuther K, Masters CL. Alzheimer’s disease amyloid beta and prion protein
amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced
proliferative response to CSF-1 (M-CSF). Brain Res 2002; 940: 49-54.
02.03 Halliday G, Ng T, Rodriguez M, Harding A, Blumbergs P, Evans W, Fabian V, Fryer J,
Gonzales M, Harper C, Kalnins R, Masters CL, McLean C, Milder DG, Pamphlett R,
Scott G, Tannenberg A, Kril J. Consensus neuropathological diagnosis of common
dementia syndromes: testing and standardising the use of multiple diagnostic criteria.
Acta Neuropathol 2002; 104: 72-78.
02.04 Li Q-X, Beyreuther K, Masters CL. Alzheimer’s Disease. In: Platelets. Edited by
Michelson AD. New York: Academic Press; 2002: 503-511.
43

June, 2012
02.05 Li Q-X, Campbell BCV, McLean CA, Thyagarajan D, Gai W-P, Kapsa RM, Beyreuther
K, Masters CL, Culvenor JG. Platelet α- and γ-synucleins in Parkinson’s disease and
normal control subjects. J Alzheimer Dis 2002; 4: 309-315.
02.06 Lichtenthaler SF, Beher D, Grimm HS, Wang R, Shearman MS, Masters CL, Beyreuther
K. The intramembrane cleavage site of the amyloid precursor protein depends on the
length of its transmembrane domain. Proc Natl Acad Sci USA 2002; 99: 1365-1370.
02.07 Holsinger RMD, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression
of the amyloid precursor β-secretase in Alzheimer’s disease. Ann Neurol 2002; 51: 783-
786.
02.08 Collins S, Boyd A, Fletcher A, Kaldor J, Hill A, Farish S, McLean C, Ansari Z, Smith M,
Masters CL. Creutzfeldt-Jakob disease cluster in an Australian rural city. Ann Neurol
2002; 52: 115-118.
02.09 Evin G, Smith MJ, Tziotis A, McLean C, Canterford L, Sharples RA, Cappai R,
Weidemann A, Beyreuther K, Cotton RGH, Masters CL, Culvenor JG. Alternative
transcripts of presenilin-1 associated with frontotemporal dementia. Neuroreport 2002;
13: 719-723. [See corrected version reprinted, 13: 917-921]
02.10 Simons A, Ruppert T, Schmidt C, Schlicksupp A, Pipkorn R, Reed J, Masters CL White
AR, Cappai R, Beyreuther K, Bayer TA, Multhaup G. Evidence for a copper-binding
superfamily of the amyloid precursor protein. Biochemistry 2002; 41: 9310-9320.
02.11 Fodero LR, Sáez-Valero J, McLean CA, Martins RN, Beyreuther K, Masters CL,
Robertson TA, Small DH. Altered glycosylation of acetylcholinesterase in APP (SW)
Tg2576 transgenic mice occurs prior to amyloid plaque deposition. J Neurochem 2002;
81: 441-448.
02.12 Culvenor JG, Rietze RL, Bartlett PF, Masters CL, Li Q-X. Oligodendrocytes from neural
stem cells express α-synuclein: increased numbers from presenilin 1 deficient mice.
Neuroreport 2002; 13: 1305-1308.
02.13 White AR, Multhaup G, Galatis D, McKinstry WJ, Parker MW, Pipkorn R, Beyreuther
K, Masters CL, Cappai R. Contrasting, species-dependent modulation of coppermediated
neurotoxicity by the Alzheimer’s disease amyloid precursor protein. J
Neurosci 2002; 22: 365-376.
02.14 Weidemann A, Eggert S, Reinhard FBM, Vogel M, Paglia K, Baier G, Masters CL,
Beyreuther K, Evin G. A novel ε-cleavage within the transmembrane domain of the
Alzheimer amyloid precursor protein demonstrates homology with Notch processing.
Biochemistry 2002; 41: 2825-2835.
02.15 Filla A, De Michele G, Cocozza S, Patrignani A, Volpe G, Castaldo I, Ruggiero G,
Bonavita V, Masters C, Casari G, Bruni A. Early onset autosomal dominant dementia
with ataxia, extrapyramidal features, and epilepsy. Neurology 2002; 58: 922-928.
44

June, 2012
02.16 Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, Cappai R, Masters CL,
Tanzi RE, Inestrosa NC, Bush AI. Metalloenzyme-like activity of Alzheimer’s disease βamyloid:
Cu-dependent catalytic conversion of dopamine, cholesterol, and biological
reducing agents to neurotoxic H202. J Biol Chem 2002; 277: 40302-40308.
02.17 Mok SS, Turner BJ, Beyreuther K, Masters CL, Barrow CJ, Small DH. Toxicity of
substrate-bound amyloid peptides on vascular smooth muscle cells is enhanced by
homocysteine. Eur J Biochem 2002; 269: 3014-3022.
02.18 Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters CL. Quinacrine does not
prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002; 52:
503-506.
02.19 Collins S, Boyd A, Lee JS, Lewis V, Fletcher A, McLean CA, Law M, Kaldor J, Smith MJ,
Masters CL. Creutzfeldt-Jakob disease in Australia 1970-1999. Neurology 2002; 59:
1365-1371.
02.20 Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL,
Merlini G, Saraiva MJ, Sipe JD. Amyloid fibril protein nomenclature - 2002. Amyloid
2002; 9: 197-200.
02.21 Tammer AH, Coia G, Cappai R, Fuller S, Masters CL, Hudson P, Underwood JR.
Generation of a recombinant Fab antibody reactive with the Alzheimer’s diseaserelated
Aβ peptide. Clin Exp Immunol 2002; 129: 453-463.
02.22 Evin G, Holsinger RMD, Eggert S, Weidemann A, Canterford L, Hoke D, Gandy S,
McLean C, Beyreuther K, Masters CL. Carboxyl-terminal fragments of the amyloid
precursor protein in Alzheimer’s disease brain: detection of γ-secretase products. Brain
Aging 2002; 2: 61-66.
02.23 Laws SM, Hone E, Taddei K, Harper C, Dean B, Mc[C]Lean C, Masters C,
Lautenschlager N, Gandy SE, Martins RN. Variation at the APOE –491 promoter locus
is associated with altered brain levels of apolipoprotein E. Mol Psychiatry 2002; 7: 886-
890.
02.24 Lewis V, Boyd A, Masters CL, Collins SJ. Apparently sporadic CJD and covert healthcare
transmissions. Lancet Neurol 2002; 1: 470-471.
02.25 Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL,
Bush AI, Li Q-X. Overexpression of Alzheimer’s disease amyloid-β opposes the agedependent
elevations of brain copper and iron. J Biol Chem 2002; 277: 44670-44676.
02.26 Masters CL. [Book Review] Annual Review of Gerontology and Geriatrics, Volume 21.
Edited by Cristofalo VJ, Adelman R, Schaie KW. Int Psychogeriatr 2002; 14: 428-429.
02.27 Khalil Z, Poliviou H, Maynard CJ, Beyreuther K, Masters CL, Li Q-X. Mechanisms of
peripheral microvascular dysfunction in transgenic mice overexpressing the
Alzheimer’s disease amyloid Aβ protein. J Alzheimer Dis 2002; 4: 467-478.
45

June, 2012
2003
03.01 White AR, Maher F, Brazier MW, Jobling MR, Thyer J, Stewart LR, Thompson A,
Gibson R, Masters CL, Multhaup G, Beyreuther K, Barrow CJ, Collins SJ, Cappai R.
Diverse fibrillar peptides directly bind the Alzheimer's amyloid precursor protein and
amyloid precursor-like protein 2 resulting in cellular accumulation. Brain Res 2003;
966: 231-244.
03.02 Barnham KJ, McKinstry WJ, Multhaup G, Galatis D, Morton CJ, Curtain CC,
Williamson NA, White AR, Hinds MG, Norton RS, Beyreuther K, Masters CL, Parker
MW, Cappai R. Structure of the Alzheimer’s disease amyloid precursor protein copper
binding domain: a regulator of neuronal copper homeostasis. J Biol Chem 2003; 278:
17401-17407.
03.03 Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C,
Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT Jr, Bush AI. Cytosolic
β-amyloid deposition and supranuclear cataracts in lenses from people with
Alzehimer’s disease. Lancet 2003; 361: 1258-1265.
03.04 Shafiq-Antonacci R, Maruff P, Masters C, Currie J. Spectrum of saccade system
function in Alzheimer disease. Arch Neurol 2003; 60: 1272-1278.
03.05 Dean B, Laws SM, Hone E, Taddei K, Scarr E, Thomas EA, Harper C, Mc[C]Lean C,
Masters C, Lautenschlager N, Gandy SE, Martins RN. Increased levels of
apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biol Psychiatry
2003; 54: 616-622.
03.06 Grziwa B, Grimm MOW, Masters CL, Beyreuther K, Hartmann T, Lichtenthaler SF. The
transmembrane domain of the amyloid precursor protein in microsomal membranes is
on both sides shorter than predicted. J Biol Chem 2003; 278: 6803-6808.
03.07 Curtain CC, Ali FE, Smith DG, Bush AI, Masters CL, Barnham KJ. Metal ions, pH, and
cholesterol regulate the interactions of Alzheimer’s disease amyloid-β peptide with
membrane lipid. J Biol Chem 2003; 278: 2977-2982.
03.08 Evin G, Zhu A, Holsinger RMD, Masters CL, Li Q-X. Proteolytic processing of the
Alzheimer’s disease amyloid precursor protein in brain and platelets. J Neurosci Res
2003; 74: 386-392.
03.09 Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L Kiers L,
Cherny R, Li Q-X, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D,
Davis S, Beyreuther K, Tanzi RE, Masters CL. Metal-protein attenuation with
iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in
Alzheimer disease: a pilot Phase 2 clinical trial. Arch Neurol 2003; 60: 1685-1691.
[see also Editorial Comment: Rosenberg RN. Metal chelation therapy for Alzheimer
disease. Arch Neurol 2003; 60: 1678-1679].
46

June, 2012
03.10 Thomas EA, Laws SM, Sutcliffe JG, Harper C, Dean B, Mc[C]Lean C, Masters C,
Lautenschlager N, Gandy SE, Martins RN. Apolipoprotein D levels are elevated in
prefrontal cortex of subjects with Alzheimer’s disease: No relation to apolipoprotein E
expression or genotype. Biol Psychiatry 2003; 54: 136-141.
03.11 Miklossy J, Taddei K, Suva D, Verdile G, Fonte J, Fisher C, Gnjec A, Ghika J, Suard F,
Mehta PD, McLean CA, Masters CL, Brooks WS, Martins RN. Two novel presenilin-1
mutations (Y256S and Q222H) are associated with early-onset Alzheimer’s disease.
Neurobiol Aging 2003; 24: 655-662.
03.12 Masters CL, Beyrue[eu]ther K. Molecular pathogenesis of Alzheimer’s disease. In:
Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Edited
by Dickson D. Basel: The International Society of Neuropathology, ISN Neuropath
Press; 2003: 69-73.
03.13 Green AJE, Sivtseva TM, Danilova AP, Osakovsky VL, Vladimirtsev VA, Zeidler M,
Knight RS, Platonov FA, Shatunov A, Alekseev VP, Krivoshapkin VG, Masters CL,
Gajdusek DC, Goldfarb LG. Viliuisk encephalomyelitis: intrathecal synthesis of
oligoclonal IgG. J Neurol Sci 2003; 212: 69-73.
03.14 Sernee MF, Evin G, Culvenor JG, Villadangos JA, Beyreuther K, Masters CL, Cappai R.
Selecting cells with different Alzheimer’s disease γ-secretase activity using FACS:
differential effect of presenilin exon 9 deletion on γ- and ε-cleavage. Eur J Biochem
2003; 270: 495-506.
03.15 Beher D, Fricker M, Nadin A, Clarke EE, Wrigley JDJ, Li Y-M, Culvenor JG, Masters
CL, Harrison T, Shearman MS. In vitro characterization of the presenilin-dependent γsecretase
complex using a novel affinity ligand. Biochemistry 2003; 42: 8133-8142.
03.16 Kourie JI, Kenna BL, Tew D, Jobling MF, Curtain CC, Masters CL, Barnham KJ, Cappai
R. Copper modulation of ion channels of PrP[106-126] mutant prion peptide fragments.
J Membr Biol 2003; 193: 35-45.
03.17 Lewis V, Collins S, Hill AF, Boyd A, Mc[L]ean CA, Smith M, Masters CL. Novel prion
protein insert mutation associated with prolonged neurodegenerative illness.
Neurology 2003; 60: 1620-1624.
03.18 Evin G, Sernee MF, Barnham KJ, Holsinger RMD, Culvenor JG, Hoke DE, Li Q-X,
Smith D, Maynard C, Tickler A, Huang X, Opazo C, Carrington D, Kocak G, Volitakis I,
Mok SS, Ciccotosto G, Williamson NA, Beyreuther K, Wade J, Curtain CC, Cherny RA,
Bush AI, Masters CL, Cappai R. Modulation of Alzheimer’s disease Aβ pathways for
rational therapeutic intervention: secretase inhibition and metalloprotein active
compounds. In: Alzheimer’s Disease and Related Disorders: Research Advances. Edited by
Iqbal K, Winblad B. Bucharest: Ana Aslan International Academy of Aging; 2003: 513-
523.
47

June, 2012
03.19 Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, Lam Y-H,
Carrington D, Tew D, Kocak G, Volitakis I, Separovic F, Barrow CJ, Wade JD, Masters
CL, Cherny RA, Curtain CC, Bush AI, Cappai R. Neurotoxic, redox-competent
Alzheimer’s β-amyloid is released from lipid membrane by methionine oxidation. J
Biol Chem 2003; 278: 42959-42965.
03.20 Lau T-L, Barnham KJ, Curtain CC, Masters CL, Separovic F. Magnetic resonance
studies of β-amyloid peptides. Aust J Chem 2003; 56: 349-356.
03.21 Nunan J, Williamson NA, Hill AF, Sernee MF, Masters CL, Small DH. Proteasomemediated
degradation of the C-terminus of the Alzheimer’s disease β-amyloid protein
precursor: effect of C-terminal truncation on the production of β-amyloid protein. J
Neurosci Res 2003; 74: 378-385.
03.22 Bahadi R, Farrelly PV, Kenna BL, Curtain CC, Masters CL, Cappai R, Barnham KJ,
Kourie JI. Cu 2+ -induced modification of the kinetics of Aβ(1-42) channels. Am J Physiol
Cell Physiol 2003; 285: C873-C880.
03.23 Bush AI, Masters CL, Tanzi RE. Copper, β-amyloid, and Alzheimer’s disease: tapping a
sensitive connection. Proc Natl Acad Sci USA 2003; 100: 11193-11194.
03.24 Cherny RA, Masters CL, Bush AI. The medicinal metallochemistry of Alzheimer’s
disease. Curr Med Chem Immunol Endocr Metab Agents 2003; 3: 9-13.
03.25 Ciccotosto GD, Barnham KJ, Cherny RA, Masters CL, Bush AI, Curtain CC, Cappai R,
Tew D. Methionine oxidation: implications for the mechanism of toxicity of the βamyloid
peptide from Alzheimer’s disease. Lett Pept Sci 2003; 10: 413-417.
2004
04.01 Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies.
Lancet 2004; 363: 51-61.
04.02 Culvenor JG, Ilaya NT, Ryan MT, Canterford L, Hoke DE, Williamson NA, McLean
CA, Masters CL, Evin G. Characterization of presenilin complexes from mouse and
human brain using blue native gel electrophoresis reveals high expression in
embryonic brain and minimal change in complex mobility with pathogenic presenilin
mutations. Eur J Biochem 2004; 271: 375-385.
04.03 Barnham KJ, Cherny RA, Cappai R, Melov S, Masters CL, Bush AI. Metal-protein
attenuating compounds (MPACs) for the treatment of Alzheimer’s disease. Drug
Design Rev-Online 2004; 1: 75-82.
04.04 Brooke FJ, Boyd A, Klug GM, Masters CL, Collins SJ. Lyodura use and the risk of
iatrogenic Creutzfeldt-Jakob disease in Australia. Med J Aust 2004; 180: 177-181.
04.05 Smith MJ, Sharples RA, Evin G, McLean CA, Dean B, Pavey G, Fantino E, Cotton RGH,
Imaizumi K, Masters CL, Cappai R, Culvenor JG. Expression of truncated presenilin 2
splice variant in Alzheimer’s disease, bipolar disorder, and schizophrenia brain cortex.
Mol Brain Res 2004; 127: 128-135.
48

June, 2012
04.06 Robins-Browne RM, Strugnell RA, Masters CL. Vaccines against Alzheimer’s disease.
In: New Generation Vaccines, Third Edition, Revised and Expanded. Edited by Levine MM,
Kaper JB, Rappuoli R, Liu MA, Good MF. New York: Marcel Dekker; 2004: 997-1002.
04.07 White AR, Barnham KJ, Huang X, Vol[i]takis I, Beyreuther K, Masters CL, Cherny RA,
Bush AI, Cappai R. Iron inhibits neurotoxicity induced by trace copper and biological
reductants. J Biol Inorg Chem 2004; 9: 269-280.
04.08 Yao S, Cherny RA, Bush AI, Masters CL, Barnham KJ. Characterizing bathocuproine
self-association and subsequent binding to Alzheimer’s disease amyloid β-peptide by
NMR. J Pept Sci 2004; 10: 210-217.
04.09 Maruff P, Collie A, Darby D, Weaver-Cargin J, Masters C, Currie J. Subtle memory
decline over 12 months in mild cognitive impairment. Dement Geriatr Cogn Disord
2004; 18: 342-348.
04.10 Barnham KJ, Haeffner F, Ciccotosto GD, Curtain CC, Tew D, Mavros C, Beyreuther K,
Carrington D, Masters CL, Cherny RA, Cappai R, Bush AI. Tyrosine gated electron
transfer is key to the toxic mechanism of Alzheimer’s disease β-amyloid. FASEB J 2004;
18: 1427-1429.
04.11 Ilaya NT, Evin G, Masters CL, Culvenor JG. Nicastrin expression in mouse peripheral
tissues is not co-ordinated with presenilin and is high in muscle. J Neurochem 2004; 91:
230-237.
04.12 Holsinger RMD, McLean CA, Collins SJ, Masters CL, Evin G. Increased β-secretase
activity in cerebrospinal fluid of Alzheimer’s disease subjects. Ann Neurol 2004; 55:
898-899.
04.13 Eggert S, Paliga K, Soba P, Evin G, Masters CL, Weidemann A, Beyreuther K. The
proteolytic processing of the amyloid precursor protein gene family members APLP-1
and APLP-2 involves α-, β-, γ-, and ε-like cleavages: modulation of APLP-1 processing
by N-glycosylation. J Biol Chem 2004; 279: 18146-18156.
04.14 Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress.
Nat Rev Drug Discov 2004; 3: 205-214.
04.15 George AJ, Holsinger RMD, McLean CA, Laughton KM, Beyreuther K, Evin G, Masters
CL, Li Q-X. APP intracellular domain is increased and soluble Aβ is reduced with dietinduced
hypercholesterolemia in a transgenic mouse model of Alzheimer disease.
Neurobiol Dis 2004; 16: 124-132.
04.16 Bellingham SA, Ciccotosto GD, Needham BE, Fodero LR, White AR, Masters CL,
Cappai R, Camakaris J. Gene knockout of amyloid precursor protein and amyloid
precursor-like protein-2 increases cellular copper levels in primary mouse cortical
neurons and embryonic fibroblasts. J Neurochem 2004; 91: 423-428.
49

June, 2012
04.17 Rekas A, Adda CG, Aquilina JA, Barnham KJ, Sunde M, Galatis D, Williamson NA,
Masters CL, Anders RF, Robinson CV, Cappai R, Carver JA. Interaction of the
molecular chaperone αB-crystallin with α-synuclein: effects on amyloid fibril formation
and chaperone activity. J Mol Biol 2004; 340: 1167-1183.
04.18 Masters CL. Halford Oration – Testing the Amyloid Theory. Chiron 2004; 5: 10-13.
04.19 Ciccotosto GD, Tew D, Curtain CC, Smith D, Carrington D, Masters CL, Bush AI,
Cherny RA, Cappai R, Barnham KJ. Enhanced toxicity and cellular binding of a
modified amyloid β peptide with a methionine to valine substitution. J Biol Chem
2004; 279: 42528-42534.
04.20 Turner BJ, Li Q-X, Laughton KM, Masters CL, Lopes EC, Atkin JD, Cheema SS. Brain
β–amyloid accumulation in transgenic mice expressing mutant superoxide dismutase
1. Neurochem Res 2004; 29: 2281-2286.
04.21 Zhu A-Q, Li Q-X, Zhang X-S, Teng C-Q, Chu Y-D, Masters CL, George A,
Cardamon[g]e T, Evin G. Effects of Rhodiola on Alzheimer pathology and open field
activity in APP-C100 transgenic mice. Chin J Gerontol 2004; 24: 530-533.
04.22 Klug GM, Lewis V, Boyd A, Lee JS, Masters CL, Collins SJ. Creutzfeldt-Jakob disease
surveillance in Australia January 1970 to December 2003. Commun Dis Intell 2004; 28:
356-358.
04.23 Ritchie CW, Bush AI, Masters CL. Metal-protein attenuating compounds and
Alzheimer’s disease. Expert Opin Investig Drugs 2004; 13: 1585-1592.
04.24 Tyler KL. Commentary: Gibbs CJ Jr, Amyx HL, Bacote A, Masters CL, Gajdusek DC.
Oral transmission of kuru, Creutzfeldt-Jakob disease, and scrapie to nonhuman
primates. J Infect Dis 1980; 142: 205-208. J Infect Dis 2004; 190: 653-660. [Commentary
on, and reprint of, reference 80.06]
2005
05.01 Masters CL, Beyreuther K. The neuropathology of Alzheimer’s disease in the year 2005.
In: Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics. Edited by Beal
MF, Lang AE, Ludolph AC. Cambridge: Cambridge University Press; 2005: 433-440.
05.02 Ali FE, Separovic F, Barrow CJ, Cherny RA, Fraser F, Bush AI, Masters CL, Barnham
KJ. Methionine regulates copper/hydrogen peroxide oxidation products of Aβ. J Pept
Sci 2005; 11: 353-360.
05.03 Collins SJ, Lewis V, Brazier MW, Hill AF, Lawson VA, Klug GM, Masters CL. Extended
period of asymptomatic prion disease after low dose inoculation: assessment of
detection methods and implications for infection control. Neurobiol Dis 2005; 20: 336-
346.
50

June, 2012
05.04 Andersen OM, Reiche J, Schimdt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim
CAF, Breiderhoff T, Jansen P, Wu X, Bales KR, Cappai R, Masters CL, Gliemann J,
Mufson EJ, Hyman BT, Paul SM, Nykjær A, Willnow TE. Neuronal sorting proteinrelated
receptor sorLA/LR11 regulates processing of the amyloid precursor protein.
Proc Natl Acad Sci USA 2005; 102: 13461-13466.
05.05 Cappai R, Cheng F, Ciccotosto GD, Needham BE, Masters CL, Multhaup G, Fransson
L-Å, Mani K. The amyloid precursor protein (APP) of Alzheimer disease and its
paralog, APLP2, modulate the Cu/Zn-nitric oxide-catalyzed degradation of glypican-1
heparan sulfate in vivo. J Biol Chem 2005; 280: 13913-13920.
05.06 Maynard CJ, Bush AI, Masters CL, Cappai R, Li Q-X. Metals and amyloid-β in
Alzheimer’s disease. Int J Exp Pathol 2005; 86: 147-159.
05.07 Soba P, Eggert S, Wagner K, Zentgraf H, Siehl K, Kreger S, Löwer A, Langer A, Merdes
G, Paro R, Masters CL, Müller U, Kins S, Beyreuther K. Homo- and heterodimerization
of APP family members promotes intercellular adhesion. EMBO J 2005; 24: 3624-3634.
05.08 Masters CL. Neuropathology of Alzheimer’s disease. In: Dementia, Third Edition. Edited
by Burns A, O’Brien J, Ames D. London: Hodder Arnold; 2005: 393-407.
05.09 Ritchie CW, McLean C, Beyreuther K, Masters CL. Role of Aβ amyloid in the
pathogenesis of Alzheimer’s disease. In: Dementia, Third Edition. Edited by Burns A,
O’Brien J, Ames D. London: Hodder Arnold; 2005: 426-435.
05.10 Lewis V, Hill AF, Klug GM, Boyd A, Masters CL, Collins SJ. Australian sporadic CJD
analysis supports endogenous determinants of molecular-clinical profiles. Neurology
2005; 65: 113-118.
05.11 Evin G, Canterford LD, Hoke DE, Sharples RA, Culvenor JG, Masters CL. Transitionstate
analogue γ–secretase inhibitors stabilize a 900 kDa presenilin/nicastrin complex.
Biochemistry 2005; 44: 4332-4341.
05.12 Duncan RE, Delatycki MB, Collins SJ, Boyd A, Masters CL, Savulescu J. Ethical
considerations in presymptomatic testing for variant CJD. J Med Ethics 2005; 31: 625-
630.
05.13 Crouch PJ, Blake R, Duce JA, Ciccotosto GD, Li Q-X, Barnham KJ, Curtain CC, Cherny
RA, Cappai R, Dyrks T, Masters CL, Trounce IA. Copper-dependent inhibition of
human cytochrome c oxidase by a dimeric conformer of amyloid-β1-42. J Neurosci 2005;
25: 672-679.
05.14 Kong GK-W, Galatis D, Barnham KJ, Polekhina G, Adams JJ, Masters CL, Cappai R,
Parker MW, McKinstry WJ. Crystallization and preliminary crystallographic studies of
the copper-binding domain of the amyloid precursor protein of Alzheimer’s disease.
Acta Crystallogr 2005; 61: 93-95.
05.15 Lawson VA, Collins SJ, Masters CL, Hill AF. Prion protein glycosylation. J Neurochem
2005; 93: 793-801.
51

June, 2012
05.16 Cappai R, Leck S-L, Tew DJ, Williamson NA, Smith DP, Galatis D, Sharples RA,
Curtain CC, Ali FE, Cherny RA, Culvenor JG, Bottomley SP, Masters CL, Barnham KJ,
Hill AF. Dopamine promotes α–synuclein aggregation into SDS-resistant soluble
oligomers via a distinct folding pathway. FASEB J 2005; 19: 1377-1399.
05.17 Novakovic KE, Villemagne VL, Rowe CC, Masters CL. Rare genetically defined causes
of dementia. Int Psychogeriatr 2005; 17: S149-S194.
05.18 Tickler AK, Smith DG, Ciccotosto GD, Tew DJ, Curtain CC, Carrington D, Masters CL,
Bush AI, Cherny RA, Cappai R, Wade JD, Barnham KJ. Methylation of the imidazole
side chains of the Alzheimer disease amyloid-β peptide results in abolition of
superoxide dismutase-like structures and inhibition of neurotoxicity. J Biol Chem 2005;
280: 13355-13363.
05.19 Papazian V, Jackson T, Pham T, Liu X, Greguric I, Loc’h C, Rowe C, Villemagne V,
Masters CL, Katsifis A. The preparation of 123/125 I-clioquinol for the study of Aβ protein
in Alzheimer’s disease. J Labelled Comp Radiopharm 2005; 48: 473-484.
05.20 Yarovaya N, Schot R, Fodero L, McMahon M, Mahoney A, Williams R, Verbeek E, de
Bondt A, Hampson M, van der Spek P, Stubbs A, Masters CL, Verheijen FW, Mancini
GMS, Venter DJ. Sialin, an anion transporter defective in sialic acid storage diseases,
shows highly variable expression in adult mouse brain, and is developmentally
regulated. Neurobiol Dis 2005; 19: 351-365.
05.21 Villemagne VL, Rowe CC, Macfarlane S, Novakovic KE, Masters CL. Imaginem
oblivionis: the prospects of neuroimaging for early detection of Alzheimer’s disease.
J Clin Neurosci 2005; 12: 221-230.
05.22 Yuan FF, Biffin S, Brazier MW, Suarez M, Cappai R, Hill AF, Collins, SJ, Sullivan JS,
Middleton D, Multhaup G, Geczy AF, Masters CL. Detection of prion epitopes on PrP c
and PrP sc of transmissible spongiform encephalopathies using specific monoclonal
antibodies to PrP. Immunol Cell Biol 2005; 83: 632-637.
05.23 Hoke DE, Tan J-L, Ilaya NT, Culvenor JG, Smith SJ, White AR, Masters CL, Evin GM. In
vitro gamma-secretase cleavage of the Alzheimer’s amyloid precursor protein correlates
to a subset of presenilin complexes and is inhibited by zinc. FEBS J 2005; 272: 5544-
5557.
05.24 Klug GM, Boyd A, Lewis V, Kvasnicka M, Lee JS, Masters CL, Collins SJ. Creutzfeldt-
Jakob disease: Australian surveillance update to 31 December 2004. Commun Dis
Intell 2005; 29: 269-271.
05.25 Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S-I, Masters
CL, Merlini G, Saraiva MJ, Sipe JD. Amyloid: Toward terminology clarification. Report
from the Nomenclature Committee of the International Society of Amyloidosis.
Amyloid 2005; 12: 1-4.
52

June, 2012
2006
06.01 Maynard CJ, Cappai R, Volitakis I, Cherny RA, Masters CL, Li Q-X, Bush AI. Gender
and genetic background effects on brain metal levels in APP transgenic and normal
mice: implications for Alzheimer β-amyloid pathology. J Inorg Biochem 2006; 100: 952-
962.
06.02 Klug GM, Boyd A, Lewis V, Douglass SL, Argent R, Lee JS, Masters CL, Collins SJ.
Creutzfeldt-Jakob Disease: Australian surveillance update to December 2005. Commun
Dis Intell 2006; 30: 144-147.
06.03 Weaver Cargin J, Maruff P, Collie A, Masters C. Mild memory impairment in healthy
older adults is distinct from normal aging. Brain Cogn 2006; 60: 146-155.
06.04 Koh CHV, Whiteman M, Li Q-X, Halliwell B, Jenner AM, Wong BS, Laughton KM,
wenk M, Masters CL, Beart PM, Bernard O, Cheung NS. Chronic exposure to U18666A
is associated with oxidative stress in cultured murine cortical neurons. J Neurochem
2006; 98: 1278-1289.
06.05 Ritchie CW, Cappai R, Masters C. Clioquinol treatment in familiar early onset of
Alzheimer’s disease. Pharmacopsychiatry 2006; 39: 80.
[Response to Ibach B, Haen E, Marienhagen J, Hajak G. Pharmacopsychiatry 2005; 38:
178-179]
06.06 Masters CL. Obituary: Harold D Attwood. Chiron 2006; 5: 39-40.
06.07 Duce JA, Smith DP, Blake RE, Crouch PJ, Li Q-X, Masters CL, Trounce IA. Linker
histone H1 binds to disease associated amyloid-like fibrils. J Mol Biol 2006; 361: 493-
505.
06.08 Mok SS, Losic D, Barrow CJ, Turner BJ, Masters CL, Martin LL, Small DH. The βamyloid
peptide of Alzheimer’s disease decreases adhesion of vascular smooth muscle
cells to the basement membrane. J Neurochem 2006; 96: 53-64.
06.09 Masters CL. Amyloid-β the target for AD treatment and prevention. In: Proceedings of
the 2006 Master Class in Alzheimer’s disease: April 7-9, 2006: Sydney. Pfizer, Australia.
2006; 17-18.
06.10 Brazier MW, Lewis V, Ciccotosto GD, Klug GM, Lawson VA, Cappai R, Ironside JW,
Masters CL, Hill AF, White AR, Collins S. Correlative studies support lipid
Peroxidation is linked to PrPres propagation as an early primary pathogenic event in
prion disease. Brain Res Bull 2006; 68: 346-354..
06.11 Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for
Alzheimer’s disease: Implications for neuroimaging and therapeutics. J Neurochem
2006; 97: 1700-1725.
06.12 Masters CL, Beyreuther K. Alzheimer’s centennial legacy: prospects for rational
therapeutic intervention targeting the Aβ amyloid pathway. Brain 2006; 129: 2823-2839.
53

June, 2012
06.13 Masters CL. Towards a unitary theory of neurodegeneration in the aging brain. In:
Proceedings of the 4th Dubai International Conference for Medical Sciences: Dubai. SHAMS J
Med Sci 2006: 7-10.
06.14 George AJ, Holsinger RMD, McLean CA, Tan S-S, Scott HS, Cardamone T, Cappai R,
Masters CL, Li Q-X. Decreased phosphatidylethanolamine binding protein expression
correlates with Aβ accumulation in the Tg2576 mouse model of Alzheimer’s disease.
Neurobiol Aging 2006; 27: 614-623.
06.15 Evin G, Sernee MF, Masters CL. Inhibition of γ–secretase as a therapeutic intervention
for Alzheimer’s disease: prospects, limitations and strategies. CNS Drugs 2006; 20: 351-
372.
06.16 Barnham KJ, Cappai R, Beyreuther K, Masters CL, Hill AF. Delineating common
molecular mechanisms in Alzheimer’s and prion diseases. Trends Biochem Sci 2006;
31: 465-472.
06.17 Masters CL, Beyreuther K. Pathways to the discovery of the neuronal origin and
proteolytic biogenesis of Aβ amyloid of Alzheimer’s disease. In: Alzheimer: 100 Years
and Beyond. Edited by Jucker M, Beyreuther K, Haass C, Nitsch R, Christen Y. Berlin:
Springer; 2006: 142-149.
06.18 Li Q-X, Mok SS, Laughton KM, McLean CA, Volitakis I, Cherny RA, Cheung NS, White
AR, Masters CL. Overexpression of Aβ is associated with acceleration of onset of motor
impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral
sclerosis mouse model. Aging Cell 2006; 5: 153-165.
06.19 Crouch PJ, Barnham KJ, Duce JA, Blake RE, Masters CL, Trounce IA. Copperdependent
inhibition of cytochrome c oxidase by Aβ1-42 requires reduced methionine
at residue 35 of the Aβ peptide. J Neurochem 2006; 99: 226-236.
06.20 Smith DP, Smith DG , Curtain CC, Boas JF, Pilbrow JR, Ciccotosto GD, Lau T-L, Tew
DJ, Perez K, Wade JD, Bush AI, Drew SC, Separovic F, Masters CL, Cappai R, Barnham
KJ. Copper-mediated amyloid-β toxicity is associated with an intermolecular histidine
bridge. J Biol Chem 2006; 281: 15145-15154.
06.21 Holsinger RMD, Lee JS, Boyd A, Masters CL, Collins SJ. CSF BACE1 activity is
increased in CJD and Alzheimer disease versus other dementias. Neurology 2006; 67:
710-712. [See also Correction: Neurology 2006; 67: 1105]
06.22 Masters CL, Beyreuther K. Pathways to the discovery of the Aβ amyloid of Alzheimer’s
disease. J Alzheimer Dis 2006; 9: S155-S161.
06.23 White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE,
Holsinger RMD, Evin G, Cherny RA, Hill AF, Barnham KJ, Li Q-X, Bush AI, Masters
CL. Degradation of the Alzheimer disease amyloid β-peptide by metal-dependent upregulation
of metalloprotease activity. J Biol Chem 2006; 281: 17670-17680.
54

June, 2012
06.24 Gralle M, Oliveira CLP, Guerreiro LH, McKinstry WJ, Galatis D, Masters CL, Cappai R,
Parker MW, Ramos CHI, Torriani I, Ferreira ST. Solution conformation and heparininduced
dimerization of the full-length extracellular domain of the human amyloid
precursor protein. J Mol Biol 2006; 357: 493-508.
06.25 Lau T-L, Ambroggio EE, Tew DJ, Cappai R, Masters CL, Fidelio GD, Barnham KJ,
Separovic F. Amyloid-β peptide disruption of lipid membranes and the effect of metal
ions. J Mol Biol 2006; 356: 759-770.
06.26 Andersen OM, Schmidt V, Spoelgen R, Gliemann J, Behlke J, Galatis D, McKinstry WJ,
Parker MW, Masters CL, Hyman BT, Cappai R, Willnow TE. Molecular dissection of
the interaction between amyloid precursor protein and its neuronal trafficking receptor
SorLA/LR11. Biochemistry 2006; 45: 2618-2628.
06.27 Collins SJ, Sanchez-Juan P, Masters CL, Klug GM, van Duijn C, Poleggi A, Pocchiari M,
Almonti S, Cuadrado-Corrales N, de Pedro-Cuesta J, Budka H, Gelpi E, Glatzel M,
Tolnay M, Hewer E, Zerr I, Heinemann U, Kretszchmar HA, Jansen GH, Olsen E,
Mitrova E, Alpérovitch A, Brandel J-P, Mackenzie J, Murray K, Will RG. Determinants
of diagnostic investigation sensitivities across the clinical spectrum of sporadic
Creutzfeldt-Jakob disease. Brain 2006; 129: 2278-2287.
06.28 Villemagne VL, Ng S, Cappai R, Barnham KJ, Fodero-Tavoletti MT, Rowe CC, Masters
CL. La Lunga Attesa: Towards a molecular approach to neuroimaging and therapeutics
in Alzheimer’s disease. Neuroradiol J 2006; 19: 453-474.
06.29 Collie A, Maruff P, Darby DG, Masters C, Currie J. The Melbourne Aging Study. In:
Mild Cognitive Impairment: International Perspectives. Edited by Tuokko HA, Hultsch DF.
New York: Taylor & Francis; 2006: 93-113.
06.30 Opazo C, Luza S, Villemagne VL, Volitakis I, Rowe C, Barnham KJ, Strozyk D, Masters
CL, Cherny RA, Bush AI. Radioiodinated clioquinol as a biomarker for β-amyloid:
Zn2+ complexes in Alzheimer’s disease. Aging Cell 2006; 5: 69-79.
06.31 Sim CH, Lio DSS, Mok SS, Masters CL, Hill AF, Culvenor JG, Cheng H-C. C-terminal
truncation and Parkinson’s disease-associated mutations down-regulate the protein
serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet 2006; 15:
3251-3262.
2007
07.01 Ritchie CW, Ames D, Masters CL, Cummings J (Eds.). Therapeutic Strategies in Dementia.
Oxford: Clinical Publishing; 2007: 362pp.
07.02 Masters CL, Beyreuther K. Disease-modifying therapeutic strategies for Alzheimer’s
disease: targeting the APP/Aβ pathway. In: Therapeutic Strategies in Dementia. Edited by
Ritchie CW, Ames D, Masters CL, Cummings J. Oxford: Clinical Publishing; 2007: 91-
110.
07.03 Li Q-X, Masters CL. Alzheimer’s disease. In: Platelets, Second Edition. Edited by
Michelson AD. New York: Elsevier/Academic Press; 2007: 779-789.
55

June, 2012
07.04 Villemagne VL, Cappai R, Barnham KJ, Cherny RA, Opazo C, Novakovic KE, Rowe
CC, Masters CL. The Aβcentric pathway of Alzheimer’s disease. In: Abeta Peptide and
Alzheimer’s Disease: Celebrating a Century of Research. Edited by Barrow CJ, Small DH.
London: Springer; 2007: 5-36.
07.05 Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL,
Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O’Keefe G,
Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging β-amyloid
burden in aging and dementia. Neurology 2007; 68: 1718-1725. [See also Rowe CC,
Villemagne VL, Masters CL. Correspondence: In reply to Linazasoro G. Neurology
2008; 70: 1650]
07.06 Smith DP, Ciccotosto GD, Tew DJ, Fodero-Tavoletti MT, Johanssen T, Masters CL,
Barnham KJ, Cappai R. Concentration dependent Cu 2+ induced aggregation and
dityrosine formation of the Alzheimer’s disease amyloid-β peptide. Biochemistry 2007;
46: 2881-2891.
07.07 Li Q-X, Mok SS, Laughton, KM, McLean CA, Cappai R, Masters CL, Culvenor JG,
Horne MK. Plasma α-synuclein is decreased in subjects with Parkinson’s disease.
Exp Neurol 2007; 204: 583-588.
07.08 Vella LJ, Sharples RA, Lawson VA, Masters CL, Cappai R, Hill AF. Packaging of prions
into exosomes is associated with a novel pathway of PrP processing. J Pathol 2007; 211:
582-590.
07.09 Kong GK-W, Adams JJ, Harris HH, Boas JF, Curtain CC, Galatis D, Masters CL,
Barnham KJ, McKinstry WJ, Cappai R, Parker MW. Structural studies of the
Alzheimer’s amyloid precursor protein copper-binding domain reveal how it binds
copper ions. J Mol Biol 2007; 367: 148-161.
07.10 Masters CL. Epilogue. In: Prions in Humans and Animals. Edited by Hörnlimann B,
Riesner D, Kretzschmar H. Berlin: Walter De Gruyter; 2007: 655.
07.11 Lawson VA, Stewart JD, Masters CL. Enzymatic detergent treatment protocol that
reduces protease-resistant prion protein load and infectivity from surgical-steel
monofilaments contaminated with a human-derived prion strain. J Gen Virol 2007; 88:
2905-2914.
07.12 Melov S, Adlard PA, Morten K, Johnson F, Golden TR, Hinerfeld D, Schilling B,
Mavros C, Masters CL, Volitakis I, Li Q-X, Laughton K, Hubbard A, Cherny RA,
Gibson B, Bush AI. Mitochondrial oxidative stress causes hyperphosphorylation of tau.
PloS ONE 2007; 2: e536.
07.13 Rowe DB, Lewis V, Needham M, Rodriguez M, Boyd A, McLean C, Roberts H, Masters
CL, Collins SJ. Novel prion protein gene mutation presenting with subacute PSP-like
syndrome. Neurology 2007; 68: 868-870.
56

June, 2012
07.14 Weaver Cargin J, Maruff P, Collie A, Shafiq-Antonacci R, Masters C. Decline in verbal
memory in non-demented older adults. J Clin Exp Neuropsychol 2007; 29: 706-718.
07.15 Ng S, Villemagne VL, Berlangieri S, Lee S-T, Cherk M, Gong SJ, Ackermann U, Saunder
T, Tochon-Danguy H, Jones G, Smith C, O’Keefe G, Masters CL, Rowe CC. Visual
assessment versus quantitative assessment of 11 C-PIB PET and 18 F-FDG PET for
detection of Alzheimer’s Disease. J Nucl Med 2007; 48: 547-552.
07.16 Ng SY, Villemagne VL, Masters CL, Rowe CC. Evaluating atypical dementia
syndromes using positron emission tomography with carbon 11-labeled Pittsburgh
Compound B. Arch Neurol 2007; 64: 1140-1144.
07.17 Melrose HL, Kent CB, Taylor JP, Dachsel JC, Hinkle KM, Delldonne A, Lincoln SJ, Mok
SS, Culvenor JG, Masters CL, Tyndall GM, Ross OA, Dickson DW, Farrer MJ. A
comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain
and Lewy body disease. Neuroscience 2007; 147: 1047-1058.
07.18 Khalil Z, LoGuidice D, Khodr B, Maruff P, Masters C. Impaired peripheral endothelial
microvascular responsiveness in Alzheimer’s disease. J Alzheimer Dis 2007; 11: 25-32.
07.19 Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE,
Masters CL, Rowe CC. β-amyloid imaging and memory in non-demented individuals:
evidence for preclinical Alzheimer’s disease. Brain 2007; 130: 2837-2844.
07.20 Lau T-L, Gehman JD, Wade JD, Perez K, Masters CL, Barnham KJ, Separovic F.
Membrane interactions and the effect of metal ions of the amyloidogenic fragment
Aβ(25-35) in comparison to Aβ(1-42). BBA-Biomembranes 2007; 1768: 2400-2408.
07.21 Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE,
Leone L, Perez K, Cortés M, Culvenor JG, Li Q-X, Laughton KN, Rowe CC, Masters CL,
Cappai R, Villemagne VL. In vitro characterization of Pittsburgh compound-B binding
to Lewy bodies. J Neurosci 2007; 27: 10365-10371.
07.22 Masters CL. Future directions: the Aβ amyloid pathway as the target for diagnosing,
preventing, or treating Alzheimer’s disease. In: Molecular and Cellular Neurobiology
Series. Neurobiology of Alzheimer’s Disease, Third edition. Edited by Dawbarn D, Allen SJ.
Oxford: Oxford University Press; 2007: 413-438.
07.23 Caragounis A, Du T, Filiz G, Laughton KM, Volitakis I, Sharples RA, Cherny RA,
Masters CL, Drew SC, Hill AF, Li Q-X, Crouch PJ, Barnham KJ, White AR. Differential
modulation of Alzheimer’s disease amyloid β-peptide accumulation by diverse classes
of metal ligands. Biochem J 2007; 407: 435-450.
07.24 Westermark P,Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S-I, Masters
CL, Merlini G, Saraiva MJ, Sipe JD. A primer of amyloid nomenclature. Amyloid 2007;
14: 179-183.
07.25 Masters CL. Journal of Environmental Neuroscience and Biomedicine – A new journal
and a new experiment. J Environ Neurosci Biomed 2007; 1: 74-75.
57

June, 2012
07.26 Klug GM, Boyd A, Lewis V, Douglass SL, Roberts H, Argent R, Masters CL, Collins SJ.
Creutzfeldt-Jakob Disease: Australian surveillance update to March 2007.
Commun Dis Intell 2007; 31: 194-197.
07.27 Lau T-L, Gehman JD, Wade JD, Masters CL, Barnham KJ, Separovic F. Cholesterol and
clioquinol modulation of Aβ(1-42) interaction with phospholipid bilayers and metals.
BBA-Biomembranes 2007; 1768: 3135-3144.
07.28 Vladimirtsev VA, Nikitina RS, Renwick N, Ivanova AA, Danilova AP, Platonov FA,
Krivoshapkin VG, McLean CA, Masters CL, Gajdusek DC, Goldfarb LG. Family
clustering of Viliuisk Encephalomyelitis in traditional and new geographic regions.
Emerg Infect Dis 2007; 13: 1321-1326.
2008
08.01 Crouch PJ, Harding S-ME, White AR, Camakaris J, Bush AI, Masters CL. Mechanisms
of Aβ mediated neurodegeneration in Alzheimer’s disease. Int J Biochem Cell Biol
2008; 40: 181-198.
08.02 Smith DP, Tew DJ, Hill AF, Bottomley SP, Masters CL, Barnham KJ, Cappai R.
Formation of a high affinity lipid-binding intermediate during the early aggregation
phase of α-synuclein. Biochemistry 2008; 47: 1425-1434.
08.03 Weaver Cargin J, Collie A, Masters C, Maruff P. The nature of cognitive complaints in
healthy older adults with and without objective memory decline. J Clin Exp
Neuropsychol 2008; 30: 245-257.
08.04 Donnelly PS, Caragounis A, Du T, Laughton KM, Volitakis I, Cherny RA, Sharples RA,
Hill AF, Li Q-X, Masters CL, Barnham KJ, White AR. Selective intracellular release of
copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of
Alzheimer disease amyloid-β peptide. J Biol Chem 2008; 283: 4568-4577.
08.05 Sharples RA, Vella LJ, Nisbet RM, Naylor R, Perez K, Barnham KJ, Masters CL, Hill AF.
Inhibition of γ-secretase causes increased secretion of amyloid precursor protein Cterminal
fragments in association with exosomes. FASEB J 2008; 22: 1469-1478.
08.06 Du T, Ciccotosto GD, Cranston GA, Kocak G, Masters CL, Crouch PJ, Cappai R, White
AR. Neurotoxicity from glutathione depletion is mediated by Cu-dependent p53
activation. Free Radic Biol Med 2008; 44: 44-55.
08.07 Filiz G, Caragounis A, Bica L, Du T, Masters CL, Crouch PJ, White AR. Clioquinol
inhibits peroxide-mediated toxicity through up-regulation of phosphoinositol-3-kinase
and inhibition of p53 activity. Int J Biochem Cell Biol 2008; 40: 1030-1042.
08.08 Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF,
Currie J, Chan SG, Jones G, Tochon-Danguy H, O’Keefe GO, Masters CL, Rowe CC. Aβ
deposits in older non-demented individuals with cognitive decline are indicative of
preclinical Alzheimer’s disease. Neuropsychologia 2008; 46: 1688-1697.
58

08.09 Brazier MW, Doctrow SR, Masters CL, Collins SJ. A manganese-superoxide
dismutase/catalase mimetic extends survival in a mouse model of human prion
disease. Free Radic Biol Med 2008; 45: 184-192.
June, 2012
08.10 Giannakis E, Pacífico J, Smith DP, Hung LW, Masters CL, Cappai R, Wade JD,
Barnham KJ. Dimeric structures of α-synuclein bind preferentially to lipid membranes.
BBA-Biomembranes 2008; 1778: 1112-1119.
08.11 Price KA, Filiz G, Caragounis A, Du T, Laughton KM, Masters CL, Sharples RA, Hill
AF, Li Q-X, Donnelly PS, Barnham KJ, Crouch PJ, White AR. Activation of epidermal
growth factor receptor by metal-ligand complexes decreases levels of extracellular
amyloid beta peptide. Int J Biochem Cell Biol 2008; 40: 1901-1917.
08.12 George S, van den Buuse M, Mok SS, Masters CL, Li Q-X, Culvenor JG. α-synuclein
transgenic mice exhibit reduced anxiety-like behaviour. Exp Neurol 2008; 210: 788-792.
08.13 Miles LA, Wun KS, Crespi GAN, Fodero-Tavoletti MT, Galatis D, Bagley CJ,
Beyreuther K, Masters CL, Cappai R, McKinstry WJ, Barnham KJ, Parker MW.
Amyloid-β-anti-amyloid-β complex structure reveals an extended conformation in the
immunodominant B-cell epitope. J Mol Biol 2008; 377: 181-192.
08.14 Du T, La Fontaine SL, Abdo M, Bellingham SA, Greenough M, Volitakis I, Cherny RA,
Bush AI, Hudson P, Camakaris J, Mercer JF, Crouch PJ, Masters CL, Perreau VN, White
AR. Investigating copper-regulated protein expression in Menkes fibroblasts using
antibody microarrays. Proteomics 2008; 8: 1819-1831.
08.15 Tew DJ, Bottomley SP, Smith DP, Ciccotosto GD, Babon J, Hinds MG, Masters CL,
Cappai R, Barnham KJ. Stabilization of neurotoxic soluble β-sheet-rich conformations
of the Alzheimer’s disease amyloid-β peptide. Biophys J 2008; 94: 2752-2766.
08.16 Barnham KJ, Kenche VB, Ciccotosto GD, Smith DP, Tew DJ, Liu X, Perez K, Cranston
GA, Johanssen TJ, Volitakis I, Bush AI, Masters CL, White AR, Smith JP, Cherny RA,
Cappai R. Platinum-based inhibitors of amyloid-β as therapeutic agents for
Alzheimer’s disease. Proc Natl Acad Sci USA 2008; 105: 6813-6818.
08.17 Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O’Keefe
G, Någren K, Chaudhury KR, Masters CL, Brooks DJ. Amyloid load in Parkinson’s
disease dementia and Lewy Body dementia measured with [11C]PIB-positron emission
tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331-1338.
08.18 Villemagne VL, Fodero-Tavoletti MT, Pike KE, Cappai R, Masters CL, Rowe CC. The
ART of loss: Aβ imaging in the evaluation of Alzheimer’s disease and other dementias.
Mol Neurobiol 2008; 38: 1-15.
08.19 Lawson VA, Vella LJ, Stewart JD, Sharples RA, Klemm H, Machalek DM, Masters CL,
Cappai R, Collins SJ, Hill AF. Mouse-adapted sporadic human Creutzfeldt-Jakob
disease prions propagate in cell culture. Int J Biochem Cell Biol 2008; 40: 2793-2801.
59

June, 2012
08.20 Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X,
Smith JP, Perez K, Laughton K, Li Q-X, Charman SA, Nicolazzo JA, Wilkins S, Deleva
K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI.
Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy
quinoline analogs is associated with decreased interstitial Aβ. Neuron 2008; 59: 43-55.
08.21 Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, Tochon-Danguy
H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung
MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Luhman L, Lindemann S,
Dinkelborg LM, Masters CL, Villemagne VL. Imaging of amyloid β in Alzheimer’s
disease with 18 F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol
2008; 7: 129-135.
08.22 Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, Jones G, O’Keefe G,
Masters CL, Ames D, Ellis KA, Maruff P, Currie J, Villemagne VL, Rowe CC, Salvado
O, Ourselin S. Appearance modeling of 11 C PiB PET images: Characterizing amyloid
deposition in Alzheimer’s disease, mild cognitive impairment and healthy aging.
Neuroimage 2008; 43: 430-439.
08.23 Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade
JD, Barnham KJ. Amyloid-β peptide (Aβ) neurotoxicity is modulated by the rate of
peptide aggregation: Aβ dimers and trimers correlate with neurotoxicity. J Neurosci
2008; 28: 11950-11958.
08.24 Needham BE, Wlodek ME, Ciccotosto GD, Fam BC, Masters CL, Proietto J,
Andrikopoulos, S, Cappai R. Identification of the Alzheimer’s disease amyloid
precursor protein (APP) and its homologue APLP2 as essential modulators of glucose
and insulin homeostasis and growth. J Pathol 2008; 215: 155-163.
08.25 Drew SC, Leong SL, Pham CLL, Tew DJ, Masters CL, Miles LA, Cappai R, Barnham KJ.
Cu 2+ binding modes of recombinant α-synuclein – insights from EPR spectroscopy. J
Am Chem Soc 2008; 130: 7766-7773.
08.26 Wun KS, Miles LA, Crespi GAN, Wycherley K, Ascher DB, Barnham KJ, Cappai R,
Beyreuther K, Masters CL, Parker MW, McKinstry WJ. Crystallization and preliminary
X-ray diffraction analysis of the Fab fragment of WO2, an anitibody specific for the Aβ
peptides associated with Alzheimer’s disease. Acta Crystallogr 2008; F64: 438-441.
08.27 Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL,
Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW on behalf of the PBT2-201-EURO
Study Group. Safety, efficacy and biomarker findings of PBT2 in targeting Aβ as a
modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised,
placebo-controlled trial. Lancet Neurol 2008; 7: 779-786. [See also Erratum. Lancet
Neurol 2009; 8: 981.]
08.28 Streltsov VA, Titmuss SJ, Epa VC, Barnham KJ, Masters CL, Varghese JN. The structure
of the amyloid-β peptide high-affinity copper II binding site in Alzheimer disease.
Biophys J 2008; 95: 3447-3456.
60

June, 2012
08.29 Raniga P, Bourgeat P, Fripp J, Acosta O, Villemagne VL, Rowe C, Masters CL, Jones G,
O’Keefe G, Salvado O, Ourselin S. Automated 11 C-PiB standardized uptake value ratio.
Academic Radiol 2008; 15: 1376-1389.
08.30 Klug GM, Boyd A, Lewis V, McGlade AR, Roberts H, Douglass SL, Masters CL, Collins
SJ. Surveillance of Creutzfeldt-Jakob disease in Australia: 2008. Commun Dis Intell
2008; 32: 232-236.
08.31 Masters CL. Community Corner – Anti-inflammatory drugs fall short in Alzheimer’s
disease. Nat Med 2008; 14: 916-916.
2009
09.01 Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo
N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C,
Taddei K, Villemagne V, Woodward M, Ames D and the AIBL Research Group. The
Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and
baseline characteristics of 1112 individuals recruited for a longitudinal study of
Alzheimer’s disease. Int Psychogeriatr 2009; 21: 672-687.
09.02 Crouch PJ, Tew DJ, Du T, Nguyen DN, Caragounis A, Filiz G, Blake RE, Trounce IA,
Soon CPW, Laughton K, Perez KA, Li Q-X, Cherny RA, Masters CL, Barnham KJ, White
AR. Restored degradation of the Alzheimer’s amyloid-β peptide by targeting amyloid
formation. J Neurochem 2009; 108: 1198-1207.
09.03 Tinsley RB, Bye CR, Parish CL, Tziotis-Vais A, George S, Culvenor JG, Li Q-X, Masters
CL, Finkelstein DI, Horne MK. Dopamine D-2 receptor knockout mice develop features
of Parkinson disease. Ann Neurol 2009; 66: 472-484.
09.04 McColl G, Roberts BR, Gunn AP, Perez KA, Tew DJ, Masters CL, Barnham KJ, Cherny
RA, Bush AI. The Caernorhabditis elegans Aβ1-42 model of Alzheimer’s disease
predominantly expresses Aβ3-42. J Biol Chem 2009; 284: 22697-22702.
09.05 Drew SC, Masters CL, Barnham KJ. Alanine-2 carbonyl is an oxygen ligand in Cu2+
coordination of Alzheimer’s disease amyloid-β peptide – relevance to N-terminally
truncated forms. J Am Chem Soc 2009; 131: 8760-8761.
09.06 Maynard CJ, Cappai R, Volitakis I, Laughton KM, Masters CL, Bush AI, Li Q-X. Chronic
exposure to high levels of zinc or copper has little effect on brain metal homestasis or
Aβ accumulation in transgenic APP-C100 mice. Cell Mol Neurobiol 2009; 29: 757-67.
09.07 Bates KA, Verdile G, Li Q-X, Ames D, Hudson P, Masters CL, Martins RN. Clearance
mechanisms of Alzheimer’s amyloid-β peptide: implications for therapeutic design and
diagnostic tests. Mol Psychiatry 2009; 14: 469-486. [See also Erratum. Mol Psychiatry
2009; 14: 1144.]
09.08 Fodero-Tavoletti MT, Cappai R, McLean CA, Pike KE, Adlard PA, Cowie T, Connor
AR, Masters CL, Rowe CC, Villemagne VL. Amyloid imaging in Alzheimer’s disease
and other dementias. Brain Imag Behav 2009; 3: 246-261.
61

June, 2012
09.09 Smith JP, Lal V, Bowser D, Cappai R, Masters CL, Ciccotosto GD. Stimulus pattern
dependence of the Alzheimer’s disease amyloid-β 42 peptide’s inhibition of long term
potentiation in mouse hippocampal slices. Brain Res 2009; 1269: 176-184.
09.10 Minniti AN, Rebolledo DL, Grez PM, Fadic R, Aldunate R, Volitakis I, Cherny RA,
Opazo C, Masters C, Bush AI, Inestrosa NC. Intracellular amyloid formation in muscle
cells of Aβ-transgenic Caenorhabditis elegans: determinants and physiological role in
copper detoxification. Mol Neurodegneration 2009; 4: 2 (1-17).
09.11 Klug GM, Wand H, Boyd A, Law M, Whyte S, Kaldor J, Masters CL, Collins S.
Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob
disease cluster. Brain 2009; 132: 493-501.
09.12 Evered LA, Silbert BS, Scott DA, Maruff P, Laughton KM, Volitakis I, Cowie T, Cherny
RA, Masters CL, Li Q-X. Plasma amyloid β42 and amyloid β40 levels are associated with
early cognitive dysfunction after cardiac surgery. Ann Thoracic Surg 2009; 88: 1426-
1432.
09.13 Crouch PJ, Hung LW, Adlard PA, Cortes M, Lal V, Filiz G, Perez KA, Nurjono M,
Caragounis A, Du T, Laughton K, Volitakis I, Bush AI, Li Q-X, Masters CL, Cappai R,
Cherny RA, Donnelly PS, White AR, Barnham KJ. Increasing Cu bioavailability inhibits
Aβ oligomers and tau phosphorylation. Proc Nat Acad Sci USA 2009; 106: 381-386.
09.14 Robert R, Dolezal O, Waddington L, Hattarki MK, Cappai R, Masters CL, Hudson PJ,
Wark KL. Engineered antibody intervention strategies for Alzheimer’s disease and
related dementias by targeting amyloid and toxic oligomers. Prot Eng Design Select
2009; 22: 199-208.
09.15 Bellingham SA, Coleman LA, Masters CL, Camakaris J, Hill AF. Regulation of prion
gene expression by transcription factors SP1 and metal transcription factor-1. J Biol
Chem 2009; 284: 1291-1301.
09.16 Brazier MW, Wall V, Brazier BW, Masters CL, Collins SJ. Therapeutic interventions
ameliorating prion disease. Expert Rev Anti Infect Ther 2009; 7: 83-105.
09.17 Leong SL, Pham CLL, Galatis D, Fodero-Tavoletti MT, Perez K, Hill AF, Masters CL, Ali
FE, Barnham KJ, Cappai R. Formation of dopamine-mediated α-synuclein soluble
oligomers requires methionine oxidation. Free Rad Biol Med 2009; 46: 1328-1337.
09.18 Haigh CL, Drew SC, Boland M, Masters CL, Barnham KJ, Lawson VA, Collins SJ.
Dominant roles of the polybasic proline motif and copper in PrP23-89-mediated stress
protection response. J Cell Sci 2009; 122: 1518-1528.
09.19 Drew SC, Noble CJ, Masters CL, Hanson GR, Barnham KJ. Pleomorphic copper
coordination by Alzheimer’s disease amyloid-β peptide. J Am Chem Soc 2009; 131:
1195-1207.
62

June, 2012
09.20 Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG. Aβ aggregation and
possible implications in Alzheimer’s disease pathogenesis. J Cell Mol Med 2009; 13:
412-421.
09.21 Biran Y, Masters CL, Barnham KJ, Bush AI, Adlard PA. Pharmacotherapeutic targets in
Alzheimer’s disease. J Cell Mol Med 2009; 13: 61-86.
09.22 Price KA, Crouch PJ, Donnelly PS, Masters CL, White AR, Curtain CC. Membranetargeted
strategies for modulating APP and Aβ-mediated toxicity. J Cell Mol Med
2009; 13: 249-261.
09.23 Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li QX, Masters CL, Cappai R,
Villemagne VL. Characterization of PiB binding to white matter in AD and other
dementias. J Nucl Med 2009; 50: 198-204.
09.24 Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y,
Masters CL, Cappai R, Yanai K, Villemagne VL. In vitro characterisation of BF227
binding to α-synuclein/Lewy Bodies. Eur J Pharmacol 2009; 617:54-8.
09.25 Haigh CL, Lewis V, Vella LJ, Masters CL, Hill AF, Lawson VA, Collins SJ. PrP C related
signal transduction is influenced by copper, membrane integrity, and the alpha
cleavage site. Cell Res 2009; 19:1062-72 .
09.26 Villemagne VL, McLean CA, Reardon K, Boyd A, Lewis V, Klug G, Jones G, Baxendale
D, Masters CL, Rowe CC, Collins SJ. 11 C-PiB PET studies in typical sporadic
Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatr 2009; 80: 998-1001.
09.27 Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe
Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O’Keefe GJ, Masters CL, Mori H,
Rowe CC. High striatal amyloid β-peptide deposition across different autosomal
Alzheimer’s disease mutation types. Arch Neurol 2009; 66; 1537-1544.
09.28 Drew SC, Tew DJ, Masters CL, Cappai R, Barnham KJ. Copper coordination by familial
mutants of Parkinson’s disease-associated α-synuclein. Appl Magn Reson 2009; 36:
223-229.
09.29 Dutescu RM, Li Q-X, Crowston J, Masters CL, Baird PN, Culvenor JG. Amyloid
precursor protein processing and retinal pathology in mouse models of Alzheimer’s
disease. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1213-1221.
09.30 Masters CL. Book Review: The Collectors of Lost Souls: Turning kuru scientists into
whitemen, by Warwick Anderson. Med J Aust 2008; 189(5):1.
www.mja.com.au.ezp.lib.unimelb.edu.au/public/bookroom/2009/masters/masters.html
09.31 Lewis V, Hill AF, Haigh CL, Klug GM, Masters CL, Lawson VA, Collins SJ. Increased
proportions of C1 truncated prion protein protect against cellular M1000 prion
infection. J Neuropathol Exp Neurol 2009; 68: 1125-1135.
63

June, 2012
09.32 Hung YH, Robb EL, Volitakis I, Ho M, Evin G, Li Q-X, Culvenor JG, Masters CL,
Cherny RA, Bush AI. Paradoxical condensation of copper with elevated beta-amyloid in
lipid rafts under cellular copper deficiency conditions: implications for Alzheimer’s
disease. J Biol Chem 2009; 284: 21899-21907.
09.33 Adlard PA, James SA, Bush AI, Masters CL. β-amyloid as a molecular therapeutic
target in Alzheimer’s disease. Drugs Today 2009; 45: 293-304.
09.34 Okamura N, Fodero-Tavoletti MT, Kudo Y, Rowe CC, Furumoto S, Arai H, Masters CL,
Yanai K, Villemagne VL. Advances in molecular imaging for the diagnosis of dementia.
Expert Opin Med Diagn 2009; 3: 705-716.
09.35 Price KA, Caragounis A, Paterson BM, Filiz G, Volitakis I, Masters CL, Barnham KJ,
Donnelly PS, Crouch PJ, White AR. Sustained activation of glial cell epidermal growth
factor receptor by bis(thiosemicarbazonato) metal complexes is associated with
inhibition of protein tyrosine phosphatase activity. J Med Chem 2009; 52:6606-20.
09.36 Klug GM, Boyd A, Lewis V, McGlade A, Stehmann C, Masters CL, Collins SJ.
Surveillance of Creutzfeldt-Jakob disease in Australia: 2009 update. Commun Dis Intell
2009; 33: 188-191.
09.37 Goldfarb LG, Vladimirtsev VA, Platonov FA, Lee-H-S, McLean CA, Masters CL.
Viliuisk encephalomyelitis in Eastern Siberia – analysis of 390 cases. In memory of D.
Carleton Gajdusek. Folia Neuropathol 2009; 47:171-181.
2010
10.01 Bourgeat P, Chételat G, Villemagne VL, Fripp J, Raniga P, Pike K, Acosta O, Szoeke C,
Ourselin S, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Salvado O on behalf
of the AIBL Research Group. β-Amyloid burden in the temporal neocortex is related to
hippocampal atrophy in elderly subjects without dementia. Neurology 2010; 74:121-
127.
10.02 Masters CL. The neuropathology of Alzheimer’s disease. In: Dementia Fourth Edition.
Edited by Burns A, O’Brien J, Ames D. London: Hodder Arnold; 2010: Chapter 49,
p417-431.
10.03 Ritchie C, McLean C, Beyreuther K, Masters CL. The central role of Aβ amyloid in the
pathogenisis of Alzheimer’s Disease. In: Dementia Fourth Edition. Edited by Ames D,
Burns A, O’Brien J. London: Hodder Arnold; 2010: Chapter 51, p438-450.
10.04 George S, Mok SS, Nurjono M, Ayton S, Finkelstein DI, Masters CL, Li Q-X, Culvenor
JG. α-Synuclein transgenic mice reveal compensatory increases in Parkinson’s diseaseassociated
proteins DJ-1 and Parkin and have enhanced α-synuclein and PINK1 levels
after rotenone treatment. J Molecular Neurosci 2010; 42: 243-254.
10.05 Soon CPW, Crouch PJ, Turner BJ, McLean CA, Laughton KM, Atkin JD, Masters CL,
White AR, Li Q-X. Serum matrix metalloproteinase-9 activity is dysregulated with
disease progression in the mutant SOD1 transgenic mice. Neuromuscul Disord 2010;
20(4):260-266.
64

June, 2012
10.06 Klug GM, Boyd A, McGlade A, Stehmann C, Masters CL, Collins SJ. Surveillance of
Creutzfeldt-Jakob disease in Australia: 2010 update. Commun Dis Intell 2010: 34: 96-
101.
10.07 George AJ, Gordon L, Beissbarth T, Koukoulas I, Holsinger RMD, Perreau V, Cappai R,
Tan S-S, Masters CL, Scott HS, Li Q-X. A serial analysis of gene expression profile of the
Alzheimer’s disease Tg2576 mouse model. Neurotox Res 2010; 17:360-379.
10.08 Ellis KA, Rowe CC, Villemagne VL, Martins RN, Masters CL, Salvado O, Szoeke C,
Ames D, the AIBL research group. Addressing population aging and Alzheimer’s
disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration
with the Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s & Dementia 2010;
6: 291-296.
10.09 Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K,
Johanssen T, Greenough M A, Cho HH, Galatis D, Moir R D, Masters C L, McLean C,
Tanzi R E, Cappai R, Barnham K J, Ciccotosto GD, Rogers JT, Bush A I . Iron-export
ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer’s
Disease. Cell 2010; 142: 857-67.
10.10 Bahar-Fuchs A, Chételat G, Villemagne VL, Moss S, Pike KE, Masters CL, Rowe C,
Savage G. Olfactory deficits and amyloid-β burden in Alzheimer’s disease, mild
cognitive impairment, and healthy aging: a PiB PET study. J Alzheimers Dis 2010; 22:
1081-1087.
10.11 Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR, Bourgeat P, Salvado
O, Bedo J, Hutton CA, Faux NG, Masters CL, Barnham KJ. Blood-borne amyloid-β
dimer correlates with clinical markers of Alzheimer’s disease. J Neurosci 2010; 30:6315-
6322.
10.12 Lawson VA, Lumicisi B, Welton J, Machalek D, Gouramanis K, Klemm HM, Stewart JD,
Masters CL, Hoke DE, Collins SJ, Hill AF. Glycosaminoglycan sulphation affects the
seeded misfolding of a mutant prion protein. PLoS One 2010; 5: E12351
10.13 Harrison CF, Lawson VA, Coleman BM, Kim Y-S, Masters CL, Cappai R, Barnham KJ,
Hill AF. Conservation of a glycine-rich region in the prion protein is required for
uptake of prion infectivity. J Biol Chem 2010; 285: 20213-20223.
10.14 Perreau VM, Orchard S, Adlard PA, Belligham SA, Cappai R, Ciccotosto GD, Cowie TF,
Crouch PJ, Duce JA, Evin G, Faux NG, Hill AF, Hung YH, James S, Li Q-X, Mok SS,
Tew DJ, White AR, Bush AI, Hermjakob H, Masters CL. A domain level interaction
network of amyloid precursor protein and Aβ of Alzheimer’s disease. Proteomics 2010;
10: 2377-2395. [Supporting Information DOI 10.1002/pmic.200900773]
10.15 Chételat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, Szoeke C,
Martins RN, O’Keefe GJ, Salvado O, Masters CL, Rowe CC and the Australian Imaging
Biomarkers and Lifestyle Research Group. Relationship between atrophy and βamyloid
deposition in Alzheimer disease. Ann Neurol. 2010; 67: 317-324. [See also
65

June, 2012
editorial: Rabinovici GD and Roberson ED. Beyond diagnosis: what biomarkers are
teaching us about the “bio”logy of Alzheimer disease. Ann Neurol 2010; 67: 283-285.]
10.16 Guipponi M, Li Q-X, Hyde L, Beissbarth T, Smyth GK, Masters CL, Scott HS. SAGE
analysis of genes differentially expressed in presymptomatic TgSOD1 G93A transgenic
mice identified celluar processes involved in early stage of ALS pathology. J Mol
Neurosci 2010, 41: 172-182.
10.17 Villemagne VL, Pike K, Pejoska S, Boyd A, Power M, Jones G, Masters CL, Rowe CC.
11C-PiB PET ABri imaging in Worster-Drought syndrome (Familial British Dementia): A
case report. J Alzheimers Dis 2010; 19: 423-428.
10.18 Boon WC, van den Buuse M, Wegener N, Martin S, Chua HK, Bush AI, Masters CL,
Adlard PA, Li Q-X. Behavioural phenotype of APPC100.V717F transgenic mice overexpressing
a mutant Aβ-bearing fragment is associated with reduced NMDA receptor
density. Behav Brain Res 2010; 209: 27-35.
10.19 Caragounis A, Price KA, Soon CPW, Filiz G, Masters CL, Li Q-X, Crouch PJ, White AR.
Zinc induces depletion and aggregation of endogenous TDP-43. Free Rad Bio Med
2010; 48: 1152-1161.
10.20 Boyd A, Klug GMJA, Schonberger LB, McGlade A, Brandel J-P, Masters CL, Collins SJ.
Iatrogenic Creutzfeldt-Jakob disease in Australia: time to amend infection control
measures for pituitary-hormone recipients? Med J Aust 2010; 193: 366-369. [see also In
Reply: Boyd A, Klug GMA, Masters CL, Collins SJ. In Reply: Iatrogenic Creutzfeldt-
Jakob disease in Australia: time to amend infection control measures for pituitaryhormone
recipients? Med J Aust 2011; 194: 215.]
10.21 Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L,
Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM,
Bush AI. PBT2 rapidly improves cognition in Alzheimer’s disease: additional phase II
analyses. J Alzheimers Dis 2010; 20: 509-516.
10.22 Lui JK, Laws SM, Li Q-X, Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K,
Dromey J, Ellis KA, Faux NG, Foster J, Fowler C, Gupta V, Hudson P, Laughton K,
Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R,
Szoeke C, Taddei K, Taddei T, Trouson B, Ward V, Martins RN for the AIBL Research
Group. Plasma amyloid-β as a biomarker in Alzheimer’s disease: the AIBL study of
aging. J Alzheimers Dis 2010; 20: 1233-1242.
10.23 Brazier MW, Volitakis I, Kvasnicka M, White AR, Underwood JR, Green JE, Han S, Hill
AF, Masters CL, Collins SJ. Manganese chelation therapy extends survival in a mouse
model of M1000 prion disease. J Neurochem 2010; 114: 440-451.
10.24 Smith DG, Ciccotosto GD, Tew DJ, Perez K, Curtain CC, Boas JF, Masters CL, Cappai R,
Barnham KJ. Histidine 14 modulates membrane binding and neurotoxicity of the
Alzheimer’s disease amyloid-β peptide. J Alzheimers Dis 2010; 19: 1387-1400.
10.25 Collins SJ, Schuur M, Boyd A, Lewis V, Klug G, McGlade A, van Oosterhout A,
66

June, 2012
Breedveld G, Oostra BA, Masters C, van Duijn CM. No evidence for prion protein gene
locus multiplication in Creutzfeldt-Jakob disease. Neurosci Lett 2010; 472: 16-18.
10.26 Nisbet RM, Harrison CF, Lawson VA, Masters CL, Cappai R, Hill AF. Residues
surrounding the glycosylphosphatidylinositol anchor attachment site of PrP modulate
prion infection: insight from the resistance of rabbits to prion disease. J Virol 2010;
84:6678-6686.
10.27 Lawson VA, Haigh CL, Roberts B, Kenche VB, Klemm HMJ, Masters CL, Collins SJ,
Barnham KJ, Drew SC. Near-infrared fluorescence imaging of apoptotic neuronal cell
death in a live animal model of prion disease. ACS Chem Neurosci 2010; 1:720-727.
10.28 Boland MP, Hatty CR, Separovic F, Hill AF, Tew DJ, Barnham KJ, Haigh CL, James M,
Masters CL, Collins SJ. Anionic phospholipid interactions of the prion protein N
terminus are minimally perturbing and not driven solely by the octapeptide repeat
domain. J Biol Chem 2010; 285: 32282-32292.
10.29 Rekas A, Knott RK, Sokolova A, Barnham KJ, Perez KA, Masters CL, Drew SC, Cappai
R, Curtain CC, Pham CLL. The structure of dopamine induced α-synuclein oligomers.
Eur Biophys J 2010; 39: 1407-1419.
10.30 Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy
H, Morandeau L, O’Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C,
Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL. Amyloid imaging
results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.
Neurobiol Aging. 2010; 31:1275-1283.
10.31 Chételat G, Villemagne VL, Pike KE, Baron J-C, Bourgeat P, Jones G, Faux NG, Ellis KA,
Salvado O, Szoeke C, Martins RM, Ames D, Masters CL, Rowe CC and the Australian
Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Larger
temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010;
133: 3349-3358.
10.32 Robins-Browne RM, Masters CL. Vaccines against Alzheimer’s and other
neurodegenerative diseases. In: New Generation Vaccines. 4th edition. Levine MM,
Dougan G, Good MF, Liu MA, Nabel GJ, Nataro JP, Rappuoli R (eds.). Informa
Healthcare, New York. 2010; Chapter 87, p. 962-968.
10.33 Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, Bush AI. Tau protein: Relevance
to Parkinson's disease. Int J Biochem Cell Biol. 2010; 42: 1775-1778.
10.34 Collins SJ, McGlade A, Boyd A, Masters CL, Klug GMJA. 14-3-3 protein detection and
sporadic CJD: the status quo serves well while awaiting progress. J Neurol Neurosurg
Psychiatry 2010; 81:1181.
10.35 Gunn AP, Masters CL, Cherny RA. Pyroglutamate-Aβ: Role in the natural history of
Alzheimer’s disease. Int J Biochem Cell Biol 2010; 42: 1915-1918.
67

June, 2012
10.36 Evin G, Barakat A, Masters CL. BACE: Therapeutic target and potential biomarker for
Alzheimer’s disease. Int J Biochem Cell Biol 2010; 42: 1923-1926.
10.37 Drew SC, Masters CL, Barnham KJ. Alzheimer’s Aβ peptides with disease-associated
N-terminal modifications: influence of isomerisation, truncation and mutation on Cu 2+
coordination. PLoS One 2010; 5: e57875.
68

2011
June, 2012
11.01 Ciccotosto GD, Tew DJ, Drew SC, Smith DG, Johanssen TJ, Lal V, Lau T-L, Perez K,
Curtain CC, Wade JD, Separovic F, Masters CL, Smith JP, Barnham KJ, Cappai R.
Stereospecific interactions are necessary for Alzheimer disease amyloid-β toxicity.
Neurobiol Aging 2011; 32: 235-248.
11.02 Streltsov VA, Varghese JN, Masters CL, Nuttall SD. Crystal structure of the amyloid-β
p3 fragment provides a model for oligomer formation in Alzheimer’s disease.
J Neurosci 2011: 31: 1419-1426.
11.03 Ho M, Hoke DE, Chua YJ, Li Q-X, Culvenor JG, Masters CL, White AR, Evin G. Effect
of metal chelators on γ-secretase indicates that calcium and magnesium ions facilitate
cleavage of Alzheimer amyloid precursor substrate. Int J Alzheimer’s Dis 2011;
PMID:21253550[PubMed] doi:10.4061/2011/950932.
11.04 Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U,
Jones G, Szoeke S, Salvado O, Martins R, O’Keefe G, Mathis CA, Klunk WE, Ames D,
Masters CL, Rowe CC. Longitudinal assesment of Aβ and cognition in aging and
Alzheimer’s disease. Ann Neurol 2011; 69: 181-192.
11.05 Acevedo KM, Hung YH, Dalziel AH, Li QX, Laughton K, Wikhe K, Rembach A,
Roberts B, Masters CL, Bush AI, Camakaris J. Copper promotes the trafficking of the
amyloid precursor protein. J Biol Chem 2011; 286: 8252-8262.
11.06 Klug GM, Boyd A, McGlade A, Stehmann C, Masters CL, Collins SJ. Surveillance of
Creutzfeldt-Jakob disease in Australia: update to December 2010. Commun Dis Intell
2011; 35:149-153
11.07 Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor A, McLean CA,
Cao D, Rigopoulos A, Cartwright GA, O’Keefe G, Gong S, Adlard PA, Barnham KJ,
Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL. 18 F-THK523: a
novel in vivo tau imaging ligand for Alzheimer’s disease. Brain 2011; 134: 1089-1100.
11.08 Yates PA, Sirisriro R, Villemagne VL, Farqhuarson S, Masters CL, Rowe CC for the
AIBL Research Group. Cerebral microhaemorrhage and brain β-amyloid in aging and
Alzheimer’s disease. Neurol 2011; 77: 48-54.
11.09 Masters CL, Kril JJ, Halliday GM, Pamphlett R, Collins S, Hill AF and McLean C.
Overview and recent advances in neuopathology. Part 2: Neurodegeneration.
Pathology 2011; 43: 93-102.
11.10 Schnabel J. Little proteins, big clues. [Interviews with C.L. Masters, K Beyreuther and
others]. Nature 2011; 475: (supplement) 512-514.
11.11 Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O’Keefe G, Ackerman
U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL and
Rowe CC. Amyloid imaging with 18 F-Florbetaben in Alzheimer disease and other
dementias. J Nuclear Med 2011; 52: 1210-1217.
69

June, 2012
11.12 Lawson VA, Klemm HM, Welton JM, Masters CL, Crouch P, Cappai R, Ciccotosto GD.
Gene knockout of tau expression does not contribute to the pathogenesis of prion
disease. J Neuropathol Exp Neurol 2011; 70: 1036-1045.
11.13 Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller H-J and the WFSBP Task
Force on Treatment Guidelines for Alzheimer’s Disease and Other Dementias (Winblad
B, Schneider L, Burns A, Frölich L, Möller H-J, Blesa R, Brodaty H, Dartigues J-F,
Degrell I, DeKosky S, Endo H, Erkinjjuntti T, Förstl H, Frisoni G, Gauthier S, Giacobini
E, Gomez-Isla T, Gottfries C-G, Grundman M, Han C, Hock C, Marksteiner J, Masters
C, McKeith I, Olofsdottir M, Orgogozo J-M, Rainer M, Reisberg B, Riederer P, Rossor M,
Saletu B, Salmon E, Sunderland T, Takeda M, Vellas B, Verhey F, Waldemar G,
Whitehouse P). World Federation of Societies of Biological Psychiatry (WFSBP)
guidelines for biological treatment of Alzheimer’s disease and other dementias. World
Journal Biol Psych 2011; 12:2-32.
11.14 Corrigan F, Pham CLL, Vink R, Blumbergs PC, Masters CL, van den Heuvel C, Cappai
R. The neuroprotective domains of the amyloid precursor protein, in traumatic brain
injury, are located in the two growth factor domains. Brain Research 2011; 1378: 137-
143.
11. 15 Masters CL. Colin Masters on Seeking the Natural History of Alzheimer's Disease
Special Topic of Alzheimer's Disease Interview, May 2011. www.sciencewatch.com
http://sciencewatch.com/ana/st/alz2/11maySTAlz2Mast/
11.16 Meyerowitz J, Parker SJ, Vella LJ, Ng DCH, Price KA, Liddell J, Caragounis A, Li Q-X,
Masters CL, Nonaka T, Hasegawa M, Bogoyevitch MA, Kanninen K, Crouch PJ, White
AR. c-JUN N-terminal kinase controls TDP-43 accumulation in stress granules induced
by oxidative stress. Molecular Neurodegen 2011; 6: 57-78.
11.17 Watt AD, Perez KA, Faux NG, Pike KE, Rowe CC, Bourgeat P, Salvado O, Masters CL,
Villemagne VL, Barnham KJ. Increasing the predictive accuracy of beta-amyloid bloodborne
biomarkers in Alzheimer’s disease. J Alzheimers Dis 2011; 24: 47-59.
11.18 Pike KE, Ellis KA, Villemagne VL, Good N, Chételat G, Ames D, Szoeke C, Laws SM,
Verdile G, Martins RN, Masters CL, Rowe CC. Cognition and beta-amyloid in
preclinical Alzheimer’s disease: Data from the AIBL study. Neuropsychologia 2011; 49:
2384-2390.
11.19 Drew SC, Haigh CL, Klemm HM, Masters CL, Collins SJ, Barnham KJ, Lawson V.
Optical imaging detects apoptosis in the brain and peripheral organs of prion-infected
mice. J Neuropath Exp Neurol 2011; 70: 143-150.
11.20 Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chételat G, Ackermann
U, O’Keefe G, Jones G, Gong S, Tochon-Danguy H, Kung HF, Masters CL, Skovronsky
D, Rowe CC. In vivo assessment of vesicular monoamine transporter type 2 in
dementia with Lewy bodies and Alzheimer disease. Arch Neurol 2011; 68: 905-912.
11.21 Lim NK-H, Villemagne VL, Soon CPW, Laughton KM, Rowe CC, McLean CA, Masters
CL, Evin G, Li Q-X. Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in
70

June, 2012
plasma reveals a decrease of MMP-2 in Alzheimer’s disease. J Alzheimers Dis 2011; 26:
779-786.
11.22 Santosa C, Rasche S, Barakat A, Bellingham SA, Ho M, Tan J, Hill AF, Masters CL,
McLean C, Evin G. Decreased expression of GGA3 protein in Alzheimer’s disease
frontal cortex and increased co-distribution of BACE with the amyloid precursor
protein. Neurobiol Disease 2011; 43: 176-183.
11.23 Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O’Keefe GJ, Salvado
O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC and the Australian Imaging
Biomarkers and Lifestyle Study of ageing (AIBL) Research Group. Independent
contribution of temporal β-amyloid deposition to memory decline in the pre-dementia
phase of Alzheimer’s disease. Brain 2011; 134: 798-807.
11.24 Crouch PJ, Savva MS, Hung LW, Donnelly PS, Mot AI, Parker SJ, Greenough MA,
Volitakis I, Adlard PA, Cherny RA, Masters CL, Bush AI, Barnham KJ, White AR. The
Alzheimer’s therapeutic PBT2 promotes amyloid-β degradation and GSK3
phosphorylation via a metal chaperone activity. Journal of Neurochemistry 2011;
119:220-230.
11.25 McBride SJ, Szoeke CEI, Good NM, Ames D, Martins RN, Masters CL, Maruff PT, Rowe
CC, Savage G, Ellis KA and the AIBL Research Group. A web-based normative data
tool for assessing cognitive performance in healthy older Australians. Med J Aust
(Supplement) 2011; 194: 512-14.
11.26 Masters CL, Beyreuther K. Amyloid-β production. Neurodegeneration: The Molecular
Pathology of Dementia and Movement Disorders. Second edition. Edited by Dickson
DW, Weller RO. Oxford: Wiley-Blackwell. 2011; Chapter 11, p 92-96.
11.27 Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, Pertile KK, Rembach A,
Rowe CC, Rumble RL, Szoeke C, Taddei K, Taddei T, Trounson BO, Villemagne VL,
Ward V, Ames D, Masters CL, Bush AI and the AIBL Research Group. Homocysteine,
vitamin B12 and folic acid levels in Alzheimer’s disease, mild cognitive impairment and
healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker
Lifestyle study. J Alzheimers Dis 2011; 27:909-22.
11.28 Sittironnait G, Ames D, Bush AI, Faux N, Flicker L, Foster J, Hilmer S, Lautenschlager
NT, Maruff P, Masters CL, Martins RN, Rowe C, Szoeke C, Ellis KA, and the AIBL
research group. Effects of anticholinergic drugs on cognitive function in older
Australians: results from the AIBL study. Dement Geriatr Cogn Disord 2011; 31:173-
178.
11.29 Wang Y-J, Wang X, Lu J-J, Li Q-X, Gao C-Y, Liu X-H, Sun Y, Yang M, Lim Y, Evin G,
Zhong J-H, Masters C, Zhou X-F. p75NTR regulates Aβ deposition by increasing Aβ
production but inhibiting Aβ aggregation with its extracellular domain. J Neurosci
2011; 31: 2292-2304.
11.30 Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, Lui JK, Masters C,
Rowe CC, Szoeke C, Taddei K, Martins RN for the AIBL Research Group. Plasma
71

June, 2012
apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurol 2011; 76:
1091-1098.
11.31 Haigh CL, Mc Glade AR, Lewis V, Masters CL, Lawson VA, Collins SJ. Acute exposure
to prion infection induces transient oxidative stress progressing to be cumulatively
deleterious with chronic propagation in vitro. Free Radical Biol Med 2011; 51: 594-608.
11.32 Ritchie C,Masters CL,Mason SE, Li QX,McShane R. Plasma and CSF Abeta for the
longitudinal prediction of Alzheimer’s disease dementia and other dementias in people
with cognitive decline but no dementia. Cochrane Database of Systematic Reviews
2011, Issue 1. Art. No.: CD008782. DOI: 10.1002/14651858.CD008782.pub3.
11.33 Lambert JC, Dallongeville J, Ellis KA, Schraen-Maschke S, Lui J, Laws S, Dumont J,
Richard F, Cottel D, Berr C, Ames D, Masters, CL, Rowe CC, Szoeke C, Tzourio C,
Dartigues JF, Buée L, Martins R, Amouyel P. Association of plasma Aβ peptides with
blood pressure in the elderly. PlosOne 2011; 6(4): e18536.
11.34 Mattsson N, Andreason U, Persson S, Arai H, Batish D, Bernardini S, Bocchio-Chiavetto
L, Blankenstein RA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors
G, Duller S, Fagan A, Forlenza O, Frisoni G, Galasko D, Galimberti D, Hampel H,
Handberg A, Heneka MT, Herskovitz AZ, Herukka S-K, Holtzman DM, Humpel C,
Hyman B, Iqbal K, Jucker M, Kaeser S, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen
C, Kummer M, Liu J, Lladó A, Lewczuk P, Li Q-X, Martins R, Masters CL, McAuliffe J,
Mercken M, Moghekar A, Molinuevo JL, Montine T, Nowatzke W, O’Brien R, Otto M,
Paraskevas GP, Parnetti L, Petersen R, Prvulovic D, de Reus HPM, Rissman RA,
Scarpini E, Stefani A, Soininen H, Schroder J, Shaw LM, Skinningsrud A, Skrogstad B,
Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek R, Van Broeck B,
Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow
K. The Alzheimer’s Association external quality control program for cerebrospinal
fluid biomarkers. Alzheimer’s and Dementia 2011; 7: 386-395.
11.35 Fodero-Tavoletti MT, Villemagne VL, Rowe CC, Masters CL, Barnham KJ, Cappai R.
Amyloid-β: The seeds of darkness. Int J Biochem Cell Biol 2011; 43: 1247 – 1251.
11.36 Masters CL. Abeta toxicity - Part I and II. In Alzheimer's Disease. Edited by Hardy, J.
The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London: (online at
http://www.hstalks.com/review/HST114/2957.htm)
11.37 Ellis KA, Rowe CC, Szoeke CEI, Villemagne VL, Ames D, Chételat G, Martins RN,
Masters CL, Fripp J, Acosta O, Raniga P, Bourgeat PT, Salvado O. Advances in
structural and molecular neuroimaging in Alzheimer’s disease. Med J Aust
(Supplement) 2011; 194: 520-23.
Total publications to 31 Dec, 2011 = 744
h-factor (ISI-Thomson Scientific) at 19 July, 2011 = 87
72